

Gilaad G. Kaplan, MD, MPH, FRCPC, CAGF, AGAF, FCAHS, Killam Laureate

Curriculum Vitae

Contact 2

Biosketch..... 2

Research Interests 2

In the News: A Selection 3

Education 4

Academic Appointments..... 4

Awards and Distinctions 4

Research Funding..... 6

Administrative Activities 8

Professional Activities 9

Teaching..... 12

Supervision: Postdoctoral Fellows, Clinical Trainees 12

Supervision: Graduate Students 13

Supervision: Undergraduate Students..... 16

Patents 17

Invited Addresses 17

Publications: Peer Reviewed..... 26

Publications: Non-Peer Reviewed Manuscripts and Editorials 59

Publications: Book Chapters..... 60

Contact

Phone: 403-592-5089, **Fax:** 403-592-5090, **Email:** gkaplan@ucalgary.ca, **Twitter:** [@gilkaplan](https://twitter.com/gilkaplan)

Address:

Gilaad G. Kaplan
Teaching, Research, and Wellness Building
University of Calgary
3280 Hospital Drive NW, 3D03-18
Calgary, Alberta, CANADA, T2N 4Z6

Biosketch

Dr. Kaplan is a Professor in the Cumming School of Medicine at the University of Calgary. Dr. Kaplan is a gastroenterologist and epidemiologist who is internationally renowned for studying the global epidemiology of digestive diseases. Dr. Kaplan's research program establishes the global burden of digestive diseases, evaluates environmental determinates of the inflammatory bowel diseases (IBD), and translates this knowledge into improvement of care for patients living with digestive diseases. He graduated with a Master of Public Health from the Harvard School of Public Health and completed an IBD Fellowship at the Massachusetts General Hospital. He joined the University of Calgary in 2007 as a clinician-scientist with 80% protected time for research. He has over 350 publications with an H-index of 72 and over 27,000 lifetime citations ([Kaplan, Gil - Web of Science Core Collection](#)). As nominated principal applicant, Dr. Kaplan has held multiple operating grants from CIHR with continuous funding spanning from 2008 to 2025. He is the past chair of the Scientific and Medical Advisory Council of Crohn's and Colitis Canada (CCC), as well as the co-chair of CCC's National COVID-IBD Task Force. He is an Associate Editor of *Gastroenterology* and an Academic Editor for *PLOS Med*. He was inducted as a Fellow of the AGA and the Canadian Association of Gastroenterology. In 2019, Dr. Kaplan was selected to the International Organization of the study of IBD (IOIBD) and appointed co-chair of the Globalization IBD Task Force. Clarivate, Web of Science named Dr. Kaplan a [Highly Cited Researcher](#) (2020-2023) in recognition of being in the top one percent of cited researchers. In 2021, Dr. Kaplan received Crohn's and Colitis Canada's Research Leader Award and was inducted into the Canadian Academy of Health Sciences. He is a Killam Laureate, receiving the Killam Annual Professor Award in 2022. His research has been widely cited in the news media including [Time Magazine](#), [BBC](#), [The New York Times](#), and [Scientific American](#).

Research Interests

Inflammatory bowel disease, digestive diseases, epidemiology, global health, environmental health, health services, innovating healthcare delivery, administrative healthcare data, COVID-19 and IBD.

In the News: A Selection

Dr. Kaplan's research and expertise has been highlighted in international media. Some examples:

2023	CTV News
2023	Time Magazine
2022	Time Magazine
2021	Jerusalem Post
2021	Elemental
2020	Elemental
2019	BBC
2018	The Conversation
2018	Canada Newswire
2017	ScienceDaily
2017	Ensia
2017	Healio
2013	Scientific American
2013	The New York Times
2012	Toronto Star
2010	Reuters
2009	ABC News

Gilaad G. Kaplan, MD, MPH, FRCPC, CAGF, AGAF, FCAHS, Killam Laureate

Education

- 2007 Advanced Inflammatory Bowel Disease Fellow, Massachusetts General Hospital, Harvard University, Boston, MA, USA.
- 2006 Master of Public Health (Quantitative Methods), Harvard School of Public Health, Harvard University, Boston, MA, USA.
- 2005 Certification (Gastroenterology), Royal College of Physicians and Surgeons of Canada, Ottawa, ON, Canada.
- 2004 Licensure (Internal Medicine), Royal College of Physicians and Surgeons of Canada, Ottawa, ON, Canada.
- 2000 Doctor of Medicine, University of Calgary, Calgary, AB, Canada.
- 1997 Bachelor of Science, McMaster University, Hamilton, ON, Canada.

Academic Appointments

- 07/2019 - present Professor, Departments of Medicine (Division of Gastroenterology) and Community Health Sciences, University of Calgary, Calgary, AB, Canada.
- 07/2017 Appointment with Tenure, Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, AB, Canada.
- 2012 – 2019 Associate Professor, Departments of Medicine (Division of Gastroenterology) and Community Health Sciences, University of Calgary, Calgary, AB, Canada.
- 2007 – 2012 Assistant Professor, Departments of Medicine (Division of Gastroenterology) and Community Health Sciences, University of Calgary, Calgary, AB, Canada.

Awards and Distinctions

- 11/2020-2023 Highly Cited Researchers from Clarivate, Web of Science: Recognizes the top one percent of cited researchers (Cross Field). 2020, 2021, 2022, & 2023
- 11/2023 Outstanding Achievement Award (OAA), Cumming School of Medicine, University of Calgary
- 11/2023 COVID - Outstanding Achievement Award (OAA), Cumming School of Medicine, University of Calgary
- 06/2023 Research Mentorship Excellence Award, Division of Gastroenterology, University of Calgary, Calgary, AB, Canada.
- 04/2022 Killam Laureate, Killam Annual Professor Award (\$10,000 prize), Killam Trust
- 03/2022 Canadian Association of Gastroenterology Fellow (CAGF)

- 11/2021 Crohn's and Colitis Canada Research Leader Award
- 09/2021 Fellow, Canadian Academy of Health Sciences
- 07/2020 O'Brien Institute Mid-Career Research Leader Award, University of Calgary, Calgary.
- 06/2020 Research Mentorship Excellence Award, Division of Gastroenterology, University of Calgary, Calgary, AB, Canada.
- 11/2019 Watanabe Distinguished Achievement Award for Overall Excellence, Cumming School of Medicine, University of Calgary, AB, Canada.
- 02/2018 Classic Citation Award for a single paper cited over 1,000 times. Paper currently cited >2,400 times (Web of Science) since publication in 2012, University of Calgary:
[https://www.gastrojournal.org/article/S0016-5085\(11\)01378-3/abstract](https://www.gastrojournal.org/article/S0016-5085(11)01378-3/abstract)
- 02/2017 Honour Roll, Faculty Appreciation, Cumming School of Medicine's Class of 2018.
- 11/2016 2016 Peak Scholar Nominee, Celebrating excellence in entrepreneurship, innovation, and knowledge engagement, University of Calgary, Calgary, AB, Canada.

Gilaad G. Kaplan, MD, MPH, FRCPC, CAGF, AGAF, FCAHS, Killam Laureate

- 10/2016 *Healio Gastroenterology* 200: selected in the top 200 leading innovators in the field of gastroenterology.
- 07/2016-20
06/2016 CIHR Embedded Clinician Researcher Salary Award (Chair) \$75,000 per year.
ASG Distinguished Researcher Award, Alberta Society of Gastroenterology.
- 02/2016 Inducted as an AGA Fellow, American Gastroenterological Association.
- 2016 [Nominated] Graduate Students' Association Supervisory Excellence Award.
- 09/2015 Fostering Global Gastrointestinal Health, Highest Rated Presentation, AGA Leadership Cabinet Meeting.
- 2015 AGA Future Leaders Program, American Gastroenterological Association.
- 2015 Research Mentorship Excellence Award, Division of Gastroenterology, University of Calgary, Calgary, AB, Canada.
- 2014 American College of Gastroenterology Fellow Awards (supervisor).
- 2014 – 2017 Eyes High Doctoral Recruitment Scholarship, University of Calgary, Calgary, AB, Canada.
- 2013 Killam Laureate, Emerging Research Leader Award, Killam Trusts.
- 2013 Young Investigator Award, Canadian Association of Gastroenterology.
- 2012 UEGW Travel Grant for Oral Presentation, United European Gastroenterology Week Conference, Amsterdam, The Netherlands.
- 2012 Guest Speaker Award for highest rated talk in the 2011-12 academic year, Department of Medicine Grand Rounds, Dalhousie University, Halifax, NS, Canada.
- 2012 Dean's Publication and Mentorship Prize, University of Calgary, Calgary, AB, Canada.
- 2011 Avenue Magazine's "Calgary's Top 40 Under 40."
- 2011 Internal Medicine Research Preceptor Award, Department of Medicine, University of Calgary, Calgary, AB, Canada.
- 2011 Research Mentorship Excellence Award, Division of Gastroenterology, University of Calgary, Calgary, AB, Canada.
- 2011 Poster of Distinction, Digestive Disease Week, Chicago, IL, USA.
- 2010 – 2017 Alberta Heritage Foundation for Medical Research (AHFMR) Population Health Investigator.
- 2010 Presidential Poster. American College of Gastroenterology, San Antonio, TX, USA.
- 2009 – 2014 Canadian Institutes of Health Research (CIHR) New Investigator Award.
- 2009 Merit Award, Department of Medicine, University of Calgary, Calgary, AB, Canada.
- 2009 2009 UEGW/WCOG Travel Award for "Air Pollution and IBD: A Novel Association", UEGW/WCOG Conference, London, England, United Kingdom.
- 2009 Teaching Excellence Award, Division of Gastroenterology, University of Calgary.
- 2008 2008 ACG Presidential Poster Award Recipient for "Predicting postoperative mortality from comorbidity indices in IBD patients."
- 2006 ACG/Centocor IBD Abstract Award, American College of Gastroenterology, Las Vegas, NV, USA.
- 2006 Detweiler Traveling Fellowship, Royal College of Physicians and Surgeons of Canada.
- 2005 – 2007 Canadian Institutes of Health Research, Clinical Research Initiative Fellowship.
- 2005 – 2007 Alberta Heritage Foundation for Medical Research, Clinical Fellowship.
- 2005 Gold Star Award for teaching, GI medical school course, University of Calgary, Calgary, AB, Canada.
- 2004 Gold Star Award for clerkship teaching in internal medicine, University of Calgary.
- 2004 Poster of Distinction, Digestive Disease Week, New Orleans, LA, USA.
- 2003 Canadian Society for Clinical Investigation and Canadian Institute of Health Research award for resident research.

Research Funding

Active Grants

2024-2027	Principal Applicant. Helmsley Charitable Trust for “A Drug-Wide Scan to Identify Repurposed Medications for Crohn’s Disease.”	\$1,248,808 USD (total)
2024 - 2025	Principal Applicant. CIHR Project Scheme Bridge Grant for “Inflammatory Bowel Disease in 2035: A National Study of the Canadian Gastro-Intestinal Epidemiology Consortium (CanGIEC)”	\$200,000 (total)
2021-2024	Principal Applicant. Helmsley Charitable Trust for “Visualization of COVID-19 Vaccine Serology in Crohn’s Disease: A Knowledge Translation Strategy.”	\$351,903 USD (total)
2021 – 2024	Principal Applicant. Helmsley Charitable Trust for “The Changing Epidemiology and Demographics of Crohn’s Disease in the Western World over the Next Decade.”	\$688,432 USD (total)
2020 – 2025	Co-Principal Applicant. Helmsley Charitable Trust for “IBD GIVES-21: Global IBD Visualization of Epidemiology Studies (GIVES) in the 21st Century.”	\$1,995,507 USD (total)
2019 – 2024	Principal Applicant. CIHR Project Scheme for “Predicting the Future Burden of the Inflammatory Bowel Diseases: A Study of the Canadian Gastro-Intestinal Epidemiology Consortium (CanGIEC).”	\$845,325 (total)

Completed Grants

2021-2023	Co-Principal Applicant. Public Health Agency of Canada [under the Seroprevalence and Research (COVID-19 Immunity Task Force Initiative) Program] for “Safety immUnogenicity of Covid-19 vaCcines in systEmic immunE mediated inflammatory Diseases (SUCCEED)”.	\$3,131,216 (total)
2020-2022	Co-Investigator. CIHR for “Distributed Network Meta-Analysis of Multi-Provincial Data to Evaluate Temporal Trends and the Impact of Anti-TNF Therapy on the Risks of Inflammatory Bowel Diseases-Associated Cancers.”	\$330,000
2020 – 2021	Principal Applicant. CIHR COVID-19 Rapid Research (Social Policy and Public Health Responses) for “Serological Testing to Outline Protocols for COVID19 in Inflammatory Bowel Disease: STOP COVID-19 in IBD.”	\$636,750 (total)
2020 – 2021	Principal Applicant. Crohn’s and Colitis Canada for “COVID-19 and IBD Webinar Series.”	\$15,000 (total)
2020-2021	Co-Investigator. CIHR for “Distributed Network Meta-Analysis of Multi-Provincial Data to Evaluate Temporal Trends and the Impact of Anti-TNF Therapy on the Risks of Inflammatory Bowel Diseases-Associated Cancers.”	\$100,000
2016 – 2021	Co-Applicant. CIHR Strategy for Patient-Oriented Research (SPOR) Networks in Chronic Disease for “Inflammation, Microbiome, and Alimentation: Gastro-Intestinal and Neuropsychiatric Effects: the IMAGINE-SPOR chronic disease network.”	\$4,980,000/y
2018 – 2019	Co-Principal Applicant. CIHR Operating Grant Secondary Data Analysis for “Preventable Acute Care Spending Among High System Users.”	\$75,000 (total)
2014 – 2019	Co-Investigator. CIHR Team Grant (Health Challenges in Chronic Inflammation) for “Brain Dysfunction in Chronic Inflammatory Disease:	\$500,000/y

Gilaad G. Kaplan, MD, MPH, FRCPC, CAGF, AGAF, FCAHS, Killam Laureate

	Reciprocal Effects of CNS and Periphery Crosstalk.”	
2014 – 2019	Co-Investigator. CIHR Team Grant (Health Challenges in Chronic Inflammation) for “PRECISION: Preventing Complications from Inflammatory Skin, Joint and Bowel Conditions.”	\$500,000/y
2017 – 2018	Principal Applicant. CIHR Project Scheme Bridge Grant for “Innovating Healthcare Delivery for Sustainable Management of the Inflammatory Bowel Diseases.”	\$100,000 (total)
2013 – 2018	Co-Principal Applicant. CHILD-CIHR for “Canadian Children Inflammatory Bowel Disease Network.”	\$1,000,000/y
2014 – 2017	Principal Investigator. CIHR for “Preventing Myocardial Infarctions with the Air Quality Health Index.”	\$74,138/y
2014 – 2017	Co-Principal Applicant. AI-HS PRIHS for “Reassessment of Clinical Practices for Patient Presenting to the Emergency Department with Upper Gastrointestinal Bleeding.”	\$250,000/y
2014 – 2017	Co-Investigator. CIHR for “Do altitude-related air pressure differences influence susceptibility to cardiovascular disease?”	\$121,395/y
2015 – 2016	Co-Principal Investigator. CIHR Catalyst Grant (Methods in Post-Market Drug Safety and Effectiveness Research) for “Bayesian models for synthesizing random controlled trials and patients’ preferences for treatment options in early rheumatoid arthritis and Crohn’s disease.”	\$100,000 (total)
2014 – 2016	Co-Investigator. CIHR for “The Effect of Air Pollution in Developing Type 1 Diabetes Mellitus.”	\$59,125/y
2013 – 2016	Co-Investigator. CIHR for “An enhanced method to measure chronic disease burdens using health administrative data.”	\$60,681/y
2014 – 2015	Principal Investigator. Health Canada for “Preventing Strokes with the Air Quality Health Index.”	\$30,000 (total)
2013 – 2015	Co-Investigator. Crohn's and Colitis Foundation of Canada for “Aberrant dendritic cell and T cell immune function driven by IBD associated genetic mutations.”	\$100,000/y
2012 – 2015	Co-leader. The Faculty of Medicine Emerging Research Teams Grant Program for “A translational approach to understanding and managing primary sclerosing cholangitis.”	\$100,000/y
2013 – 2014	Co-Investigator. Clinical Research Award from the American College of Gastroenterology for “Serological technologies and profiles to deliver precision diagnostics for inflammatory bowel disease patients.”	\$35,000 (total)
2011 – 2013	Principal Investigator. CIHR for “The effect of acute air pollution exposure on the incidence of appendicitis: a multi-city study.”	\$89,567/y
2011	Co-Principal Investigator. Canadian Foundation for Innovation Leaders of Opportunity Funding for “Translational Health Research Collaboratorium.”	\$175,391 (total)
2011	Co-Principal Investigator. Alberta Advanced Education and Technology Small Equipment Grant Program for “Translational Health Research Collaboratorium.”	\$175,391 (total)
2011 – 2013	Principal Investigator. Shire Pharmaceutical contract for “The Incidence, Morbidity and Mortality of Diverticulitis.”	\$179,180 (total)

Gilaad G. Kaplan, MD, MPH, FRCPC, CAGF, AGAF, FCAHS, Killam Laureate

2011 – 2012	Principal Investigator. Abbott Pharmaceutical contract for “Long-Term Outcomes Following Colectomy for Ulcerative Colitis.”	\$76,232 (total)
2010	Co-Investigator. Department of Medicine Research Fund for “Pregnancy Outcomes in IBD.”	\$10,000 (total)
2010 – 2013	Co-Investigator. Crohn’s and Colitis Foundation of Canada Grant in Aid for “Genetic Markers of Outcomes in Crohn’s Disease.”	\$125,000/y
2010 – 2013	Alberta Heritage Foundation for Medical Research Population Health Investigator, Establishment Grant.	\$100,000/y
2009 – 2010	Principal Investigator, Health Canada contract for “Air Pollution and Appendicitis.”	\$100,000 (total)
2009 – 2014	Co-investigator. AHFMR Team Grant for “Etiology of Inflammatory Bowel Disease: Gene, Microbe, & Environment Interactions.”	\$1,000,000/y
2008 – 2010	Principal Investigator. MSI Foundation for “Postoperative outcomes in elderly ulcerative colitis patients following colectomy.”	\$23,400/y
2008 – 2010	Co-Principal Investigator. CIHR for “The effect of outdoor air pollution on the development and the prognosis of the inflammatory bowel diseases in Canada.”	\$96,696/y
2008 – 2010	Principal Investigator. Canadian Association of Gastroenterology for “The effect of outdoor air pollution on the inflammatory bowel diseases.”	\$42,300/y
2009 – 2010	Principal Investigator. Health Canada contract for “The effect of outdoor air pollution on the development and prognosis of the inflammatory bowel diseases in Canada.”	\$49,400 (total)
2007 – 2008	Principal Investigator. Broad Medical Research Program for “The effect of air pollution on the development of the inflammatory bowel disease in England and Wales.”	\$90,200 (total)

Administrative Activities

International

2022 - present	Fellow, Canadian Association of Gastroenterology.
2022 – present	Member, Clinical Research Committee, World Gastroenterology Organisation
2021 – present	Fellow, Canadian Academy of Health Sciences
2021 – 2023	Member, Cost of IBD Commission, Lancet Gastroenterology & Hepatology
2020 – present	Co-Chair, Globalization Taskforce, International Organization for the Study of Inflammatory Bowel Disease (IOIBD).
2019 – present	Member, International Organization for the Study of Inflammatory Bowel Disease (IOIBD).
2018 – 2023	Member, Education, and Training Committee, The American Gastroenterological Association.
2019 – 2023	Chair, International Subcommittee, The American Gastroenterological Association.
2018 – 2019	Chair-elect, International Subcommittee, The American Gastroenterological Association.
2016 – present	Fellow, American Gastroenterological Association.
2015 – 2018	Member, International Committee, The American Gastroenterological Association.
2015 – 2018	Member, Research Awards Panel, The American Gastroenterological Association.
2008 – present	Steering Committee Member, Building Research in IBD Globally (BRIDGE), IBD Young Investigators Group.
2005 – 2016	Member, American Gastroenterological Association.

National

Gilaad G. Kaplan, MD, MPH, FRCPC, CAGF, AGAF, FCAHS, Killam Laureate

2020 – 2023	Co-Chair, National COVID and IBD Task Force, Crohn's and Colitis Canada.
2019 – 2023	Co-Chair, 2023 Impact of IBD Report, Crohn's and Colitis Canada.
2020 – 2022	Past Chair, Scientific and Medical Advisory Council, Crohn's and Colitis Canada.
2020 – 2021	Co-Chair, 2021 Impact of COVID-19 on IBD Report in Canada, Crohn's and Colitis Canada.
2019 – 2020	Planning Committee Member, Research Strategy, Crohn's and Colitis Canada.
2018 – 2020	Member, Board of Directors, Crohn's and Colitis Canada.
2018 – 2020	Chair, Scientific and Medical Advisory Council, Crohn's and Colitis Canada.
2017 – 2018	Co-Chair, 2018 Impact of IBD Report, Crohn's and Colitis Canada.
2015 – present	Member, Steering Committee, The Canadian Gastro-Intestinal Epidemiology Consortium (CanGIEC).
2013 – 2018	Member, Scientific and Medical Advisory Council, Crohn's and Colitis Canada.
2012 – 2013	Steering Committee Member (Canadian Association of Gastroenterology Education Representative), IBD Connect Program.
2011 – 2014	Member, Canadian Association of Gastroenterology Education Committee.
2011 – 2016	Steering Committee, National GEM Study, University of Toronto.
2009 – 2014	Team Leader, Clinical and Population Health Studies, Alberta IBD Consortium Led a team to study gene-environment-microbial interactions in a population-based Alberta-wide cohort of IBD patients and controls. Funded by a \$5 million, 5 year AHFMR team grant.

Provincial (Alberta)

2016 – 2023	Member, Core Committee, Digestive Health Strategic Clinical Network, Alberta Health Services
2016 – 2021	Scientific Director, Digestive Health Strategic Clinical Network, Alberta Health Services
2016 – 2018	Member, Nominations and Awards Committee, Cumming School of Medicine, University of Calgary.
2015 – 2017	Member, Gairdner Lecture Planning Committee, Cumming School of Medicine, University of Calgary.
2014 – 2017	Member, Executive Committee (Nominations and Awards Portfolio), O'Brien Institute for Public Health, University of Calgary.
2013 – 2015	Reviewer, Graduate Student Applications for Admissions, Department of Community Health Sciences, University of Calgary.
2011 – 2016	Founder and Director, Environmental Health Research Group (EHRG), O'Brien Institute for Public Health, University of Calgary.
2011	Search and Selection Committee for Head of the Division of Gastroenterology, University of Calgary.
2011 – present	Director of GI Resident Research, University of Calgary.
2011 – present	Executive Member, Graduate Education Committee, Division of Gastroenterology, University of Calgary.
2010 – present	Member, O'Brien Institute for Public Health, University of Calgary, Calgary, AB, Canada.
2011 – 2012	Member, Advisory Board, Health Data Access Advisory Committee (HDAAC), Alberta Health and Wellness.
2007 – present	Member, Snyder Institute for Chronic Diseases, University of Calgary, Calgary, AB, Canada.

Professional Activities

Courses

2018 – 2019	Cumming School of Medicine's Leadership Program, Haskayne School of Business, University
-------------	--

Gilaad G. Kaplan, MD, MPH, FRCPC, CAGF, AGAF, FCAHS, Killam Laureate

of Calgary.

Editorial Boards

2024 – present Academic Editor, *PLOS Medicine*
2022 – present Associate Editor, Gastroenterology.
2018 – 2020 Associate Editor, American Journal of Gastroenterology.
2017 – 2020 Associate Editor, Journal of the Canadian Association of Gastroenterology.
2009 – 2016 Section Editor, IBD Journal.

Grant Review Committees

2019 – present Canadian Institutes of Health Research, Project Scheme Grant Competition: Public, Community, and Population Health (PH1) committee.
2018 – present Canadian Institutes of Health Research, College of Reviewers
2009 – 2010 Canadian Institutes of Health Research.
2009 – 2010 Canadian Association of Gastroenterology.

Grant Reviewer

2009 – present Crohn's and Colitis Canada Grant-in-Aid Competition.

Journal Reviewer

2024 – present JAMA, Nature, PLOS Medicine
2016 – present Lancet, Lancet Gastroenterology & Hepatology
2014 – present PLoS One
2010 – present CMAJ
2008 – present American Journal of Gastroenterology, Gastroenterology, Clinical Gastroenterology and Hepatology, IBD

Abstract Reviewer

2022 – present Chair & Abstract Reviewer, Crohn's and Colitis Congress
2008 – present Abstract Reviewer for IBD: Epidemiology, Digestive Disease Week Conference.
2015 Abstract Poster Judge, Digestive Disease Week Conference, The American Gastroenterological Association.

Conference Chair

18/05/2019 Session Chair, IBD Epidemiology & Natural History, Digestive Disease Week Conference, San Diego, CA, USA.
18/05/2019 Session Chair, AGA/Asian Pacific Association of Gastroenterology (APAGE) Joint Symposium, Digestive Disease Week Conference, San Diego, CA, USA.
21/05/2016 Session Chair, IBD Epidemiology, Digestive Disease Week Conference, San Diego, CA, USA.
16/05/2015 Session Chair, IBD Epidemiology, Digestive Disease Week Conference, Washington, USA.
02/2015 Session Chair, Optimization of Crohn's Therapy, Canadian Digestive Disease Week Conference, Banff, AB, Canada.
05/2014 Session Chair, IBD Epidemiology, Digestive Disease Week Conference, Chicago, IL, USA.
02/2014 Session Chair, The Year in Review, Canadian Digestive Disease Week Conference, Toronto, ON, Canada.
03/2013 Session Chair, Breakfast with Experts, Difficult Cases in IBD, Canadian Digestive Disease Week Conference, Victoria, BC, Canada.
03/2013 Session Chair, Coming of Ages: Advances in IBD, Canadian Digestive Disease Week

Gilaad G. Kaplan, MD, MPH, FRCPC, CAGF, AGAF, FCAHS, Killam Laureate

- Conference, Victoria, BC, Canada.
- 02/2012 Session Chair, Breakfast with Experts, Difficult Cases in IBD, Canadian Digestive Disease Week Conference, Montreal, QC, Canada.
- 05/2011 Session Chair, IBD Surgery, Digestive Disease Week Conference, Chicago, IL, USA.
- 02/2011 Session Chair, Breakfast with Experts, Difficult Cases in IBD, Canadian Digestive Disease Week Conference, Vancouver, BC, Canada.
- 05/2010 Session Chair, Outcomes and Adverse Events Related to Treatment of IBD, Digestive Disease Week Conference, New Orleans, LA, USA.
- 02/2010 Breakfast with Experts, Difficult Cases in IBD, Canadian Digestive Disease Week Conference, Toronto, ON, Canada.
- 06/2009 Session Chair, Infections in IBD: Diagnosis, Consequences and Management, Digestive Disease Week Conference, Chicago, IL, USA.
- 02/2008 Small Group Chair, Environment and IBD Session, Canadian Digestive Disease Week Conference, Montreal, QC, Canada.

Conference Organizer

- June 2023 Education Chair, Alberta Digestive Disease Week, Banff Alberta
- May 2023 Chair, Epidemiology of IBD in Compounding Prevalence Nations, Calgary, Alberta
- 2013 – 2016 Co-Chair, Research Topics in GI Research, Canadian Association of Gastroenterology.
- 2009 – 2010 Gastrointestinal Research Group Annual Conference (2010).

Public Events and Community Engagement

- 10/10/2023 2023 IBD Impact Report, Board of Directors, Crohn's and Colitis Canada
- 19/05/2020 – 2022 Co-Moderator, COVID and IBD Webinar, Webinar Series (30+) during the COVID Pandemic starting on March 19, 2020, Crohn's and Colitis Canada.
- 05/04/2019 The Rising Prevalence of IBD in Canada. Board of Directors, Crohn's and Colitis Canada. Toronto, ON, Canada.
- 9/01/2018 The Origin of IBD: Lessons for a Healthy Gut. Na'amat Canada Calgary, Jewish Community Centre, Calgary, Alberta, Canada.
- 6/11/2017 One Health: How the environment influences human and animal health. Mini-Med School, University of Calgary, Calgary, AB, Canada.
- 17/05/2017 Presentation: "Tzed Talk – How healthy is your gut and why that matters". Beth Tzedec Congregation, Calgary, AB, Canada.
- 19/05/2016 Presentation: "IBD and your Brain". Crohn's and Colitis Canada, Calgary, AB, Canada.
- 10/06/2015 Webinar: "Tests, Tests, & More Tests". Crohn's and Colitis Canada.
- 10/02/2015 Presentation: "Your Poop" to Grade 2 classes of Westmount School, Calgary, AB, Canada.
- 06/26/2015 Launch of GoHere Program, Speaker, Crohn's and Colitis Canada, Calgary, AB, Canada.
- 05/20/2015 Investigating the Causes of a Modern Disease of Modern Times, Speaker, Dean's Public Talk. University of Calgary, Calgary, AB, Canada.
- 05/11/2015 Our Cities, Our Health: How Urban Environments Impact Our Health. Panel Member. CIHR Scientific Cafe, Calgary, AB, Canada.
- 05/04/2015 Dinner with the Dean. Speaker. University of Calgary, Calgary, AB, Canada.
- 05/2012 Environment, Genes and Gut Disease: Paradox of Prosperity, Organizer and Panel Member. CIHR Scientific Cafe, Calgary, AB, Canada.
- 05/2011 Genetics, Environment, and Microbes. Panel Member. CIHR Scientific Cafe, Toronto, ON, Canada.
- 05/2011 IBD and the Environment. CIHR Sponsored Journalist Workshop, Toronto, ON, Canada.
- 02/2011 Genetics, Environment, and Microbes. Panel Member. CIHR Scientific Cafe, Vancouver, BC,

Gilaad G. Kaplan, MD, MPH, FRCPC, CAGF, AGAF, FCAHS, Killam Laureate

Canada.

Policy Reports

- 01/06/2023 Co-Chair. Crohn's and Colitis Canada's 2023 Impact of IBD in Canada Report.
<https://crohnsandcolitis.ca/About-Us/Resources-Publications/Impact-of-IBD-Report>
- 07/07/2021 Co-Chair. 2021 Impact of COVID-19 & Inflammatory Bowel Disease in Canada.
https://crohnsandcolitis.ca/Crohns_and_Colitis/documents/reports/COVID-19/2021-COVID19-IBD-Report_V9.pdf
- 01/11/2018 Co-Chair. The Impact of Inflammatory Bowel Disease in Canada (2018) Report. Crohn's and Colitis Canada. <https://crohnsandcolitis.ca/About-Us/Resources-Publications/Impact-of-IBD-Report>

Teaching

Undergraduate

2007 – present Gastrointestinal Course (MDCN 408)

Graduate

2011, 2012, 2014, 2017 Meta-Analysis Course (MDCH 741)

Supervision: Postdoctoral Fellows, Clinical Trainees

Postdoctoral Fellows

- 2022 – 2024 Dr. Lindsay Hracs, Primary Supervisor
Topic: Machine Learning and Data Visualization
- 2018 – 2020 Dr. Joseph Windsor, Primary Supervisor
6 papers
8 abstracts
Topic: Knowledge Translation in IBD
- 2011 – 2012 Dr. Vineet Saini, Co-Supervisor
1 paper
1 abstract
Topic: Environmental Health and Air Pollution

Current Position

Postdoctoral Fellow, University of Calgary
Knowledge Translation Manager, University of Calgary
Epidemiologist, Alberta Health

Clinical Trainees – Research Supervisor

- 2020 – 2022 Dr. Jared Cooper, Primary Supervisor
- 2019 – 2022 Dr. Jordan Iannuzzi, Primary Supervisor
Topic: Global Epidemiology of Pancreatitis
- 2018-2019 Dr. Paulo Kotze, Co-Supervisor
Topic: Epidemiology of IBD in Latin America
- 2017 – 2020 Dr. Hassan Azhari, Primary Supervisor
Topic: Global Epidemiology of peptic ulcer disease
- 2015 – 2018 Dr. Chris Ma, Co-Supervisor
Topic: Risk of surgery for IBD
- 2014 – 2016 Dr. Aziz Shaheen, Co-Supervisor
Topic: Epidemiology of primary biliary cholangitis
- 2013 – 2015 Dr. Sunny Singh, Primary Supervisor
Topic: Postoperative mortality in IBD

Current Position

Internal Medicine Resident, University of Calgary
GI Fellow, University of Calgary
Colorectal Surgeon & Assistant Professor, Pontifícia Universidade Católica, Brazil
Advanced Hepatology Fellow, Mayo Clinic
Gastroenterologist & Assistant Professor, University of Calgary
Gastroenterologist & Assistant Professor, University of Calgary
Gastroenterologist, Kelowna

Gilaad G. Kaplan, MD, MPH, FRCPC, CAGF, AGAF, FCAHS, Killam Laureate

2013 – 2017	Dr. Ahmed Al-Darmaki, Primary Supervisor Topic: Environmental health and IBD	Gastroenterologist, Oman Hospital, Oman
2011 – 2012	Dr. Gordon Moran, Co-Supervisor Topic: IBD phenotypes and prognosis	Gastroenterologist & Clinical Associate Professor, University of Nottingham, UK
2010 – 2013	Dr. Ali Rezaie, Primary Supervisor Topic: Epidemiology of IBD in Alberta	Gastroenterologist & Assistant Professor, Cedars Sinai, US
2010 – 2014	Dr. Mathew Sadler, Primary Supervisor Topic: Epidemiology of ischemic colitis	Hepatologist & Clinical Assistant Professor, Foothills Medical Centre, Calgary
2009 – 2010	Dr. Allen Lim, Primary Supervisor Topic: Venous thromboembolism in IBD	Gastroenterologist & Clinical Lecturer, University of Alberta
2008 – 2009	Dr. Shani DeSilva, Primary Supervisor Topic: Postoperative complications for IBD	Gastroenterologist, The Dudley Group, UK
2007 – 2012	Dr. Liisa Meddings, Primary Supervisor Topic: Epidemiology of pyogenic liver abscess	Gastroenterologist, Rocky View Hospital, Calgary

Supervision: Graduate Students

Primary Supervisor

Current

Ante Markovinovic, MSc, Epidemiology, Department of Community Health Sciences, University of Calgary

2023 – current MSc Thesis
Topic: Long COVID-19 in those with IBD

Elizabeth Buie, MSc, Masters of Science, Department of Medicine, University of Calgary

2023 – current MSc Thesis
Topic: Global epidemiology of appendicitis

Quinn Goddard, MSc, Epidemiology, Department of Community Health Sciences, University of Calgary

2023 – current MSc Thesis
Topic: Cancer in those with IBD

Graduated

Lea Caplan, MSc, Epidemiology, Department of Community Health Sciences, University of Calgary

2021 – 2023 MSc Thesis (defended May 2023)
Topic: Risk factors for COVID-19 in those with IBD

Nastaran Sharifi, MSc, Epidemiology, Department of Community Health Sciences, University of Calgary

2021 – 2023 MSc Thesis (defended June 2023)
Topic: COVID-19 Serology and IBD

Michael Buie, MSc, Epidemiology, Department of Community Health Sciences, University of Calgary

2020 – 2022 MSc Thesis (defended June 2022)
Topic: Global Hospitalization Trends in IBD

Joshua Quan, MSc, Epidemiology, Department of Community Health Sciences, University of Calgary

2020 – 2022 MSc Thesis (defended May 13, 2022)
Topic: COVID-19 and IBD

Gilaad G. Kaplan, MD, MPH, FRCPC, CAGF, AGAF, FCAHS, Killam Laureate

Tawnya Hansen, MSc, Epidemiology, Department of Community Health Sciences, University of Calgary

2019 – 2021 MSc Thesis (defended November 8, 2021)

2 abstracts Topic: Risk of Surgery for IBD

Current Position: Gastroenterologist, Winnipeg

Kiarash Riazi, MSc, Epidemiology, Department of Community Health Sciences

2019 - 2021 MSc Thesis (defended July 8, 2021)

Topic: Global Epidemiology of NAFLD

Current Position: Research Associate, University of Calgary

James King, MSc, Epidemiology, Department of Community Health Sciences

2017 – 2019 MSc Thesis (defended September 8, 2019)

2 papers, Topic: Global Epidemiology of Celiac Disease

4 abstracts Funded by a JA Campbell Young Investigator Award from the National Celiac Association.

Current Position: Senior Analyst, Alberta Health Services

Stephanie Coward, PhD & MSc, Epidemiology, Department of Community Health Sciences

2014 – 2019 PhD Thesis (defended June 4, 2019)

9 papers Topic: Predicting the Burden of Inflammatory Bowel Disease in Canada

3 abstracts Funded by a Killam Scholarship

Current Position: Epidemiologist, IBD Unit, University of Calgary

2012 – 2014 MSc Thesis (defended June 16, 2014)

1 paper Topic: Funding a Smoking Cessation Program for Crohn's Disease: An Economic Evaluation

7 abstracts

Ellen Kuenzig, PhD, Epidemiology, Department of Community Health Sciences

2012 – 2016 PhD Thesis (defended September 21, 2016)

9 papers Topic: Gene-environment Interactions in Crohn's Disease

12 abstracts Funded by AIMS Award

Current Position: Senior Research Associate, SickKids Hospital, Toronto

Alex Frolkis, PhD, Epidemiology, Department of Community Health Sciences

2010 – 2014 PhD Thesis (defended May 16, 2014)

9 papers Topic: Smoking and Surgery in Crohn's Disease

16 abstracts Funded by AHFMR Studentship Award

Current Position: Gastroenterology Fellow, University of Calgary

Ing Soon, MSc, Epidemiology, Department of Community Health Sciences

2009 – 2012 MSc Thesis (defended February 3, 2012)

5 papers Topic: Epidemiology of Pediatric Inflammatory Bowel Disease

5 papers Funded by Alberta Children's Hospital Research Institute Research Fellowship

Current Position: Pediatric Gastroenterologist in Brunei

Natalie Molodecky, MSc, Epidemiology, Department of Community Health Sciences

2009 – 2011 MSc Thesis (defended June 3, 2011)

7 papers Topic: Validating a coding algorithm for PSC

4 abstracts Funded by AHFMR Studentship

Gilaad G. Kaplan, MD, MPH, FRCPC, CAGF, AGAF, FCAHS, Killam Laureate

Current Position: Epidemiologist, Imperial College London, UK

Co-Supervisor

James King, PhD, Epidemiology, Department of Community Health Sciences
2022 – present PhD Thesis

Jocelyn Jeong, MSc, Epidemiology, Department of Community Health Sciences
2017 – 2021 MSc Thesis

Sangmin (Sarah) Lee, MSc, Epidemiology, Department of Community Health Sciences
2015 – 2017 MSc Thesis (defended April 5, 2017)
1 paper Topic: Vitamin D in Pregnancy in Inflammatory Bowel Disease
2 abstracts Current Position: Medical Student, University of Calgary

Maria Negron, PhD, Epidemiology, Department of Veterinary Medicine
2010 – 2014 PhD Thesis (defended June 27, 2014)
2 papers Topic: Colectomy Risk for Ulcerative Colitis Patients
8 abstracts Funded by Eyes High International PhD Scholarship
Current Position: Epidemiologist at the Centers of Disease Control (CDC), Atlanta, GA, USA

Fox Underwood, MSc, Geography, Department of Geography
2010 – 2012 MSc Thesis (defended December 20, 2012)
2 abstracts Topic: A Geographical Exploration of Inflammatory Bowel Disease
Funded by Alberta IBD Consortium Trainee Award
Current Position: Health Geographer, University of Calgary

Thesis Committee Member

Elnaz Afshar, MSc Thesis Committee
2014 – 2021 Department of Community Health Sciences, Cumming School of Medicine
Department of Geography, Faculty of Arts

Xiaoxiao Liu, PhD Thesis Committee
2012 – 2017 Department of Geography, Faculty of Arts

Michelle North, PhD Thesis Committee
2014 – 2017 Department of Ecosystem and Public Health, Faculty of Veterinary Medicine

Bushra Khokhar, MSc Thesis Committee
2012 – 2014 Department of Community Health Sciences, Cumming School of Medicine

Bijoy Menon, MSc Thesis Committee
2012 – 2014 Department of Community Health Sciences, Cumming School of Medicine

Jennifer deBruyn, MSc Thesis Committee
2008 – 2010 Department of Community Health Sciences, Cumming School of Medicine

Supervision: Undergraduate Students

Primary Supervisor

Michael Buie, BSc

2018, 2019 Summer Studentships
Funded by O'Brien Centre Summer Studentship (2018)

Joshua Quan, BKin

2017, 2018, 2019 Summer Studentships
Funded by CAG Summer Studentship Award (2017)

Nicola Panaccione, BSc

2017 Summer Studentship

Samuel Quan, BHSc

2010 – 2013, 2015 Summer Studentships
Funded by AHFMR/AI-HS Summer Studentship Awards (2010 – 2012)
2012 – 2013 BSc Honours Thesis | MDSC 508
Natural History of Ulcerative Colitis
2009 – 2012 Research Supervision | MDSC 528

Chris Ma, BSc, MD

2008 – 2012 Research Supervision (MDSC 528, Med 440)
2008 – 2009 Summer Studentships
Funded by AHFMR/AI-HS Summer Studentship Award (2009)

Michael Diamant, MD

2010 – 2013 Research Supervision (Med 440)

Debbie Boulton, BHSc

2010 – 2011 Research Supervision (HSOC 408)

Hashim Kareemi, BSc

2010 – 2011 Summer Studentships
Funded by CAG Summer Studentship Award (2011)

Mollie Ferris, MD

2008 – 2010 Research Supervision

Martin Prusinkiewicz, BSc

2009 Summer Studentship
Funded by AGA Summer Studentship Award

Co-Supervisor

Fox Underwood, BSc

2009 Summer Studentship
Funded by Alberta Summer Temporary Employment Program

Patents

Swain, Mark, Abdel Aziz Shaheen, Gilaad Kaplan, and Wagdi Almishri. TREATMENT OF INFLAMMATORY DISORDERS, AUTOIMMUNE DISEASE, AND PBC. UTI Limited Partnership, assignee. Patent WO2019046959A1. PCT/CA2018/051098. 7 Sept. 2018.

Invited Addresses

International

1. 30/09/2024 Four Epidemiologic Stages of IBD. GI Rounds, University of Amsterdam, Amsterdam, Netherlands.
2. 22/06/2024 Four Epidemiologic Stages of IBD. IBD Summit, Chinese University of Hong Kong, Hong Kong.
3. 16/04/2024 IBD around the world: Epidemiology update. Future IBD Meeting, Madrid, Spain.
4. 04/03/2024 State of the Art: Management of Crohn's Disease. University of Otago, Christchurch, New Zealand
5. 08/03/2024 Global Epidemiology of IBD. University of Otago, Christchurch, New Zealand
6. 15/12/2023 Editor's Focus in IBD: *Gastroenterology*. Advances in IBD, Orlando, USA.
7. 12/12/2023 Global Epidemiology of IBD. Brigham Women Hospital, Harvard University, Boston, USA.
8. 12/11/2023 Global Epidemiology of IBD. UCSF Updates in IBD 2023, University of California: San Francisco, San Francisco, USA.
9. 11/11/2023 State of the Art: Management of Crohn's Disease. UCSF Updates in IBD 2023, University of California: San Francisco, San Francisco, USA.
10. 27/5/2023 Looking forward to the incidence and prevalence of IBD in 21st century in the Asia-Pacific region, 2023 Oriental Inflammatory Bowel Disease Forum (Virtual), Shanghai, China.
11. 6/5/2023 Reducing Global IBD Burden: Where are the Knowledge Gaps?, Digestive Disease Week Conference, Chicago, Illinois, USA
12. 5/5/2023 Global Epidemiology of IBD, Pfizer IBD Health Equity Summit, Chicago, Illinois, USA
13. 7/12/2022 Identifying and Managing Bowel Urgency in Ulcerative Colitis. Advances in IBD Annual Meeting, Orlando, Florida, USA
14. 5/12/2022 Epidemiology of Neoplasia in IBD. Advances in IBD Annual Meeting, Orlando, Florida, USA
15. 19/11/2022 COVID-19 and IBD: Lessons Learned in an Evolving Pandemic. International Organization for the study of IBD (IOIBD), Napa, California, USA.
16. 23/9/2022 Environmental Factors: Their Role in IBD Disease Pathogenesis. Can We Prevent IBD? Keynote Address. 15th Annual Inflammatory Bowel Disease: The Art and Science in the Diagnosis and Treatment 2022, Boston, Massachusetts, USA
17. 4/9/2022 COVID-19 vaccines & immunosuppressants: What have we learned? International Digestive Disease Forum (Virtual), Hong Kong
18. 20/8/2022 COVID-19 and IBD - What have we learned so far? Annual Scientific Meeting of the

Gilaad G. Kaplan, MD, MPH, FRCPC, CAGF, AGAF, FCAHS, Killam Laureate

- Malaysian Society of Gastroenterology and Hepatology (In person), Kuala Lumpur, Malaysia
19. 21/8/2022 Stages of Global Evolution of IBD. Annual Scientific Meeting of the Malaysian Society of Gastroenterology and Hepatology (In person), Kuala Lumpur, Malaysia
 20. 22/7/2022 The Global Evolution of IBD in the Time of a Pandemic. Gastroenterology Rounds, University of Chicago, Chicago, Illinois
 21. 13/02/2022 Stages in the Global Evolution of IBD. Annual Conference of Indian Society of Gastroenterology (ISGCON), Pune, India (Virtual).
 22. 12/12/2021 IBD Epidemiology Around the Globe. Improving Care for Diverse Patient Communities with IBD Consensus Conference (In person), Atlanta, Georgia, USA.
 23. 10/12/2021 IBD Epidemiology Around the Globe (Keynote Address). Advances in Inflammatory Bowel Disease Conference (In person). Orlando, Florida, USA.
 24. 9/12/2021 Understanding Methodology for Clinical Practice (Small Group Session). Advances in Inflammatory Bowel Disease Conference (In person). Orlando, Florida, USA.
 25. 28/11/2021 Epidemiology of IBD and risk factors around the world. The Italian Group for the study of Inflammatory Bowel Disease Conference, Italy (Virtual).
 26. 19/11/2021 IBD Epidemiology: Where Are We Going? Inflammatory Bowel Disease Colombian virtual course, Colombian Gastroenterology Association, Columbia (Virtual)
 27. 20/11/2021 Four epidemiological stages of inflammatory bowel diseases. BRICS Symposium, Shanghai, China (Virtual)
 28. 20/11/2021 Use of antidepressants in the treatment of depression with IBD. BRICS Symposium, Shanghai, China (Virtual)
 29. 15/10/2021 The Four Epidemiological Stages in the Global Evolution of IBD. Annual Conference of the Asian Organization for Crohn's and Colitis (AOCC), Guangzhou, China (Virtual)
 30. 13/10/2021 Can we prevent IBD? Crohn's & Colitis Foundation Investigators Research Symposium, US (Virtual)
 31. 29/03/2021 The Global Evolution of IBD in the Time of a Pandemic. 5th Annual VEOIBD Consortium Meeting. Boston, MA, USA (Webinar)
 32. 27/03/2021 Epidemiology of IBD: The Great Shift from West to East. Janssen Immunology Summit. Beijing, China. (Webinar)
 33. 16/03/2021 The Global Evolution of IBD in the Time of a Pandemic. Massachusetts General Hospital Gastroenterology Rounds, Boston, MA, USA. (Webinar)
 34. 02/02/2021 The Global Evolution of IBD in the Time of a Pandemic. Mount Sinai Hospital Gastroenterology Rounds, New York, NY, USA. (Webinar)
 35. 14/10/2020 Epidemiology of IBD Latin America. Virtual IBD Brazil Program. (Webinar)
 36. 30/09/2020 The Global Evolution of IBD in the Time of a Pandemic. University of Pennsylvania Gastroenterology Rounds, Philadelphia, PA, USA. (Webinar)
 37. 10/12/2019 The evolution of IBD: from Darwin's Origin of Species to the origin of a modern disease. Gastroenterology Rounds, University of Michigan, Ann Arbor, MI, USA.

Gilaad G. Kaplan, MD, MPH, FRCPC, CAGF, AGAF, FCAHS, Killam Laureate

38. 29/06/2019 Global Epidemiology of IBD: East Meets West. 2019 Oriental Inflammatory Bowel Disease Forum. Shanghai, China.
39. 28/06/2019 Is there still a role for 5-ASA in Crohn's disease? 2019 Asia America Assembly of Inflammatory Bowel Disease. Shanghai, China.
40. 18/05/2019 The Global Epidemiology of IBD: West Meets East. Digestive Disease Week (DDW). San Diego, CA, USA.
41. 27/04/2019 Trends in Hospitalizations and Surgeries in the Biological Era. Annual IBD Conference Multidisciplinary Management of Inflammatory Bowel Diseases. Washington University. St. Louis, MS, USA.
42. 26/04/2019 How environmental risk factors influence the epidemiology of IBD. Gastroenterology Research Conference Rounds. Washington University. St. Louis, MS, USA.
43. 23/03/2019 The evolution of IBD: from Darwin's Origin of Species to the origin of a modern disease. International Organization for the study of IBD (IOIBD). Havana, Cuba.
44. 8/02/2019 Environmental Exposures: 'Doctor, Could I Have Prevented My IBD? Crohn's and Colitis Congress. Las Vegas, NV, USA.
45. 14/01/2019 Clinical Epidemiology: The Rising Incidence of IBD Associated with Industrialization. Keystone Symposium: Host and the Environment in IBD. Taos, New Mexico, USA.
46. 30/06/2018 Risk factors for surgery in IBD. XI Encontro Sulbrasileiro de Doencas Inflamatorias Intestinais, Blumenau, Brazil.
47. 29/06/2018 Are we reducing surgical rates in the biological era? XI Encontro Sulbrasileiro de Doencas Inflamatorias Intestinais, Blumenau, Brazil.
48. 29/06/2018 Epidemiology of IBD in developing countries: what is changing in the 21st century? XI Encontro Sulbrasileiro de Doencas Inflamatorias Intestinais, Blumenau, Brazil.
49. 21/04/2018 The Global Epidemiology of IBD in the 21st Century. Peking Union Medical College Hospital International Digestive Disease Forum, Beijing, China.
50. 20/04/2018 Studying the Epidemiology of IBD: From Systematic Reviews to Clinical Cohorts to Administrative Healthcare Databases. IBD Clinical Epidemiology Workshop. Peking Union Medical College Hospital, Beijing, China.
51. 16/10/2017 Evolving Trends in the Epidemiology of IBD in the 21st Century: A Systematic Review of Population-Based Studies. Presidential Plenary Session, World Congress of Gastroenterology at ACG2017, Orlando, FL, USA.
52. 9/06/2017 Winter is Coming! Addressing the Global Rise of IBD. The Ginzburg and Oppenheimer Annual Lecture. Mount Sinai Hospital, New York, NY, USA.
53. 04/30/2015 IBD in the Next Decade: Preparing for the Challenges Ahead. Gastroenterology Rounds, Northwestern University, Chicago, IL, USA.
54. 04/18/2015 The Global Rise of IBD: Comparing the Western World to Asia. Digestive Endoscopy & Gastrointestinal Disease Conference, Beijing, China.
55. 04/16/2015 Development of a Surveillance Cohort: The Alberta Experience. Peking Union College Medical Hospital Gastroenterology Rounds, Beijing, China.
56. 04/16/2015 Use of Secondary Data in Gastrointestinal Research. Peking Union College Medical

Gilaad G. Kaplan, MD, MPH, FRCPC, CAGF, AGAF, FCAHS, Killam Laureate

- Hospital Epidemiology Rounds, Beijing, China.
57. 05/05/2014 Minimizing risk in the pre- and post-operative period. Symposium: Severe Colitis: more medicines or time for surgery? Digestive Disease Week, Chicago, IL, USA.
58. 27/02/2014 The Global Rise of IBD. Gastroenterology Rounds. University of Texas Southwestern (UTSW), Dallas, TX, USA.
59. 26/02/2013 Lessons from a Regional IBD Cohort in Calgary, Canada. CCFA-CDC Epidemiologic Research in IBD Meeting, Philadelphia, PA, USA.
60. 04/2012 IBD: The New Epidemiology of a Global Disease. Crohn's and Colitis Foundation of America (CCFA) Education Symposium, Chicago, IL, USA.
61. 11/2009 IBD: Molecules to Medicines, Research Rounds, Tel Aviv University, Tel Aviv, Israel.
62. 04/2009 Predicting outcomes and changing natural history in Crohn's disease, CME GI Grand Rounds, New York University School of Medicine, New York, NY, USA.
63. 04/2009 Predicting outcomes and changing natural history in Crohn's disease, CME Grand Rounds, Cleveland Clinic, FL, USA.
64. 03/2009 Tools to predict outcomes in Crohn's disease, CME Grand Rounds, Wright State University, Dayton, OH, USA.
65. 02/2009 Air Pollution and IBD: A Novel Association, Broad Medical Research Program Investigator Meeting, Los Angeles, CA, USA.
66. 01/2009 Environmental Perspectives in IBD, Epidemiology Seminar Rounds, Karolinski Institute, Stockholm, Sweden.
- National***
67. 16/6/2023 2023 Crohn's and Colitis Canada Impact of IBD Report, 26th Annual GI Symposium, University of Manitoba, Winnipeg, MN
68. 03/03/2023 Unmasking our best practices in IBD: How COVID-19 shifted the normal in patient care. Joint Canadian Digestive Disease Week and Canadian Liver Meeting, Halifax, NS
69. 28/01/2023 Epidemiology of IBD – What are the clues? 10th Canadian GI Trainees Program in Inflammatory Bowel Disease, Toronto, ON
70. 8/6/2022 Succeeding in Gastroenterology Research and Practice: Mentorship ABCs. Keynote Address, Resident Research Day, University of Toronto, Toronto, ON
71. 22/02/2022 COVID-19 and IBD, Quebec (Virtual).
72. 07/04/2021 When COVID Meets IBD: What we Know About the Vaccine. McGill University, Montreal, Quebec. (Webinar)
73. 17/03/2021 The Global Epidemiology of Inflammatory Bowel Disease in the Time of a Pandemic, Gastroenterology Rounds, McGill University, Montreal, Quebec (Webinar)
74. 10/03/2021 A year in a Pandemic: COVID-19 and IBD—where we have come, and what lies ahead, GI Connect Program, Atlantic Canada. (Webinar)
75. 10/03/2021 A year in a Pandemic: COVID-19 and IBD—where we have come, and what lies

Gilaad G. Kaplan, MD, MPH, FRCPC, CAGF, AGAF, FCAHS, Killam Laureate

- ahead, GI Connect Program, Ontario. (Webinar)
76. 08/03/2021 A year in a Pandemic: COVID-19 and IBD—where we have come, and what lies ahead, GI Connect Program, Quebec. (Webinar)
 77. 07/11/2020 IBD Research in the COVID-19 World. Canada Future Directions in IBD 2020. Toronto, Ontario. (Webinar)
 78. 18/06/2020 The Global Evolution of IBD in the Time of a Pandemic. QEII GI Rounds, Dalhousie University, Halifax, NS, Canada. (Webinar)
 79. 17/06/2020 The Global Evolution of IBD in the Time of a Pandemic. CHEO Department of Pediatrics Rounds, University of Ottawa, Ottawa, ON, Canada. (Webinar)
 80. 24/10/2019 Addressing the Rising Burden of IBD in Canada. Gastroenterology Rounds. Hamilton, ON, Canada.
 81. 30/10/2019 The evolution of IBD: from Darwin’s Origin of Species to the origin of a modern disease. Department of Medicine, Grand Rounds. University of Saskatchewan. Saskatoon, SK, Canada.
 82. 30/10/2019 Ulcerative Colitis Today and Tomorrow: Making Sense of a Buffet of Medical Options. Gastroenterology Rounds. Saskatoon, SK, Canada.
 83. 16/09/2019 Seniors with IBD. Gastroenterology Rounds. Winnipeg, MB, Canada.
 84. 10/09/2019 Addressing the Rising Burden of IBD in Canada. Gastroenterology Rounds. Vancouver, BC, Canada.
 85. 09/09/2019 Addressing the Rising Burden of IBD in Canada. Gastroenterology Rounds. Victoria, BC, Canada.
 86. 03/11/2018 The Impact of Inflammatory Bowel Disease in Canada (2018) Report. Crohn’s and Colitis Canada Future Directions in IBD Meeting. Toronto, ON, Canada.
 87. 03/04/2018 The IBD Clinic of the Future. City Wide Gastroenterology Rounds, Toronto, ON.
 88. 03/04/2018 Winter is Coming! Addressing the Global Rise of IBD. Gastroenterology Rounds, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada.
 89. 17/01/2018 Winter is Coming! Addressing the Global Rise of IBD. Gastroenterology Rounds, Ottawa University, Ottawa, ON, Canada.
 90. 16/01/2018 Winter is Coming! Addressing the Global Rise of IBD. Gastroenterology Rounds, Queens University, Kingston, ON, Canada.
 91. 4/11/2017 Nature versus Nurture in IBD: Where do we stand? Canada Future Directions in IBD, Crohn’s and Colitis Canada, Toronto, ON, Canada.
 92. 2/11/2017 Can IBD patients access care? Solutions from an Alberta Perspective. National IBD Access Summit, Toronto, ON, Canada.
 93. 26/10/2017 Winter is Coming! Addressing the Global Rise of IBD. GI Grand Rounds, Dalhousie University, Halifax, NS, Canada.
 94. 22/11/2016 Winter is Coming! Addressing the Global Rise of IBD. Connaught Symposium, Toronto, ON, Canada.
 95. 25/07/2016 Environmental Studies in GEM. Crohn’s and Colitis Canada GEM Symposium, Toronto, ON, Canada.

Gilaad G. Kaplan, MD, MPH, FRCPC, CAGF, AGAF, FCAHS, Killam Laureate

96. 02/25/2016 Social Media in Science & Medicine. Research Topics Meeting, Canadian Digestive Disease Week Conference, Montreal, QC, Canada.
97. 07/11/2015 Dietary & Environmental Questions in IBD. Canada Future Directions in IBD. Crohn's and Colitis Canada, Toronto, ON, Canada.
98. 04/24/2015 Globalization of IBD: Meeting the Challenges of the Next Decade. International Organization of IBD, Montreal, QC, Canada.
99. 05/11/2014 IBD and the Environment: Past, Present, and Future. Fancombe Rounds, McMaster University, Hamilton, ON, Canada.
100. 10/02/2014 Non-response to anti-TNF therapy. Canadian Digestive Disease Week, Toronto, ON, Canada.
101. 26/06/2013 Opportunities and Challenges to Advance Environmental Health Research. Plenary Symposium. Canadian Society for Epidemiology and Biostatistics Biennial Conference, St. John's, NL, Canada.
102. 31/05/2013 Preventing Colectomies in Ulcerative Colitis. Hot Topics in Gastroenterology, Annual GI Forum. University of Manitoba, Winnipeg, MB, Canada.
103. 03/03/2013 IBD in the Year 2023: Challenges and Opportunities. 2013 Canadian Association of Gastroenterology Young Investigator Award Lecture. Canadian Digestive Disease Week Conference, Victoria, BC, Canada.
104. 01/03/2013 The Global Rise of IBD. Canadian Digestive Disease Week Conference, Victoria, BC.
105. 06/2012 IBD: The New Epidemiology of a Global Disease. Department of Medicine Grand Rounds, Dalhousie University, Halifax, NS, Canada.
106. 06/2012 The Sick Ulcerative Colitis Patient: 21st Century Approach to Management. St. Joseph Hospital, Hamilton, ON, Canada.
107. 06/2012 The Sick Ulcerative Colitis Patient: 21st Century Approach to Management. Sunnybrook Hospital, Toronto, ON, Canada.
108. 06/2012 The Sick Ulcerative Colitis Patient: 21st Century Approach to Management. South Western Ontario Gastroenterology Association Annual Conference, ON, Canada.
109. 02/2012 The Environment and IBD: Challenges and Future Directions, CIHR Workshop 'Environment, Genes, and Chronic Diseases', Ottawa, ON, Canada.
110. 11/2011 IBD and the Environment, Canada Future Directions in IBD, Toronto, ON, Canada.
111. 11/2011 Rising Star Seminar: How do I succeed in IBD, Canada Future Directions in IBD, Toronto, ON, Canada.
112. 06/2011 Environment and IBD, Memorial University, Department of Medicine Grand Rounds, St. Johns, NL, Canada.
113. 06/2011 Ulcerative Colitis Management in the 21st Century, Dalhousie University GI Rounds, Halifax, NB, Canada.
114. 06/2011 Environment and IBD, McGill University, Royal Victoria Hospital, GI Rounds, Montreal, QC, Canada.
115. 06/2011 Environment and IBD, University of Ottawa, GI Rounds, Ottawa, ON, Canada.
116. 06/2011 Ulcerative Colitis Management in the 21st Century, St. Mikes Hospital, GI Rounds,

Gilaad G. Kaplan, MD, MPH, FRCPC, CAGF, AGAF, FCAHS, Killam Laureate

- Toronto, ON, Canada.
117. 03/2011 Perianal Crohn's disease and refractory ulcerative proctitis, Small Group Session, Canadian Digestive Disease Week, Vancouver, BC, Canada.
 118. 02/2011 Biostats primer for researchers. Research Topics Meetings. Vancouver, BC.
 119. 12/2010 Ulcerative colitis management in the 21st century. GI Seminars, Regina, SK.
 120. 11/2010 Ulcerative colitis management in the 21st century. GI Seminars, Saskatoon, SK.
 121. 09/2010 Optimizing outcomes in ulcerative colitis. Grand Rounds. Hospital for Sick Children, Toronto, ON, Canada.
 122. 09/2010 Air Pollution: A Gastroenterologist's Perspective. Research Seminar. Mount Sinai Hospital, Toronto, ON, Canada.
 123. 05/2010 Biologics in Ulcerative Colitis and Crohn's Disease, B.C. Digestive Disease Weekend, Victoria, BC, Canada.
 124. 11/2009 Appendicitis and Air Pollution – A Novel Association, Gastroenterology Grand Rounds, University of Manitoba, Winnipeg, MB, Canada.
 125. 04/2009 Progress and challenges measuring the impact of the environment on IBD, IBD 2009, Toronto, ON, Canada.
 126. 01/2008 Air Pollution and IBD, Health Canada, Ottawa, ON, Canada.
- Provincial
(Alberta)***
127. 31/5/2023 Four Epidemiological Stages in the Evolution of IBD, Epidemiology of IBD Symposium, University of Calgary, Calgary, AB
 128. 07/09/2022 COVID-19 and IBD: What have we learned by September 2022? The Inflammatory Bowel Disease Group Rounds, University of Calgary, Calgary
 129. 15/12/2021 COVID-19 Antibodies Following Vaccination for COVID-19 in IBD, IBD Rounds, University of Calgary, Calgary, Alberta.
 130. 28/06/2021 When COVID meets IBD. Digestive Health Strategic Clinical Network, Core Committee Meeting, Alberta (Webinar)
 131. 16/02/2021 The Global Evolution of IBD in the Time of a Pandemic. Department of Medicine Grand Rounds, University of Calgary, Calgary, AB, Canada. (Webinar)
 132. 28/01/2021 The impact of COVID-19 on the IBD Community. Alberta Digestive Disease Summit Virtual Series. AB, Canada. (Webinar)
 133. 07/08/2019 The Burden of IBD: Innovating IBD Care in Alberta. Gastroenterology Rounds. Lethbridge, AB, Canada.
 134. 02/06/2019 IBD Expert Panel Discussion. Alberta Digestive Disease Summit (ADDS). Lake Louise, AB, Canada.
 135. 31/05/2019 Your Digestive Health SCN: A Roadmap to Improving Care for Digestive Diseases. Alberta Digestive Disease Summit (ADDS). Lake Louise, AB, Canada.
 136. 22/05/2019 The Burden of IBD. Gastroenterology Rounds. Red Deer, AB, Canada.
 137. 02/03/2019 Career Workshop Symposium. Canadian Digestive Disease Week Conference.

Gilaad G. Kaplan, MD, MPH, FRCPC, CAGF, AGAF, FCAHS, Killam Laureate

- Banff, AB, Canada.
138. 25/11/2018 IBD Case Challenge. Optimizing the Care of the IBD Patient: Today and Tomorrow Conference. Banff, AB, Canada.
 139. 24/11/2018 Impact of IBD in Canada. Optimizing the Care of the IBD Patient: Today and Tomorrow Conference. Banff, AB, Canada.
 140. 22/11/2018 Global Epidemiology of IBD. Taiwanese Program – IBD Clinic, University of Calgary.
 141. 24/09/2018 The Burden of IBD & A Provincial Update – The Digestive Health Strategic Clinical Network. City Wide Gastroenterology Rounds, Edmonton, AB, Canada.
 142. 16/04/2018 The IBD Clinic of the Future. City Wide Gastroenterology Rounds, Calgary, AB.
 143. 23/01/2018 An Epidemiology Update In Gastroenterology: An Alberta Perspective. Gastroenterology Rounds, Red Deer, AB, Canada.
 144. 1/05/2017 Winter is Coming! Addressing the Global Rise of IBD. Gastroenterology Grand Rounds, University of Alberta, Edmonton, AB, Canada.
 145. 26/04/2017 Winter is Coming! Addressing the Global Rise of IBD. Lunch and Learn, University of Calgary, Calgary, AB, Canada.
 146. 13/04/2017 Winter is Coming! Addressing the Global Rise of IBD. GIRG Research Day, Calgary.
 147. 13/05/2016 Innovating the Delivery of Healthcare through the Strategic Clinical Network in Digestive Health: IBD as a Model. State-of-the-Art Lecture, Division of Gastroenterology, Calgary, AB, Canada.
 148. 09/01/2016 Investigating the Cause of a Modern Disease of Modern Times. Conquering Crohn’s and Colitis, Patient Education Day. University of Calgary, Calgary, AB.
 149. 05/26/2015 Collaborative Research in Gastroenterology and Rheumatology. Immune Mediated Inflammatory Disease Working Group Seminar. Calgary, AB, Canada.
 150. 02/25/2015 Genes, Environment, and Microbes: Lessons from Inflammatory Bowel Disease. Alberta Children’s Hospital Research Institute Healthy Outcomes Theme Rounds, University of Calgary, Calgary, AB, Canada.
 151. 30/01/2015 Genes, Environment, and Microbes: Lessons from the Inflammatory Bowel Diseases and its Overlap with Asthma. Respiratory Clinical Academic Rounds, University of Calgary, Calgary, AB, Canada.
 152. 30/09/2014 Panelist, Thought Leader Forum on Coal and Health, University of Calgary, Calgary.
 153. 19/09/2014 The Clinician Scientists: An Unexpected Journey. Leaders in Medicine, University of Calgary, Calgary, AB, Canada.
 154. 16/05/2014 Colectomy for Ulcerative Colitis: The dodo bird of UC management? Gastroenterology Rounds, University of Calgary, Calgary, AB, Canada.
 155. 21/03/2014 The Health Improvement Network (THIN) Database, The Department of Community Health Sciences and the Institute for Public Health Seminar, University of Calgary, Calgary, AB, Canada.
 156. 31/01/2014 Environmental Health Research in the 21st Century: IBD as a Model. Autoimmune Disease Network. University of Calgary, Calgary, AB, Canada.
 157. 20/01/2014 The Global Burden of IBD, Working Together for Better Health Symposium,

Gilaad G. Kaplan, MD, MPH, FRCPC, CAGF, AGAF, FCAHS, Killam Laureate

- University of Calgary, Calgary, AB, Canada.
158. 08/05/2013 The Global Rise of IBD. Rotary Club, Calgary, AB, Canada.
 159. 11/04/2013 Advisory Board Presentation, CIHR's Institute of Health Services and Policy Research, Calgary, AB, Canada.
 160. 11/2012 IBD and the Elderly. Western Canadian IBD Symposium, Banff, AB, Canada.
 161. 11/2012 IBD and EIM: What is the right treatment? Immune Mediated Inflammatory Disease Working Group Seminar, Calgary, AB, Canada.
 162. 03/2012 The Sick Ulcerative Colitis Patient: 21st Century Approach to Management. Gut Journal Club, Edmonton, AB, Canada.
 163. 03/2012 Genetics, Environment and the Inflammatory Bowel Diseases. CCFC Chapter Symposium, Lethbridge, AB, Canada.
 164. 03/2012 Air Pollution and IBD: Blowing Smoking? Alberta Occupational and Environmental Health Symposium, Calgary, AB, Canada.
 165. 06/2011 The Top Clinical Studies from Administrative Databases, Post DDW Review Course, Lake Louise, AB, Canada.
 166. 03/2011 Air pollution as a trigger for the inflammatory bowel disease. Gastrointestinal Research Group Conference, Banff, AB, Canada.
 167. 08/2010 Air Pollution: A Gastroenterologist's Perspective. Medical School Reunion. CME Talk, Kananaskis, AB, Canada.
 168. 06/2010 The Presidential Posters, Post DDW Review Course, Lake Louise, AB, Canada.
 169. 05/2010 Epidemiology of IBD: Clues to Pathogenesis, CME Talk, Division of Gastroenterology, University of Calgary, Calgary, AB, Canada.
 170. 02/2010 The Environment and IBD: Challenge and Progress, Department of Community Health Sciences Seminar Rounds, University of Calgary, Calgary, AB, Canada.
 171. 01/2010 Appendicitis and Air Pollution: Clues to Pathogenesis, Internal Medicine Grand Rounds, University of Calgary, Calgary, AB, Canada.
 172. 11/2009 Population-based Alberta IBD Study. CCFC and You Symposium, Calgary, AB.
 173. 09/2009 Combination Therapy in IBD – The Final Word, Alberta Society of Gastroenterology Annual Meeting, Kananaskis, AB, Canada.
 174. 02/2009 IBD: Past, Present, and Future, CAG Symposium, CDDW, Banff, AB, Canada.
 175. 11/2008 Optimizing Postoperative Outcomes in IBD, Western Canada IBD Symposium, Lake Louise, AB, Canada.
 176. 11/2008 Epidemiology of IBD: Clues for future research, Canadian GI Resident Program in IBD, Calgary, AB, Canada.
 177. 10/2008 Gene-environment interactions in IBD: Clues to Pathogenesis, Canadian MAP Researchers Meeting, Banff, AB, Canada.
 178. 09/2008 Environment and IBD: A Translational Approach, Alberta Society for Gastroenterology, Banff, AB, Canada.
 179. 09/2008 Translational Research in IBD, Snyder III Research Day, University of Calgary,

Gilaad G. Kaplan, MD, MPH, FRCPC, CAGF, AGAF, FCAHS, Killam Laureate

- Calgary, AB, Canada.
180. 01/2008 Administrative databases for IBD Research, Gastrointestinal Research Group Conference, Banff, AB, Canada.
 181. 11/2007 Environmental Risk Factors of IBD. Gastrointestinal Research Group Seminars, Calgary, AB, Canada.
 182. 11/2007 IBD and the Environment. Western Canada IBD Retreat, Banff, AB, Canada.
 183. 09/2007 Historical Perspective on Ulcerative Colitis, Department of Medicine Grand Rounds, University of Calgary, Calgary, AB, Canada.

Publications: Peer Reviewed

Citations by Year (Citations as of October 25, 2024): [Gilaad G. Kaplan | Web of Science](#)



Kaplan, Gilaad G. ✓

Highly cited

University of Calgary

Web of Science ResearcherID: AAH-2335-2021

72

H-Index

28,904

Sum of Times Cited

312

Publications

22,134

Citing Articles

Senior Author Papers that Highlight My Career

1. Gros B, Kaplan GG. Ulcerative colitis in adults: a review. *JAMA*. 2023;330(10):951-965.
2. Molodecky N, Soon IS, Rabi D, Ghali W, Ferris M, Chernoff G, Benchimol E, Panaccione R, Ghosh S, Barkema H, and Kaplan GG. Increasing Incidence of Inflammatory Bowel Disease with Time and Among Regions, Based on Systematic Review. *Gastroenterology*. (Impact Factor: 22.68). 2012 Jan; 142(1): 46-54. Citations: 3,447.
3. Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, Panaccione R, Ghosh S, Wu JCY, Chan FKL, Sung JY, Kaplan GG. The Worldwide Incidence and Prevalence of Inflammatory Bowel Disease in the 21st Century: A Systematic Review of Population-Based Studies. *The Lancet*. (Impact Factor: 202.7). 2017 Dec 23;390(10114):2769-2778. Citations: 3,570.
4. Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. *Nature Reviews: Gastroenterology and Hepatology*. (Impact Factor: 73.08). 2021 Jan;18(1):56-66. Citations: 550.
5. Kaplan GG. The Global Burden of Inflammatory Bowel Disease: From 2015 to 2025. *Nature Reviews: Gastroenterology and Hepatology*. (Impact Factor: 73.08). 2015 Dec;12(12):720-7. Citations: 1,652.
6. Coward S, Clement F, Benchimol EI, Bernstein CN, Avina-Zubieta A, Bitton A, Carroll MW, Hazlewood G, Jacobson K, Jelinski S, Deardon R, Jones JL, Kuenzig ME, Leddin D, McBrien KA, Murthy SK, Nguyen GC, Otley AR, Panaccione R, Rezaie A, Rosenfeld G, Peña-Sánchez JN, Singh H, Targownik LE, and Kaplan GG. Past and Future Burden of Inflammatory Bowel Diseases Based on Modeling of Population-based Data. *Gastroenterology*. (Impact Factor: 33.88). 2019 Apr;156(5):1345-1353. Citations: 234.
7. Quan J, Ma C, Panaccione R, Hracs L, Sharifi N, Herauf M, Markovinović A, Coward S, Windsor JW, Caplan L, Ingram RJM, Charlton C, Kanji JN, Tipples G, Holodinsky JK, Bernstein CN, Mahoney DJ, Bernatsky S, Benchimol EI, Kaplan GG; STOP COVID-19 in IBD Research Group. Serological responses

to the first four doses of SARS-CoV-2 vaccine in patients with inflammatory bowel disease. *Lancet Gastroenterol Hepatol.* (Impact Factor: 33.9). 2022 Dec;7(12):1077-1079.

8. King JA, Jeong J, Underwood FE, Quan J, Panaccione N, Windsor JW, Coward S, deBruyn J, Ronksley PE, Shaheen AA, Quan H, Godley J, Veldhuyzen van Zanten S, Lebowitz B, Ng SC, Ludvigsson JF, **Kaplan GG**. Incidence of Celiac Disease Is Increasing Over Time: A Systematic Review and Meta-analysis. *American Journal of Gastroenterology.* (Impact Factor: 12.05) 2020 Apr;115(4):507-525. Citations: 200.
9. Frolkis AD, Dykeman J, Negron ME, deBruyn J, Jette N, Fiest KM, Frolkis T, Barkema H, Rioux KP, Panaccione R, Ghosh S, Wiebe S, **Kaplan GG**. Risk of Surgery for the Inflammatory Bowel Diseases has Decreased Over Time: A Systematic Review and Meta-Analysis of Population-Based Studies. *Gastroenterology.* (Impact Factor: 33.88). Nov 2013;145(5):996-1006. Citations: 610.
10. **Kaplan GG**, Hubbard JN, Korzenik J, Sands BE, Panaccione R, Ghosh S, Wheeler AJ, and Villeneuve P. The Inflammatory Bowel Diseases and Ambient Air Pollution: A Novel Association. *American Journal of Gastroenterology.* (Impact Factor: 12.05). 2010; 105(11): 2412-9. Citations: 172.

All Peer-Reviewed Publications *Denotes Senior Author. Trainees underlined.

1. Hitchon CA, Bowdish DME, Boire G, Fortin PR, Flamand L, Chandran V, Dayam RM, Gingras AC, Card CM, Colmegna I, Larché MJ, **Kaplan GG**, Lukusa L, Lee JLF, Bernatsky S, On Behalf Of The Succeed Investigative Team. Methotrexate and Tumor Necrosis Factor Inhibitors Independently Decrease Neutralizing Antibodies after SARS-CoV-2 Vaccination: Updated Results from the SUCCEED Study. *Vaccines (Basel)*. 2024 Sep 17;12(9):1061. doi: 10.3390/vaccines12091061. PMID: 39340091; PMCID: PMC11436066.
2. Tsyruk O, **Kaplan GG**, Fortin PR, Hitchon CA, Chandran V, Larché MJ, Avina-Zubieta A, Boire G, Colmegna I, Lacaille D, Lalonde N, Proulx L, Richards DP, Boivin N, DeBow C, Kovalova-Wood L, Paleczny D, Wilhelm L, Lukusa L, Pereira D, Lee JL, Bernatsky S, On Behalf Of The Succeed Investigative Team. How Safe Are COVID-19 Vaccines in Individuals with Immune-Mediated Inflammatory Diseases? The SUCCEED Study. *Vaccines (Basel)*. 2024 Sep 8;12(9):1027. doi: 10.3390/vaccines12091027. PMID: 39340057; PMCID: PMC11436126.
3. Burisch J, Claytor J, Hernandez I, Hou JK, **Kaplan GG***. The cost of IBD care - how to make it sustainable. *Clin Gastroenterol Hepatol*. 2024 Aug 14:S1542-3565(24)00729-8. doi: 10.1016/j.cgh.2024.06.049. Epub ahead of print. PMID: 39151644.
4. Ahmed NS, Krawchuk S, Buhler KA, Solitano V, Jairath V, Shaheen AA, Seow CH, Novak KL, Ingram RJM, Lu C, Kotze PG, **Kaplan GG**, Panaccione R, Ma C. US National Estimates of Contemporary Mortality Rates in Patients with Ulcerative Colitis Undergoing Colectomy. *Am J Gastroenterol*. 2024 Aug 14. doi: 10.14309/ajg.0000000000003031. Epub ahead of print. PMID: 39140476.
5. **Kaplan GG***. Monoclonal Antibody Risankizumab for Ulcerative Colitis. *JAMA*. 2024 Sep 17;332(11):877-878. doi: 10.1001/jama.2024.8819. PMID: 39037779.
6. Kuenzig ME, Walters TD, Mack DR, Griffiths AM, Duchon R, Bernstein CN, **Kaplan GG**, Otley AR, El-Matary W, Yu W, Wang X, Guan J, Crowley E, Sherlock M, Carman N, Fung SG, Benchimol EI. High Healthcare Costs in Childhood Inflammatory Bowel Disease: Development of a Prediction Model Using Linked Clinical and Health Administrative Data. *Inflamm Bowel Dis*. 2024 Jul 19:izae148. doi: 10.1093/ibd/izae148. Epub ahead of print. PMID: 39028498.
7. Systrom HK, Rai V, Singh S, Baidoo L, Cheifetz AS, Devlin SM, Gecse KB, Irving PM, **Kaplan GG**, Kozuch PL, Ullman T, Sparrow MP, Melmed GY, Siegel CA. When Perfect Is the Enemy of Good: Results of a

RAND Appropriateness Panel on Treat to Target in Asymptomatic IBD. *Am J Gastroenterol.* 2024 Jul 15. doi: 10.14309/ajg.0000000000002964. Epub ahead of print. PMID: 39008539.

8. Murthy SK, Tandon P, Matthews P, Ahmed F, Pugliese M, Taljaard M, **Kaplan GG**, Coward S, Bernstein C, Benchimol EI, Kuenzig ME, Targownik LE, Singh H; Canadian Gastro-Intestinal Epidemiology Consortium (CanGIEC). A Population-Based Matched Cohort Study of Digestive System Cancer Incidence and Mortality in Individuals With and Without Inflammatory Bowel Disease. *Am J Gastroenterol.* 2024 Jun 25. doi: 10.14309/ajg.0000000000002900. Epub ahead of print. PMID: 38916226.
9. Bowdish DME, Chandran V, Hitchon CA, **Kaplan GG**, Avina-Zubieta JA, Fortin PR, Larché MJ, Boire G, Gingras AC, Dayam RM, Colmegna I, Lukusa L, Lee JLF, Richards DP, Pereira D, Watts TH, Silverberg MS, Bernstein CN, Lacaille D, Benoit J, Kim J, Lalonde N, Gunderson J, Allard-Chamard H, Roux S, Quan J, Hracs L, Turnbull E, Valerio V, Bernatsky S; SUCCEED Investigative Team. When Should I Get My Next COVID-19 Vaccine? Data From the Surveillance of Responses to COVID-19 Vaccines in Systemic Immune-Mediated Inflammatory Diseases (SUCCEED) Study. *J Rheumatol.* 2024 Jul 1;51(7):721-727. doi: 10.3899/jrheum.2023-1214. PMID: 38621797.
10. Marshall DA, MacDonald KV, Kao D, Bernstein CN, **Kaplan GG**, Jijon H, Hazlewood G, Panaccione R, Nasser Y, Raman M, Moayyedi P. Patient preferences for active ulcerative colitis treatments and fecal microbiota transplantation. *Ther Adv Chronic Dis.* 2024 Mar 26;15:20406223241239168. doi: 10.1177/20406223241239168. PMID: 38544906; PMCID: PMC10966996.
11. Bernstein CN, Panaccione R, Nugent Z, Marshall DA, **Kaplan GG**, Vanner S, Dieleman LA, Graff LA, Otley A, Jones J, Buresi M, Murthy S, Borgaonkar M, Bressler B, Bitton A, Croitoru K, Sidani S, Fernandes A, Moayyedi P. Crohn's Disease Phenotypes and Associations With Comorbidities, Surgery Risk, Medications and Nonmedication Approaches: The MAGIC in IMAGINE Study. *Inflamm Bowel Dis.* 2024 Mar 27:iaze055. doi: 10.1093/ibd/iaze055. Epub ahead of print. PMID: 38537257.
12. Herauf M, Coward S, Peña-Sánchez JN, Bernstein CN, Benchimol EI, **Kaplan GG***; Canadian Gastro-Intestinal Epidemiology Consortium. Commentary on the Epidemiology of Inflammatory Bowel Disease in Compounding Prevalence Nations: Toward Sustaining Healthcare Delivery. *Gastroenterology.* 2024 Jun;166(6):949-956. doi: 10.1053/j.gastro.2024.02.016. Epub 2024 Feb 18. PMID: 38378092.
13. Kuenzig ME, Stukel TA, Carroll MW, **Kaplan GG**, Otley AR, Singh H, Bitton A, Fung SG, Spruin S, Coward S, Cui Y, Nugent Z, Griffiths AM, Mack DR, Jacobson K, Nguyen GC, Targownik LE, El-Matary W, Bernstein CN, Dummer TJB, Jones JL, Lix LM, Murthy SK, Peña-Sánchez JN, Nasiri S, Benchimol EI; Canadian Gastro-Intestinal Epidemiology Consortium. Variation in the Care of Children with Inflammatory Bowel Disease Within and Across Canadian Provinces: A Multi-Province Population-Based Cohort Study. *Clin Epidemiol.* 2024 Feb 14;16:91-108. doi: 10.2147/CLEP.S449183. PMID: 38374886; PMCID: PMC10875172.
14. Kuenzig ME, Bitton A, Carroll MW, Otley AR, Singh H, **Kaplan GG**, Stukel TA, Mack DR, Jacobson K, Griffiths AM, El-Matary W, Targownik LE, Nguyen GC, Jones JL, Murthy SK, Bernstein CN, Lix LM, Peña-Sánchez JN, Dummer TJB, Spruin S, Fung SG, Nugent Z, Coward S, Cui Y, Coulombe J, Filliter C, Benchimol EI. Health Services Utilization and Specialist Care in Pediatric Inflammatory Bowel Disease: A Multiprovince Population-Based Cohort Study. *Inflamm Bowel Dis.* 2024 Feb 16:iaze010. doi: 10.1093/ibd/iaze010. Epub ahead of print. PMID: 38366807.
15. Brunet-Mas E, Garcia-Sagué B, Vela E, Melcarne L, Llovet LP, Pontes C, García-Iglesias P, Puy A, Lario S, Ramirez-Lazaro MJ, Villoria A, Burisch J, **Kaplan GG**, Calvet X. Economic impact of inflammatory

- bowel disease in Catalonia: a population-based analysis. *Therap Adv Gastroenterol*. 2024 Feb 14;17:17562848231222344. doi: 10.1177/17562848231222344.
16. Balderramo D, Quaresma AB, Olivera PA, Savio MC, Villamil MPG, Panaccione R, Ng SC, **Kaplan GG**, Kotze PG. Challenges in the diagnosis and treatment of inflammatory bowel disease in Latin America. *Lancet Gastroenterol Hepatol*. 2024 Mar;9(3):263-272. doi: 10.1016/S2468-1253(23)00284-4. PMID: 38340754.
 17. Coward S, Benchimol EI, Bernstein CN, Avina-Zubieta A, Bitton A, Carroll MW, Cui Y, Hoentjen F, Hrats L, Jacobson K, Jones JL, King J, Kuenzig ME, Lu N, El-Matary W, Murthy SK, Nugent Z, Otley AR, Panaccione R, Peña-Sánchez JN, Singh H, Targownik LE, White D, Windsor JW, **Kaplan GG***; Canadian Gastro-Intestinal Epidemiology Consortium (CanGIEC). Forecasting the Incidence and Prevalence of Inflammatory Bowel Disease: A Canadian Nationwide Analysis. *Am J Gastroenterol*. 2024 Aug 1;119(8):1563-1570. doi: 10.14309/ajg.0000000000002687. Epub 2024 Feb 1. PMID: 38299598; PMCID: PMC11288393.
 18. Forbes AJ, Frampton CMA, Day AS, **Kaplan GG**, Gearry RB. The Epidemiology of Inflammatory Bowel Disease in Oceania: A Systematic Review and Meta-Analysis of Incidence and Prevalence. *Inflamm Bowel Dis*. 2023 Dec 30:izad295. doi: 10.1093/ibd/izad295. Epub ahead of print. PMID: 38159083.
 19. Ray CM, **Kaplan GG**, Ma C. Eosinophilic Esophagitis: Seeing Only the Tip of the Iceberg. *Clin Gastroenterol Hepatol*. 2024 Sep;22(9):1958-1959. doi: 10.1016/j.cgh.2023.12.017. Epub 2023 Dec 24. PMID: 38147944.
 20. Cooper J, Markovinovic A, Coward S, Herauf M, Shaheen AA, Swain M, Panaccione R, Ma C, Lu C, Novak K, Kroeker KI, Ng SC, **Kaplan GG***. Incidence and Prevalence of Primary Sclerosing Cholangitis: A Meta-analysis of Population-based Studies. *Inflamm Bowel Dis*. 2023 Dec 5:izad276. doi: 10.1093/ibd/izad276. Epub ahead of print. PMID: 38052097.
 21. Quan J, Markovinović A, Hrats L, Ma C, Panaccione R, **Kaplan GG***; STOP COVID-19 in IBD Research Group. Bivalent mRNA SARS-CoV-2 vaccination in patients with inflammatory bowel disease. *Lancet Gastroenterol Hepatol*. 2023 Dec;8(12):1074-1075. doi: 10.1016/S2468-1253(23)00310-2. Epub 2023 Oct 6. PMID: 37813111.
 22. Khan R, Kuenzig ME, Tang F, Im JHB, Widdifield J, McCurdy JD, **Kaplan GG**, Benchimol EI. Venous Thromboembolism After COVID-19 Infection Among People With and Without Immune-Mediated Inflammatory Diseases. *JAMA Netw Open*. 2023 Oct 2;6(10):e2337020. doi: 10.1001/jamanetworkopen.2023.37020. PMID: 37812417; PMCID: PMC10562941.
 23. Gros B, **Kaplan GG***. Ulcerative colitis in adults: a review. *JAMA*. 2023;330(10):951-965. doi:10.1001/jama.2023.15389
 24. Windsor JW, Kuenzig ME, Murthy SK, Bitton A, Bernstein CN, Jones JL, Lee K, Targownik LE, Peña-Sánchez JN, Rohatinsky N, Ghandeharian S, Im JHB, Davis T, Weinstein J, Goddard Q, Benchimol EI, **Kaplan GG***. The 2023 Impact of Inflammatory Bowel Disease in Canada: Executive Summary. *J Can Assoc Gastroenterol*. 2023 Jun 1;6(Suppl 2):S1-S8. doi: 10.1093/jcag/gwad003. PMID: 37674500.
 25. Coward S, Benchimol EI, Kuenzig ME, Windsor JW, Bernstein CN, Bitton A, Jones JL, Lee K, Murthy SK, Targownik LE, Peña-Sánchez JN, Rohatinsky N, Ghandeharian S, Im JHB, Davis T, Weinstein J, Goddard Q, Bennett J, Caplan L, Bergevin M, Yang XY, Mason K, Sanderson R, Brass C, **Kaplan GG***. The 2023 Impact of Inflammatory Bowel Disease in Canada: Epidemiology of IBD. *J Can Assoc Gastroenterol*. 2023 Sep 5;6(Suppl 2):S9-S15. doi: 10.1093/jcag/gwad004. PMID: 37674492.
 26. El-Matary W, Carroll MW, Deslandres C, Griffiths AM, Kuenzig ME, Mack DR, Wine E, Weinstein J, Geist R, Davis T, Chan J, Khan R, Matthews P, **Kaplan GG**, Windsor JW, Bernstein CN, Bitton A, Coward S, Jones JL, Lee K, Murthy SK, Targownik LE, Peña-Sánchez JN, Rohatinsky N, Ghandeharian

- S, Im JHB, Goddard Q, Gorospe J, Verdugo J, Morin SA, Morganstein T, Banning L, Benchimol EI. The 2023 Impact of Inflammatory Bowel Disease in Canada: Special Populations-Children and Adolescents with IBD. *J Can Assoc Gastroenterol*. 2023 Sep 5;6(Suppl 2):S35-S44. doi: 10.1093/jcag/gwad016. PMID: 37674497; PMCID: PMC10478811.
27. Shaffer SR, Kuenzig ME, Windsor JW, Bitton A, Jones JL, Lee K, Murthy SK, Targownik LE, Peña-Sánchez JN, Rohatinsky N, Ghandeharian S, Tandon P, St-Pierre J, Natt N, Davis T, Weinstein J, Im JHB, Benchimol EI, **Kaplan GG**, Goddard Q, Gorospe J, Bergevin M, Silver K, Bowles D, Stewart M, Pearlstein M, Dawson EH, Bernstein CN. The 2023 Impact of Inflammatory Bowel Disease in Canada: Special Populations-IBD in Seniors. *J Can Assoc Gastroenterol*. 2023 Sep 5;6(Suppl 2):S45-S54. doi: 10.1093/jcag/gwad013. PMID: 37674503; PMCID: PMC10478801.
28. Targownik LE, Bollegala N, Huang VH, Windsor JW, Kuenzig ME, Benchimol EI, **Kaplan GG**, Murthy SK, Bitton A, Bernstein CN, Jones JL, Lee K, Peña-Sánchez JN, Rohatinsky N, Ghandeharian S, Davis T, Weinstein J, Im JHB, Jannati N, Khan R, Matthews P, Jones May T, Tabatabavakili S, Jogendran R, Hazan E, Browne M, Meka S, Vukovic S, Jogendran M, Hu M, Osei JA, Wang GY, Sheekha TA, Dahlwi G, Goddard Q, Gorospe J, Nisbett C, Gertsman S, Sousa J, Morganstein T, Stocks T, Weber A, Seow CH. The 2023 Impact of Inflammatory Bowel Disease in Canada: The Influence of Sex and Gender on Canadians Living With Inflammatory Bowel Disease. *J Can Assoc Gastroenterol*. 2023 Sep 5;6(Suppl 2):S55-S63. doi: 10.1093/jcag/gwad011. PMID: 37674498; PMCID: PMC10478807.
29. Kuenzig ME, Im JHB, Coward S, Windsor JW, **Kaplan GG**, Murthy SK, Benchimol EI, Bernstein CN, Bitton A, Jones JL, Lee K, Peña-Sánchez JN, Rohatinsky N, Ghandeharian S, Jones May T, Tabatabavakili S, Jogendran R, Weinstein J, Khan R, Hazan E, Browne M, Davis T, Goddard Q, Gorospe J, Latos K, Mason K, Kerr J, Balche N, Sklar A, Targownik LE. The 2023 Impact of Inflammatory Bowel Disease in Canada: Indirect (Individual and Societal) and Direct Out-of-Pocket Costs. *J Can Assoc Gastroenterol*. 2023 Sep 5;6(Suppl 2):S16-S22. doi: 10.1093/jcag/gwad009.
30. Kuenzig ME, Coward S, Targownik LE, Murthy SK, Benchimol EI, Windsor JW, Bernstein CN, Bitton A, Jones JL, Lee K, Peña-Sánchez JN, Rohatinsky N, Ghandeharian S, Im JHB, Jogendran R, Meka S, Weinstein J, Jones May T, Jogendran M, Tabatabavakili S, Hazan E, Hu M, Osei JA, Khan R, Wang G, Browne M, Davis T, Goddard Q, Gorospe J, Latos K, Mason K, Kerr J, Balche N, Sklar A, **Kaplan GG***. The 2023 Impact of Inflammatory Bowel Disease in Canada: Direct Health System and Medication Costs. *J Can Assoc Gastroenterol*. 2023 Sep 5;6(Suppl 2):S23-S34. doi: 10.1093/jcag/gwad008.
31. Graff LA, Geist R, Kuenzig ME, Benchimol EI, **Kaplan GG**, Windsor JW, Bitton A, Coward S, Jones JL, Lee K, Murthy SK, Peña-Sánchez JN, Targownik LE, Jannati N, Jones May T, Akhtar Sheekha T, Davis T, Weinstein J, Dahlwi G, Im JHB, Amankwah Osei J, Rohatinsky N, Ghandeharian S, Goddard Q, Gorospe J, Gertsman S, Louis M, Wagner R, Brass C, Sanderson R, Bernstein CN. The 2023 Impact of Inflammatory Bowel Disease in Canada: Mental Health and Inflammatory Bowel Disease. *J Can Assoc Gastroenterol*. 2023 Sep 5;6(Suppl 2):S64-S75. doi: 10.1093/jcag/gwad012. PMID: 37674499.
32. Murthy SK, Kuenzig ME, Windsor JW, Matthews P, Tandon P, Benchimol EI, Bernstein CN, Bitton A, Coward S, Jones JL, **Kaplan GG**, Lee K, Targownik LE, Peña-Sánchez JN, Rohatinsky N, Ghandeharian S, Meka S, Chis RS, Gupta S, Cheah E, Davis T, Weinstein J, Im JHB, Goddard Q, Gorospe J, Loschiavo J, McQuaid K, D'Addario J, Silver K, Oppenheim R, Singh H. The 2023 Impact of Inflammatory Bowel Disease in Canada: Cancer and IBD. *J Can Assoc Gastroenterol*. 2023 Sep 5;6(Suppl 2):S83-S96. doi: 10.1093/jcag/gwad006. PMID: 37674502; PMCID: PMC10478814.
33. Murthy SK, Weizman AV, Kuenzig ME, Windsor JW, **Kaplan GG**, Benchimol EI, Bernstein CN, Bitton A, Coward S, Jones JL, Lee K, Peña-Sánchez JN, Rohatinsky N, Ghandeharian S, Sabrie N, Gupta S, Brar G, Khan R, Im JHB, Davis T, Weinstein J, St-Pierre J, Chis R, Meka S, Cheah E, Goddard Q, Gorospe J, Kerr J, Beaudion KD, Patel A, Russo S, Blyth J, Blyth S, Charron-Bishop D, Targownik LE. The 2023

- Impact of Inflammatory Bowel Disease in Canada: Treatment Landscape. *J Can Assoc Gastroenterol.* 2023 Sep 5;6(Suppl 2):S97-S110. doi: 10.1093/jcag/gwad015. PMID: 37674501.
34. **Kaplan GG***, Kuenzig ME, Windsor JW, Bernstein CN, Bitton A, Coward S, Jones JL, Lee K, Murthy SK, Targownik LE, Peña-Sánchez JN, Ghandeharian S, Rohatinsky N, Weinstein J, Jones May T, Browne M, Jannati N, Tabatabavakili S, Im JHB, Meka S, Vukovic S, Davis T, Goddard Q, Gorospe J, Stocks T, Caplan L, Kanaan N, Stuart D, Ramsay T, Robinson KJ, Charron-Bishop D, Benchimol EI. The 2023 Impact of Inflammatory Bowel Disease in Canada: COVID-19 and IBD. *J Can Assoc Gastroenterol.* 2023 Sep 5;6(Suppl 2):S76-S82. doi: 10.1093/jcag/gwad019. PMID: 37674494.
35. Mathias H, Rohatinsky N, Murthy SK, Novak K, Kuenzig ME, Nguyen GC, Fowler S, Benchimol EI, Coward S, **Kaplan GG**, Windsor JW, Bernstein CN, Targownik LE, Peña-Sánchez JN, Lee K, Ghandeharian S, Jannati N, Weinstein J, Khan R, Im JHB, Matthews P, Davis T, Goddard Q, Gorospe J, Latos K, Louis M, Balche N, Dobranowski P, Patel A, Porter LJ, Porter RM, Bitton A, Jones JL. The 2023 Impact of Inflammatory Bowel Disease in Canada: Access to and Models of Care. *J Can Assoc Gastroenterol.* 2023 Sep 5;6(Suppl 2):S111-S121. doi: 10.1093/jcag/gwad007. PMID: 37674496.
36. Galanis E, Goshtasebi A, Hung YW, Chan J, Matsell DG, Chapman K, **Kaplan GG**, Patrick DM, Zhang BY, Taylor M, Panagiotoglou D, Majowicz SE. Developing International Classification of Disease code definitions for the study of enteric infection sequelae in Canada. *Can Commun Dis Rep* 2023;49(7/8):299–309. <https://doi.org/10.14745/ccdr.v49i78a01>
37. Lee S, Seow CH, Nerenberg K, Bertazzon S, Leung Y, Huang V, Whitten T, Coward S, Panaccione R, **Kaplan GG**, Metcalfe A. Despite Increased Disease Activity, Women who Attended a Dedicated Inflammatory Bowel Disease and Pregnancy Clinic Had Infants With Higher Apgar Scores: A Population-Based Study. *Inflamm Bowel Dis.* 2024 Jul 3;30(7):1071-1079. doi: 10.1093/ibd/izad147. PMID: 37499061.
38. Li L, Etminan M, **Kaplan GG**, Tremlett H, Xie H, Aviña-Zubieta JA. Multiple sclerosis risk among anti-tumor necrosis factor alpha users: A methodological review of observational studies based on real-world data. *Curr Drug Saf.* 2023 Jul 26. doi: 10.2174/1574886318666230726162245. Epub ahead of print. PMID: 37496244.
39. Mak JWY, Sun Y, Limsrivilai J, Abdullah M, Kaibullayeva J, Balderramo D, Vergara BI, Paudel MS, Banerjee R, Hilmi I, Ali RAR, Wei SC, Ng KK, Altuwaijri M, Kelly P, Yamamoto-Furusho JK, Kotze PG, Ahuja V, Chong VH, Dao HV, Abbey Y, Ching JYL, Ho A, Chan AKW, Bernstein CN, Garry RB, Abreu M, Rubin DT, Dotan I, Hracs L, **Kaplan GG**, Ng SC; GIVES-21 Consortium. Development of the global inflammatory bowel disease visualization of epidemiology studies in the 21st century (GIVES-21). *BMC Med Res Methodol.* 2023 May 25;23(1):129. doi: 10.1186/s12874-023-01944-2.
40. Markovinović A, Quan J, Herauf M, Hracs L, Windsor JW, Sharifi N, Coward S, Caplan L, Gorospe J, Ernest-Suarez K, Ma C, Panaccione R, Ingram RJM, Kanji JN, Tipples G, Holodinsky JK, Bernstein CN, Mahoney DJ, Bernatsky S, Benchimol EI, **Kaplan GG***; STOP COVID-19 in IBD Research Group. Adverse Events and Serological Responses After SARS-CoV-2 Vaccination in Individuals With Inflammatory Bowel Disease. *Am J Gastroenterol.* 2023 Sep 1;118(9):1693-1697. doi: 10.14309/ajg.0000000000002337. PMID: 37216598.
41. Lam AY, Lee JK, Coward S, **Kaplan GG**, Dellon ES, Bredenoord AJ, Jairath V, Crowley E, Gupta M, Jijon H, Nasser Y, Andrews CN, Chehade M, Gonsalves N, Hirano I, Ma C. Epidemiologic Burden and Projections for Eosinophilic Esophagitis-Associated Emergency Department Visits in the United States: 2009-2030. *Clin Gastroenterol Hepatol.* 2023 May 8:S1542-3565(23)00328-2. doi: 10.1016/j.cgh.2023.04.028. Epub ahead of print. PMID: 37164113.
42. King JA, Bakal JA, Li B, Whitten TA, Gidrewicz D, Turner JM, van Zanten SV, Huynh HQ, Heitman SJ, Shaheen AA, Quan H, Godley J, Underwood FE, Hracs L, Bergman D, Ludvigsson JF, Lebwohl B,

- Benchimol EI, Williamson T, **Kaplan GG***. Variation in Testing for and Incidence of Celiac Autoimmunity in Canada: A Population-Based Study. *Gastroenterology*. 2023 Apr;164(4):567-578.e7. doi: 10.1053/j.gastro.2022.12.040.
43. **Buie MJ**, Coward S, Shaheen AA, Holroyd-Leduc J, **Hracs L**, Ma C, Panaccione R, Benchimol EI, Bernstein CN, Bitton A, Otley AR, Jones JL, Murthy SK, Ellen Kuenzig M, Peña-Sánchez JN, Targownik LE, Singh H, Avina-Zubieta A, **Kaplan GG***. Hospitalization Rates for Inflammatory Bowel Disease Are Decreasing Over Time: A Population-based Cohort Study. *Inflamm Bowel Dis*. 2023 Mar 14:izad020. doi: 10.1093/ibd/izad020. Epub ahead of print. PMID: 36917200.
44. Cooper JL, Rosentreter RE, Filyk A, Premji ZA, Shen H, Ingram R, **Kaplan GG**, Ma C, Novak K, Panaccione R, Seow CH, Rieder F, Raman M, Lu C. Nutritional interventions in adult fibrostenotic Crohn's disease: A systematic review. *Front Nutr*. 2023 Feb 21;10:1017382. doi: 10.3389/fnut.2023.1017382. PMID: 36895272; PMCID: PMC9988909.
45. Burisch J, Zhao M, Odes S, De Cruz P, Vermeire S, Bernstein CN, **Kaplan GG**, Duricova D, Greenberg D, Melberg HO, Watanabe M, Ahn HS, Targownik L, Pittet VEH, Annese V, Park KT, Katsanos KH, Høivik ML, Krznaric Z, Chaparro M, Loftus EV Jr, Lakatos PL, Gisbert JP, Bemelman W, Moum B, Geary RB, Kappelman MD, Hart A, Pierik MJ, Andrews JM, Ng SC, D'Inca R, Munkholm P. The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission. *Lancet Gastroenterol Hepatol*. 2023 May;8(5):458-492. doi: 10.1016/S2468-1253(23)00003-1.
46. Hamilton P, Buhler K, MacDonald JK, **Kaplan GG**, Seow CH, Lu C, Novak KL, Andrews CN, Singh S, Jairath V, Panaccione R, Ma C. Meta-analysis: Placebo rates in microscopic colitis randomised trials and applications for future drug development using a historical control arm. *Aliment Pharmacol Ther*. 2023 Apr;57(8):837-850. doi: 10.1111/apt.17433. Epub 2023 Feb 24. PMID: 36825479.
47. Shaheen AA, **Kaplan GG**, Sharkey KA, Lethebe BC, Swain MG. Impact of depression and antidepressant use on clinical outcomes of hepatitis B and C: a population-based study. *Hepatol Commun*. 2023 Feb 14;7(3):e0062. doi: 10.1097/HC9.000000000000062. PMID: 36790342.
48. Jeong J, Walters TD, Huynh HQ, Lawrence S, Mack DR, Deslandres C, Otley A, El-Matary W, Sherlock M, Griffiths AM, Wine E, Jacobson K, Church P, Carroll MW, Benchimol EI, Brill H, Critch J, Bax K, Jantchou P, Rashid M, **Kaplan GG**, Seow CH, Novak K, deBruyn JC. Inflammatory Bowel Disease Among Canadian Children: Comparison Between Children of Non-European Descent and Children of European Descent. *Inflamm Bowel Dis*. 2023 Nov 2;29(11):1760-1768. doi: 10.1093/ibd/izac276. PMID: 36688453; PMCID: PMC10628923.
49. Hazlewood GS, Colmegna I, Hitchon C, Fortin PR, Bernatsky S, Clarke AE, Mosher D, Wilson T, Thomas M, Barber CEH, Harrison M, Bansback N, Proulx L, Richards DP, **Kaplan GG**. Preferences for COVID-19 Vaccination in People With Chronic Immune-Mediated Inflammatory Diseases. *J Rheumatol*. 2023 Jul;50(7):949-957. doi: 10.3899/jrheum.220697. Epub 2023 Jan 15. PMID: 36642432.
50. Lu C, Ma C, Ingram RJM, Chan M, Kheirkhahrahimabadi H, Martin ML, Seow CH, **Kaplan GG**, Heatherington J, Devlin SM, Panaccione R, Novak KL. Innovative Care for Inflammatory Bowel Disease Patients during the COVID-19 Pandemic: Use of Bedside Intestinal Ultrasound to Optimize Management. *J Can Assoc Gastroenterol*. 2022 Mar 10;6(1):e1-e6. doi: 10.1093/jcag/gwac006. PMID: 36785574; PMCID: PMC8992330.
51. Dahiya M, Olayinka L, **Kaplan GG**, Reeb L, Ma C, Panaccione R, Kroeker KI. The Impact of the COVID-19 Pandemic on IBD Care in Alberta: Patient and Provider Perspectives. *J Can Assoc Gastroenterol*. 2022 Jan 18;6(1):42-49. doi: 10.1093/jcag/gwab042. PMID: 36785573; PMCID: PMC8807203.

52. Quaresma AB, Damiao AOMC, Coy CSR, Magro DO, Hino AAF, Valverde DA, Panaccione R, Coward SB, Ng SC, **Kaplan GG**, Kotze PG. Temporal trends in the epidemiology of inflammatory bowel diseases in the public healthcare system in Brazil: A large population-based study. *Lancet Reg Health Am.* 2022 Jun 9;13:100298. doi: 10.1016/j.lana.2022.100298. PMID: 36777324; PMCID: PMC9903988.
53. Gohari MR, Taylor M, MacKinnon MC, Panagiotoglou D, Galanis E, **Kaplan GG**, Cook RJ, Patrick DM, Ethelberg S, Majowicz SE. Patterns of enteric infections in a population-wide cohort study of sequelae, British Columbia, Canada. *Epidemiol Infect.* 2022 Dec 14;151:e7.
54. Seow CH, Coward S, Kroeker KI, Stach J, Devitt KS, Targownik LE, Nguyen GC, Ma C, deBruyn JC, Carroll MW, Peerani F, Baumgart DC, Ryan DJ, Veldhuyzen van Zanten S, Benchimol EI, **Kaplan GG**, Panaccione R. Declining Corticosteroid Use for Inflammatory Bowel Disease Across Alberta: A Population-Based Cohort Study. *J Can Assoc Gastroenterol.* 2022 Jul 21;5(6):276-286.
55. Riaz K, Swain MG, Congly SE, **Kaplan GG**, Shaheen AA. Race and Ethnicity in Non-Alcoholic Fatty Liver Disease (NAFLD): A Narrative Review. *Nutrients.* 2022 Oct 28;14(21):4556. doi: 10.3390/nu14214556. PMID: 36364818; PMCID: PMC9658200.
56. Atia O, Benchimol EI, Ledderman N, Greenfeld S, Kariv R, Weisband YL, Matz E, Ollech J, Dotan I, Assa A, Shouval DS, Uhlig HH, Muise AM, Olén O, Kuenzig ME, **Kaplan GG**, Turner D. Incidence, Management, and Outcomes of Very Early Onset Inflammatory Bowel Diseases and Infantile-Onset Disease: An Epi-IIRN Study. *Clin Gastroenterol Hepatol.* 2023 Sep;21(10):2639-2648.e6. doi: 10.1016/j.cgh.2022.10.026. Epub 2022 Nov 3. PMID: 36336312.
57. Ravichandar JD, Rutherford E, Chow CT, Han A, Yamamoto ML, Narayan N, **Kaplan GG**, Beck PL, Claesson MJ, Dabbagh K, Iwai S, DeSantis TZ. Strain level and comprehensive microbiome analysis in inflammatory bowel disease via multi-technology meta-analysis identifies key bacterial influencers of disease. *Front Microbiol.* 2022 Oct 14;13:961020.
58. Li L, Aviña-Zubieta JA, Bernstein CN, **Kaplan GG**, Tremlett H, Xie H, Peña-Sánchez JN, Marrie RA, Etminan M. Risk of Multiple Sclerosis Among Users of Antitumor Necrosis Factor α in 4 Canadian Provinces: A Population-Based Study. *Neurology.* 2023 Feb 7;100(6):e558-e567. doi: 10.1212/WNL.000000000201472. Epub 2022 Oct 28. PMID: 36307225; PMCID: PMC9946189.
59. Ramji A, Doucette K, Cooper C, Minuk GY, Ma M, Wong A, Wong D, Tam E, Conway B, Truong D, Wong P, Barrett L, Ko HH, Haylock-Jacobs S, Patel N, **Kaplan GG**, Fung S, Coffin CS. Nationwide retrospective study of hepatitis B virological response and liver stiffness improvement in 465 patients on nucleos(t)ide analogue. *World J Gastroenterol.* 2022 Aug 21;28(31):4390-4398.
60. Dorn-Rasmussen M, Lo B, Zhao M, **Kaplan GG**, Malham M, Wewer V, Burisch J. The Incidence and Prevalence of Paediatric- and Adult-Onset Inflammatory Bowel Disease in Denmark During a 37-Year Period: A Nationwide Cohort Study (1980-2017). *J Crohns Colitis.* 2023 Mar 18;17(2):259-268. doi: 10.1093/ecco-jcc/jjac138. PMID: 36125076.
61. Azhari H, King JA, Coward S, Windsor JW, Ma C, Shah SC, Ng SC, Mak JWY, Kotze PG, Ben-Horin S, Loftus EV Jr, Lees CW, Garry R, Burisch J, Lakatos PL, Calvet X, Bosques Padilla FJ, Underwood FE, **Kaplan GG***. The Global Incidence of Peptic Ulcer Disease Is Decreasing Since the Turn of the 21st Century: A Study of the Organisation for Economic Co-Operation and Development (OECD). *Am J Gastroenterol.* 2022 Sep 1;117(9):1419-1427. PMID: 35973143.
62. Lakatos PL, **Kaplan GG**, Bressler B, Khanna R, Targownik L, Jones J, Rahal Y, McHugh K, Panaccione R. Cost-Effectiveness of Tight Control for Crohn's Disease With Adalimumab-Based Treatment: Economic Evaluation of the CALM Trial From a Canadian Perspective. *J Can Assoc Gastroenterol.* 2022 Mar 10;5(4):169-176. PMID: 35919766.

63. [Buie MJ](#), [Quan J](#), Windsor JW, Coward S, [Hansen TM](#), King JA, Kotze PG, Gearry RB, Ng SC, Mak JWY, Abreu MT, Rubin DT, Bernstein CN, Banerjee R, Yamamoto-Furusho JK, Panaccione R, Seow CH, Ma C, Underwood FE, Ahuja V, Panaccione N, Shaheen AA, Holroyd-Leduc J, **Kaplan GG***; Global IBD Visualization of Epidemiology Studies in the 21st Century (GIVES-21) Research Group; Balderramo D, Chong VH, Juliao-Baños F, Dutta U, Simadibrata M, Kaibullayeva J, Sun Y, Hilmi I, Raja Ali RA, Paudel MS, Altuwajri M, Hartono JL, Wei SC, Limsrivilai J, El Ouali S, Vergara BI, Dao VH, Kelly P, Hodges P, Miao Y, Li M. Global Hospitalization Trends for Crohn's Disease and Ulcerative Colitis in the 21st Century: A Systematic Review With Temporal Analyses. *Clin Gastroenterol Hepatol*. 2023 Aug;21(9):2211-2221. doi: 10.1016/j.cgh.2022.06.030. Epub 2022 Jul 19. PMID: 35863682.
64. [Buie MJ](#), [Quan J](#), Windsor JW, Coward S, [Hansen TM](#), King JA, Kotze PG, Gearry RB, Ng SC, Mak JWY, Abreu MT, Rubin DT, Bernstein CN, Banerjee R, Yamamoto-Furusho JK, Panaccione R, Seow CH, Ma C, Underwood FE, Ahuja V, Panaccione N, Shaheen AA, Holroyd-Leduc J, **Kaplan GG***; Global IBD Visualization of Epidemiology Studies in the 21st Century (GIVES-21) Research Group, Balderramo D, Chong VH, Juliao-Baños F, Dutta U, Simadibrata M, Kaibullayeva J, Sun Y, Hilmi I, Raja Ali RA, Paudel MS, Altuwajri M, Hartono JL, Wei SC, Limsrivilai J, El Ouali S, Vergara BI, Dao VH, Kelly P, Hodges P, Miao Y, Li M. Global Hospitalization Trends for Crohn's Disease and Ulcerative Colitis in the 21st Century: A Systematic Review With Temporal Analyses. *Clin Gastroenterol Hepatol*. 2022 Jul 19:S1542-3565(22)00670-X. PMID: 35863682.
65. Liu JJ, Abraham BP, Adamson P, Barnes EL, Brister KA, Damas OM, Glover SC, Hooks K, Ingram A, **Kaplan GG**, Loftus EV, McGovern DPB, Narain-Blackwell M, Odufalu FD, Quezada S, Reeves V, Shen B, Stappenbeck TS, Ward L. The Current State of Care for Black and Hispanic Inflammatory Bowel Disease Patients. *Inflamm Bowel Dis*. 2023 Feb 1;29(2):297-307. doi: 10.1093/ibd/izac124. PMID: 35816130; PMCID: PMC10210746.
66. Riaz K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, Swain MG, Congly SE, **Kaplan GG**, Shaheen AA. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol*. 2022 Sep;7(9):851-861. PMID: 35798021.
67. He YM, Mao R, Yuan G, Liang RM, Long JY, Ye XQ, Iacucci M, Ghosh S, Ben-Horin S, **Kaplan GG**, He Y, Sung JY, Peng S, Wang HB, Chen MH. The hospitalization burden of inflammatory bowel disease in China: a nationwide study from 2013 to 2018. *Therap Adv Gastroenterol*. 2022 Jun 13;15:17562848221102307. PMID: 35721841.
68. Kuenzig ME, Benchimol EI, Bernstein CN, Bitton A, Carroll MW, Griffiths AM, **Kaplan GG**, Nguyen GC, Otley AR, Stukel TA, Dummer TJB, El-Matary W, Jacobson K, Jones JL, Lix LM, Mack DR, Murthy SK, Peña-Sánchez JN, Targownik LE, Fung SG, Spruin S, Coward S, Cui Y, Filliter C, Nugent Z, Siddiq S, Singh H; Canadian Gastro-Intestinal Epidemiology Consortium (CanGIEC). Hospitalization With *Clostridioides difficile* in Pediatric Inflammatory Bowel Disease: a Population-Based Study. *J Pediatr Gastroenterol Nutr*. 2022 Aug 1;75(2):173-180. PMID: 35675701.
69. [Quan J](#), Ma C, Panaccione R, [Hracs L](#), [Sharifi N](#), Herauf M, [Makovinović A](#), Coward S, Windsor JW, Caplan L, Ingram RJM, Kanji JN, Tipples G, Holodinsky JK, Bernstein CN, Mahoney DJ, Bernatsky S, Benchimol EI, **Kaplan GG***; STOP COVID-19 in IBD Research Group. Serological responses to three doses of SARS-CoV-2 vaccination in inflammatory bowel disease. *Gut*. 2023 Apr;72(4):802-804. doi: 10.1136/gutjnl-2022-327440. Epub 2022 May 23. PMID: 35606090; PMCID: PMC10086278.
70. Dheri AK, Kuenzig ME, Mack DR, Murthy SK, **Kaplan GG**, Donelle J, Smith G, Benchimol EI. Meta-analysis of multi-jurisdictional health administrative data from distributed networks approximated individual-level multivariable regression. *J Clin Epidemiol*. 2022 Sep;149:23-35. doi: 10.1016/j.jclinepi.2022.05.006. Epub 2022 May 20. PMID: 35605885.

71. Goodyear BG, Heidari F, Ingram RJM, Cortese F, Sharifi N, **Kaplan GG**, Ma C, Panaccione R, Sharkey KA, Swain MG. Multimodal Brain MRI of Deep Gray Matter Changes Associated With Inflammatory Bowel Disease. *Inflamm Bowel Dis*. 2023 Mar 1;29(3):405-416. doi: 10.1093/ibd/izac089. PMID: 35590449; PMCID: PMC9977255.
72. Brunet E, Vela E, Melcarne L, Llovet LP, Puy A, Clèries M, Pontes C, García-Iglesias P, Villòria A, **Kaplan GG**, Calvet X. Heterogeneity in pharmacological treatment and outcomes in Crohn's disease patients in Catalonia: a population-based observational study. *Ann Med*. 2022 Dec;54(1):1255-1264.
73. Kuenzig ME, Fung SG, Marderfeld L, Mak JWY, **Kaplan GG**, Ng SC, Wilson DC, Cameron F, Henderson P, Kotze PG, Bhatti J, Fang V, Gerber S, Guay E, Kotteduwa Jayawarden S, Kadota L, Maldonado D F, Osei JA, Sandarage R, Stanton A, Wan M; InsightScope Pediatric IBD Epidemiology Group, Benchimol EI. Twenty-first Century Trends in the Global Epidemiology of Pediatric-Onset Inflammatory Bowel Disease: Systematic Review. *Gastroenterology*. 2022 Apr;162(4):1147-1159.e4. doi: 10.1053/j.gastro.2021.12.282.
74. Stukalin I, Ahmed NS, Fundytus AM, Qian AS, Coward S, **Kaplan GG**, Hilsden RJ, Burak KW, Lee JK, Singh S, Ma C. Trends and Projections in National U.S. Healthcare Spending for Gastrointestinal Malignancies (1996-2030). *Gastroenterology*. 2022 Apr;162(4):1098-1110.e2. doi: 10.1053/j.gastro.2021.12.244.
75. Ananthakrishnan AN, **Kaplan GG**, Bernstein CN, Burke KE, Lochhead PJ, Sasson AN, Agrawal M, Tiong JHT, Steinberg J, Kruis W, Steinwurz F, Ahuja V, Ng SC, Rubin DT, Colombel JF, Geary R; International Organization for Study of Inflammatory Bowel Diseases. Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus. *Lancet Gastroenterol Hepatol*. 2022 Jul;7(7):666-678. Epub 2022 Apr 27.
76. Widdifield J, Kwong JC, Chen S, Eder L, Benchimol EI, **Kaplan GG**, Hitchon C, Aviña-Zubieta JA, Lacaille D, Chung H, Bernatsky S. Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes among individuals with immune-mediated inflammatory diseases tested between March 1 and Nov 22, 2021, in Ontario, Canada: a population-based analysis. *Lancet Rheumatol*. 2022 Jun;4(6):e430-e440.
77. Kuenzig ME, Widdifield J, Bernatsky S, **Kaplan GG**, Benchimol EI. Uptake of third doses of SARS-CoV-2 vaccines among people with inflammatory bowel disease in Ontario, Canada. *Lancet Gastroenterol Hepatol*. 2022 Apr;7(4):288-289. doi: 10.1016/S2468-1253(22)00054-1.
78. Targownik LE, Bernstein CN, Benchimol EI, **Kaplan GG**, Singh H, Tennakoon A, Nugent Z, Coward SB, Kuenzig ME, Murthy SK. Earlier Anti-TNF Initiation Leads to Long-term Lower Health Care Utilization in Crohn's Disease but Not in Ulcerative Colitis. *Clin Gastroenterol Hepatol*. 2022 Nov;20(11):2607-2618.e14. doi: 10.1016/j.cgh.2022.02.021. Epub 2022 Mar 3. PMID: 35247552.
79. Halasz JB, Burak KW, Dowling SK, Murray B, Williams J, Misra T, Veldhuyzen van Zanten SJ, **Kaplan GG**, Swain M, Novak KL. Do Low-Risk Patients With Dyspepsia Need a Gastroscopy? Use of Gastroscopy for Otherwise Healthy Patients With Dyspepsia. *J Can Assoc Gastroenterol*. 2021 Jul 5;5(1):32-38. doi: 10.1093/jcag/gwab017.
80. **Kaplan GG***, Underwood FE, Coward S, Agrawal M, Ungaro RC, Brenner EJ, Geary RB, Kissous-Hunt M, Lewis JD, Ng SC, Rahier JF, Reinisch W, Steinwurz F, Zhang X, Kappelman MD, Colombel JF. The Multiple Waves of COVID-19 in Patients With Inflammatory Bowel Disease: A Temporal Trend Analysis. *Inflamm Bowel Dis*. 2022 Nov 2;28(11):1687-1695. doi: 10.1093/ibd/izab339. PMID: 35032167; PMCID: PMC8807298.
81. Syal G, Sparrow MP, Velayos F, Cheifetz AS, Devlin S, Irving PM, **Kaplan GG**, Raffals LE, Ullman T, Gecse KB, Fleshner PR, Lightner AL, Siegel CA, Melmed GY. Appropriateness of Medical and Surgical

- Treatments for Chronic Pouchitis Using RAND/UCLA Appropriateness Methodology. *Dig Dis Sci.* 2022 Oct;67(10):4687-4694. doi: 10.1007/s10620-021-07362-y. Epub 2022 Jan 10. PMID: 35006492.
82. Forss A, Clements M, Bergman D, Roelstraete B, **Kaplan GG**, Myrelid P, Halfvarson J, Olén O, Ludvigsson JF. A nationwide cohort study of the incidence of inflammatory bowel disease in Sweden from 1990 to 2014. *Aliment Pharmacol Ther.* 2022 Mar;55(6):691-699. doi: 10.1111/apt.16735.
83. Osei JA, Peña-Sánchez JN, Fowler SA, Muhajarine N, **Kaplan GG**, Lix LM. Increasing Prevalence and Direct Health Care Cost of Inflammatory Bowel Disease Among Adults: A Population-Based Study From a Western Canadian Province. *J Can Assoc Gastroenterol.* 2021 Mar 16;4(6):296-305.
84. Ben-Horin S, Novack L, Mao R, Guo J, Zhao Y, Sergienko R, Zhang J, Kobayashi T, Hibi T, Chowers Y, Peyrin-Biroulet L, Colombel JF, **Kaplan GG**, Chen MH. Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials. *Gastroenterology.* 2022 Feb;162(2):482-494. doi: 10.1053/j.gastro.2021.10.037.
85. Kuenzig M, Windsor JW, Barrett L, Bernstein CN, Bitton A, Carroll MW, Chauhan U, Coward S, Fowler S, Ghia JE, Geist R, Gibson DL, Graff LA, Griffiths AM, Guoxian Huang J, Jones JL, Khanna R, Lakatos PL, Lee K, Mack DR, Marshall JK, Mukhtar MS, Murthy SK, Nguyen GC, Panaccione R, Seow CH, Singh H, Tandon P, Targownik LE, Zelinsky S, Benchimol EI, **Kaplan GG***. Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Executive Summary. *J Can Assoc Gastroenterol.* 2021 Nov 5;4(Suppl 2):S1-S9. doi: 10.1093/jcag/gwab027.
86. **Kaplan GG***, Windsor JW, Crain J, Barrett L, Bernstein CN, Bitton A, Chauhan U, Coward S, Fowler S, Ghia JE, Gibson DL, Griffiths AM, Jones JL, Khanna R, Kuenzig ME, Lakatos PL, Lee K, Mack DR, Marshall JK, Mawani M, Murthy SK, Panaccione R, Seow CH, Targownik LE, Zelinsky S, Benchimol EI. Crohn's and Colitis Canada's 2021 Impact of COVID-19 & Inflammatory Bowel Disease in Canada: A Knowledge Translation Strategy. *J Can Assoc Gastroenterol.* 2021 Nov 5;4(Suppl 2):S10-S19. doi: 10.1093/jcag/gwab028.
87. Coward S, Windsor JW, Kuenzig ME, Bitton A, Bernstein CN, Jones JL, Khanna R, Lee K, Murthy SK, Targownik L, Benchimol E, Huang JG, Mukhtar MS, Tandon P, **Kaplan GG***. Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Epidemiology-The Trends of Disease Over Time. *J Can Assoc Gastroenterol.* 2021 Nov 5;4(Suppl 2):S20-S26. doi: 10.1093/jcag/gwab029.
88. Benchimol EI, Carroll MW, Geist R, Griffiths AM, Huang JG, Mack DR, Bernstein CN, Bitton A, Jones JL, **Kaplan GG**, Kuenzig ME, Lee K, Mukhtar MS, Murthy SK, Tandon P, Targownik LE, Windsor JW, Seow CH. Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Children and Expectant Mothers With Inflammatory Bowel Disease. *J Can Assoc Gastroenterol.* 2021 Nov 5;4(Suppl 2):S27-S33. doi: 10.1093/jcag/gwab030.
89. Bernstein CN, Singh H, Murthy SK, Nguyen GC, Benchimol EI, Bitton A, Kuenzig ME, Huang JG, Jones JL, Lee K, Targownik LE, Windsor JW, Mukhtar MS, Tandon P, **Kaplan GG***. Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Seniors With IBD. *J Can Assoc Gastroenterol.* 2021 Nov 5;4(Suppl 2):S34-S39. doi: 10.1093/jcag/gwab025.
90. Targownik LE, Bernstein CN, Lakatos PL, Murthy SK, Benchimol EI, Bitton A, Huang JG, Kuenzig ME, Jones JL, **Kaplan GG**, Lee K, Mukhtar MS, Tandon P, Windsor JW, Panaccione R. Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Risk Factors and Medications. *J Can Assoc Gastroenterol.* 2021 Nov 5;4(Suppl 2):S40-S45. doi: 10.1093/jcag/gwab032.
91. Graff LA, Fowler S, Jones JL, Benchimol EI, Bitton A, Huang JG, Kuenzig ME, **Kaplan GG**, Lee K, Mukhtar MS, Tandon P, Targownik LE, Windsor JW, Bernstein CN. Crohn's and Colitis Canada's 2021

- Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Mental Health and Quality of Life. *J Can Assoc Gastroenterol*. 2021 Nov 5;4(Suppl 2):S46-S53. doi: 10.1093/jcag/gwab031.
92. Murthy SK, Kuenzig ME, Windsor JW, Ghia JE, Griffiths AM, Panaccione R, Seow CH, Benchimol EI, Bernstein CN, Bitton A, Huang JG, Jones JL, Lee K, **Kaplan GG**, Mukhtar MS, Tandon P, Targownik LE, Gibson DL. Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: COVID-19 Vaccines-Biology, Current Evidence and Recommendations. *J Can Assoc Gastroenterol*. 2021 Nov 5;4(Suppl 2):S54-S60. doi: 10.1093/jcag/gwab033.
93. Jones JL, Benchimol EI, Bernstein CN, Huang JG, Marshall JK, Mukhtar MS, Murthy SK, Nguyen GC, **Kaplan GG**, Kuenzig ME, Tandon P, Targownik LE, Windsor JW, Bitton A. Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Health Care Delivery During the Pandemic and the Future Model of Inflammatory Bowel Disease Care. *J Can Assoc Gastroenterol*. 2021 Nov 26;4(Suppl 2):S61-S67. doi: 10.1093/jcag/gwab034.
94. Iannuzzi JP, King JA, Leong JH, Quan J, Windsor JW, Tanyingoh D, Coward S, Forbes N, Heitman SJ, Shaheen AA, Swain M, Buie M, Underwood FE, **Kaplan GG***. Global Incidence of Acute Pancreatitis Is Increasing Over Time: A Systematic Review and Meta-Analysis. *Gastroenterology*. 2022 Jan;162(1):122-134. doi: 10.1053/j.gastro.2021.09.043.
95. Ricciuto A, Lamb CA, Benchimol EI, Walker GJ, Kennedy NA, Kuenzig ME, **Kaplan GG**, Kappelman MD, Ungaro RC, Colombel JF, Brenner EJ, Agrawal M, Reinisch W, Griffiths AM, Sebastian S. Inflammatory Bowel Disease Clinical Activity is Associated with COVID-19 Severity Especially in Younger Patients. *J Crohns Colitis*. 2022 May 10;16(4):591-600. doi: 10.1093/ecco-jcc/jjab172.
96. Razik R, James PD, Khan R, Maxwell C, Ruan Y, Forbes N, Williams A, Tanyingoh D, Brenner DR, **Kaplan GG**, Hilsden RJ, Heitman SJ. Risk of adverse events associated with upper and lower endoscopic ultrasound: a population-based cohort study. *Endosc Int Open*. 2021 Aug 23;9(9):E1427-E1434. doi: 10.1055/a-1512-9341.
97. Ungaro RC, Brenner EJ, Agrawal M, Zhang X, Kappelman MD, Colombel JF; Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD) Research Group. Impact of Medications on COVID-19 Outcomes in Inflammatory Bowel Disease: Analysis of More Than 6000 Patients From an International Registry. *Gastroenterology*. 2022 Jan;162(1):316-319.e5. doi: 10.1053/j.gastro.2021.09.011.
98. **Kaplan GG***, Ma C, Charlton C, Kanji JN, Tipples G, Sharifi N, Herauf M, Coward S, Ingram RJM, Hracs L, Benchimol EI, Panaccione R. Antibody response to SARS-CoV-2 among individuals with IBD diminishes over time: a serosurveillance cohort study. *Gut*. 2022 Jun;71(6):1229-1231. doi: 10.1136/gutjnl-2021-325238. Epub 2021 Aug 2. PMID: 34340997; PMCID: PMC9120372.
99. Osei JA, Peña-Sánchez JN, Fowler SA, Muhajarine N, **Kaplan GG**, Lix LM. Population-Based Evidence From a Western Canadian Province of the Decreasing Incidence Rates and Trends of Inflammatory Bowel Disease Among Adults. *J Can Assoc Gastroenterol*. 2020 Aug 21;4(4):186-193. doi: 10.1093/jcag/gwaa028.
100. Bergman D, King J, Leibold B, Clements MS, Roelstraete B, **Kaplan GG**, Green PH, Murray JA, Ludvigsson JF. Two waves of coeliac disease incidence in Sweden: a nationwide population-based cohort study from 1990 to 2015. *Gut*. 2022 Jun;71(6):1088-1094. doi: 10.1136/gutjnl-2021-324209. Epub 2021 Jul 28.
101. Sasson AN, Ingram RJM, Zhang Z, Taylor LM, Ananthakrishnan AN, **Kaplan GG**, Ng SC, Ghosh S, Raman M. The role of precision nutrition in the modulation of microbial composition and function in people with inflammatory bowel disease. *Lancet Gastroenterol Hepatol*. 2021 Sep;6(9):754-769. doi: 10.1016/S2468-1253(21)00097-2.

102. Kuenzig ME, Bitton A, Carroll MW, **Kaplan GG**, Otley AR, Singh H, Nguyen GC, Griffiths AM, Stukel TA, Targownik LE, Jones JL, Murthy SK, McCurdy JD, Bernstein CN, Lix LM, Peña-Sánchez JN, Mack DR, Jacobson K, El-Matary W, Dummer TJB, Fung SG, Spruin S, Nugent Z, Tanyingoh D, Cui Y, Filliter C, Coward S, Siddiq S, Benchimol EI; Canadian Gastro-Intestinal Epidemiology Consortium. Inflammatory bowel disease increases the risk of venous thromboembolism in children: a population-based matched cohort study. *J Crohns Colitis*. 2021 Dec 18;15(12):2031-2040.
103. Uche-Anya E, Husby S, **Kaplan GG**, Underwood FE, Green PH, Lebwohl B. An International Reporting Registry of Patients with Celiac Disease and COVID-19: Initial Results from SECURE-CELIAC. *Clin Gastroenterol Hepatol*. 2021 Nov;19(11):2435-2437. doi: 10.1016/j.cgh.2021.06.016.
104. Agrawal M, Brenner EJ, Yan Mak JW, Zhang X, **Kaplan GG**, Ng SC, Reinisch W, Steinwurz F, Lewis JD, Kissous-Hunt M, Modesto I, Ungaro RC, Colombel JF, Kappelman MD. COVID-19 outcomes among racial and ethnic minority individuals with inflammatory bowel disease in the United States. *Clin Gastroenterol Hepatol*. 2021 Oct;19(10):2210-2213. doi: 10.1016/j.cgh.2021.05.060.
105. Shaheen AA, **Kaplan GG**, Sharkey KA, Lethebe BC, Swain MG. Impact of Major Depression and Antidepressant Use on Alcoholic and Non-Alcoholic Fatty Liver Disease: A Population-based Study. *Liver Int*. 2021 Oct;41(10):2308-2317. doi: 10.1111/liv.14973.
106. Dheri AK, Kuenzig ME, Mack DR, Murthy SK, **Kaplan GG**, Donelle J, Smith G, Benchimol EI. Shifting health care use from hospitalizations and surgeries to outpatient visits in children with inflammatory bowel disease: a population-based cohort study from Ontario, Canada. *J Crohns Colitis*. 2021 Dec 18;15(12):1991-2000. doi: 10.1093/ecco-jcc/jjab095.
107. Bernstein CN, Kuenzig ME, Coward S, Nugent Z, Nasr A, El-Matary W, Singh H, **Kaplan GG**, Benchimol EI. Increased Incidence of Inflammatory Bowel Disease after Hirschsprung Disease: A Population-based Cohort Study. *Journal of Pediatrics*. 2021 Jun;233:98-104.e2. doi: 10.1016/j.jpeds.2021.01.060
108. Quan J, Panaccione N, Jeong J, Underwood FE, Coward S, Windsor JW, Ronksley PE, Gidrewicz D, deBruyn J, Turner JM, Lebwohl B, **Kaplan GG**, King JA. Association Between Celiac Disease and Autism Spectrum Disorder: A Systematic Review. *J Pediatr Gastroenterol Nutr*. 2021 May 1;72(5):704-711. doi: 10.1097/MPG.0000000000003051.
109. Bernstein CN, Ng SC, Banerjee R, Steinwurz F, Shen B, Carbonnel F, Hamid S, Sood A, Yamamoto-Furusho JK, Griffiths A, Benchimol EI, Travis S, Lopes S, Rubin DT, **Kaplan GG**, Armstrong D, Geary R; IBD-Emerging Nations Consortium and the WGO IBD Task Force on COVID-19. Worldwide Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: An International Survey. *Inflammatory Bowel Diseases*. 2021 May 17;27(6):836-847. doi:10.1093/ibd/izaa202.
110. Agrawal M, Brenner EJ, Zhang X, Colombel JF, Kappelman MD, Ungaro RC; SECURE-IBD Advisory Committee including, Geary RB, **Kaplan GG**, Kissous-Hunt M, Lewis JD, Ng SC, Rahier JF, Reinisch W, Ruemmele FM, Steinwurz F, Underwood FE. Physician Practice Patterns in Holding Inflammatory Bowel Disease Medications due to COVID-19, in the SECURE-IBD Registry. *J Crohns Colitis*. 2021 May 4;15(5):860-863.
111. Siegel CA, Melmed GY, McGovern DP, Rai V, Krammer F, Rubin DT, Abreu MT, Dubinsky MC; International Organization for the Study of Inflammatory Bowel Disease (IOIBD). SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting. *Gut*. 2021 Apr;70(4):635-640. doi: 10.1136/gutjnl-2020-324000.
112. Mao R, Rieder F, Ben-Horin S, **Kaplan GG**, Ng SC, Wong GL, Ghosh S, Chen MH. Implications of COVID-19 for patients with pre-existing digestive diseases: an update. *Lancet Gastroenterology & Hepatology*. 2021 Apr;6(4):258-260. doi: 10.1016/S2468-1253(21)00025-X.

113. Targownik LE, Bernstein CN, Benchimol EI, **Kaplan GG**, Singh H, Tennakoon A, Nugent Z, Coward SB, Kuenzig ME, Murthy SK. Trends in Corticosteroid Use During the Era of Biologic Therapy: A Population-Based Analysis. *Am J Gastroenterol*. 2021 Jun 1;116(6):1284-1293.
114. Bishay K, Meng ZW, Frehlich L, James MT, **Kaplan GG**, Bourke MJ, Hilsden RJ, Heitman SJ, Forbes N. Prophylactic clipping to prevent delayed colonic post-polypectomy bleeding: meta-analysis of randomized and observational studies. *Surg Endosc*. 2022 Feb;36(2):1251-1262. doi: 10.1007/s00464-021-08398-x. Epub 2021 Mar 9. PMID: 33751224.
115. Elten M, Benchimol EI, Fell DB, Kuenzig ME, Smith G, **Kaplan GG**, Chen H, Crouse D, Lavigne E. Residential Greenspace in Childhood Reduces Risk of Pediatric Inflammatory Bowel Disease: A Population-Based Cohort Study. *American Journal of Gastroenterology*. 2021 Feb 1;116(2):347-353.
116. Guo H, Lam AY, Shaheen AA, Forbes N, **Kaplan GG**, Andrews CN, Laffin M, Singh S, Jairath V, Teriaky A, Lee JK, Ma C. Urban-Rural Disparities and Temporal Trends in Peptic Ulcer Disease Epidemiology, Treatment, and Outcomes in the United States. *American Journal of Gastroenterology*. 2021 Feb 1;116(2):296-305. PMID: 33105195.
117. Lee S, Kuenzig ME, Ricciuto A, Zhang Z, Shim HH, Panaccione R, **Kaplan GG**, Seow CH. Smoking may reduce the effectiveness of anti-TNF therapies to induce clinical response and remission in Crohn's disease: a systematic review and meta-analysis. *Journal of Crohn's & Colitis*. 2021 Jan 13;15(1):74-87.
118. **Kaplan GG***, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. *Nature Reviews: Gastroenterology and Hepatology*. 2021 Jan;18(1):56-66.
119. Yin X, Altman T, Rutherford E, West KA, Wu Y, Choi J, Beck PL, **Kaplan GG**, Dabbagh K, DeSantis TZ, Iwai S. A Comparative Evaluation of Tools to Predict Metabolite Profiles From Microbiome Sequencing Data. *Frontiers in Microbiology*. 2020 Dec 4;11:595910.
120. Butalia S, **Kaplan GG**, Khokhar B, Haubrich S, Rabi DM. The Challenges of Identifying Environmental Determinants of Type 1 Diabetes: In Search of the Holy Grail. *Diabetes & Metabolic Syndrome*. 2020 Dec 9;13:4885-4895.
121. Windsor JW, Underwood FE, Brenner E, Colombel JF, Kappelman MD, Ungaro R, Zhang X, **Kaplan GG***. Data Visualization in the Era of COVID-19: An Interactive Map of the SECURE-IBD Registry, *American Journal of Gastroenterology*. November 2020 - Volume 115 - Issue 11 - p 1923-1924.
122. Dotan I, Panaccione R, **Kaplan GG**, O'Morain C, Lindsay JO, Abreu MT. Best Practice Guidance for Adult Infusion Centres during the COVID-19 Pandemic: Report from the COVID-19 International Organization for the Study of IBD [IOIBD] Task Force. *Journal of Crohn's & Colitis*. 2020 Oct 21;14(Supplement_3):S785-S790. doi: 10.1093/ecco-jcc/jjaa147.
123. Targownik LE, Benchimol EI, Bernstein CN, Singh H, Tennakoon A, Zubieta AA, Coward S, Jones J, **Kaplan GG**, Kuenzig ME, Murthy SK, Nguyen GC, Peña-Sánchez JN. Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications. *Journal of Crohn's & Colitis*. 2020 Oct 5;14(10):1354-1363. doi: 10.1093/ecco-jcc/jjaa050.
124. Liu X, Bertazzon S, Villeneuve PJ, Johnson M, Stieb D, Coward S, Tanyingoh D, Windsor JW, Underwood F, Hill MD, Rabi D, Ghali WA, Wilton SB, James MT, Graham M, McMurtry MS, **Kaplan GG***. Temporal and spatial effect of air pollution on hospital admissions for myocardial infarction: a case-crossover study. *CMAJ Open*. 2020 Oct 9;8(4):E619-E626. doi: 10.9778/cmajo.20190160.
125. Ungaro RC, Brenner EJ, Gearry RB, **Kaplan GG**, Kissous-Hunt M, Lewis JD, Ng SC, Rahier JF, Reinisch W, Steinwurz F, Underwood FE, Zhang X, Colombel JF, Kappelman MD. Effect of IBD medications on

- COVID-19 outcomes: results from an international registry. *Gut*. 2021. Apr;70(4):725-732. doi: 10.1136/gutjnl-2020-322539.
126. **Kaplan GG***, Ma C, Seow CH, Kroeker KI, Panaccione R. The Argument Against a Biosimilar Switch Policy for Infliximab in Patients with Inflammatory Bowel Disease Living in Alberta. *Journal of the Canadian Association of Gastroenterology*. 2020 Oct;3(5):234-242. doi:10.1093/jcag/gwz044.
127. Iacucci M, Cannatelli R, Gui XS, Zardo D, Bazarova A, Gkoutos G, Lethebe BC, **Kaplan GG**, Panaccione R, Kiesslich R, Ghosh S. Assessment of endoscopic healing by using advanced technologies reflects histologic healing in ulcerative colitis. *Journal of Crohn's & Colitis*. 2020 Sep 16;14(9):1282-1289.
128. Majowicz SE, Panagiotoglou D, Taylor M, Gohari MR, **Kaplan GG**, Chaurasia A, Leatherdale ST, Cook RJ, Patrick DM, Ethelberg S, Galanis E. Determining the long-term health burden and risk of sequelae for 14 foodborne infections in British Columbia, Canada: protocol for a retrospective population-based cohort study. *BMJ Open*. 2020 Aug 31;10(8):e036560. doi:10.1136/bmjopen-2019-036560.
129. Brenner EJ, Ungaro RC, Geary RB, **Kaplan GG**, Kissous-Hunt M, Lewis JD, Ng SC, Rahier JF, Reinisch W, Rummel FM, Steinwurz F, Underwood FE, Zhang X, Colombel JF, Kappelman MD. Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry. *Gastroenterology*. 2020 Aug;159(2):481-491.e3. doi: 10.1053/j.gastro.2020.05.032.
130. Salgado VCL, Luiz RR, Boéchat NLF, Leão IS, Schorr BDC, Parente JML, Lima DC, Silveira Júnior ES, Silva GOS, Almeida NP, Vieira A, de Bueno MLQ, Chebli JM, Bertges ÉR, Brugnara LMDC, Junqueira Neto C, Campbell SBG, Discacciati LL, César JPS, Nunes T, **Kaplan GG**, Zaltman C. Risk factors associated with inflammatory bowel disease: A multicenter case-control study in Brazil. *World Journal of Gastroenterology*. 2020 Jul;26(25):3611-3624. doi:10.3748/wjg.v26.i25.3611.
131. Chhibba T, Guizzetti L, Seow CH, Lu C, Novak KL, Ananthakrishnan AN, Bernstein CN, **Kaplan GG**, Panaccione R, Ma C. Frequency of Opioid Prescription at Emergency Department Discharge in Patients with Inflammatory Bowel Disease: A Nationwide Analysis (2006-2017). *Clinical Gastroenterology and Hepatology*. 2020 Jul 16;S1542-3565(20)30982-4.
132. Bajaj JS, Brenner DM, Cai Q, Cash BD, Crowell M, DiBaise J, Gallegos-Orozco JF, Gardner TB, Gyawali CP, Ha C, Holtmann G, Jamil LH, **Kaplan GG**, Karsan HA, Kinoshita Y, Lebowitz B, Leontiadis GI, Lichtenstein GR, Longstreth GF, Muthusamy VR, Oxentenko AS, Pimentel M, Pisegna JR, Rubenstein JH, Russo MW, Saini SD, Samadder NJ, Shaukat A, Simren M, Stevens T, Valdovinos M, Vargas H, Spiegel B, Lacy BE. Major Trends in Gastroenterology and Hepatology Between 2010 and 2019: An Overview of Advances From the Past Decade Selected by the Editorial Board of American Journal of Gastroenterology. *American Journal of Gastroenterology*. 2020;115(7):1007-1018. doi:10.14309/ajg.0000000000000709.
133. Rubin DT, Abreu MT, Rai V, Siegel CA; International Organization for the Study of Inflammatory Bowel Disease. Management of Patients With Crohn's Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting. *Gastroenterology*. 2020;159(1):6-13.e6. doi:10.1053/j.gastro.2020.04.002.
134. Shaheen AA, Riaz K, Medellin A, Bhayana D, **Kaplan GG**, Jiang J, Park R, Schaufert W, Burak KW, Sargious M, Swain MG. Risk stratification of patients with nonalcoholic fatty liver disease using a case identification pathway in primary care: a cross-sectional study. *CMAJ Open*. 2020;8(2):E370-E376. doi:10.9778/cmajo.20200009.

135. Elten M, Benchimol EI, Fell DB, Kuenzig ME, Smith G, Chen H, **Kaplan GG**, Lavigne E. Ambient air pollution and the risk of pediatric-onset inflammatory bowel disease: A population-based cohort study. *Environment International*. 2020 May;138:105676.
136. Faye AS, Wen T, Ananthakrishnan AN, Lichtiger S, **Kaplan GG**, Friedman AM, Lawlor G, Wright JD, Attenello FJ, Mack WJ, Lebowitz B. Acute Venous Thromboembolism Risk Highest Within 60 Days After Discharge From the Hospital in Patients With Inflammatory Bowel Diseases. *Clinical Gastroenterology and Hepatology*. *Clinical Gastroenterology and Hepatology*. 2020 May;18(5):1133-1141.
137. Ananthakrishnan AN, **Kaplan GG***, Ng SC. Changing Global Epidemiology of Inflammatory Bowel Diseases: Sustaining Health Care Delivery into the 21st Century. *Clinical Gastroenterology and Hepatology*. 2020 May;18(6):1252-1260.
138. King JA, Jeong J, Underwood FE, Quan J, Panaccione N, Windsor JW*, Coward S, deBruyn J, Ronksley PE, Shaheen AA, Quan H, Godley J, Veldhuyzen van Zanten S, Lebowitz B, Ng SC, Ludvigsson JF, **Kaplan GG***. Incidence of Celiac Disease Is Increasing Over Time: A Systematic Review and Meta-analysis. *American Journal of Gastroenterology*. 2020 Apr;115(4):507-525.
139. Novak KL, Halasz J, Andrews C, Johnston C, Schoombie W, Tanyingoh D, **Kaplan GG**, Van Zanten SV, Swain S, Nurse-Led, Shared Medical Appointments for Common Gastrointestinal Conditions—Improving Outcomes Through Collaboration With Primary Care in the Medical Home: A Prospective Observational Study, *Journal of the Canadian Association of Gastroenterology*. 2020 Apr;3(2):59-66.
140. Forbes N, Hilsden RJ, Lethebe BC, Maxwell CM, Lamidi M, **Kaplan GG**, James MT, Razik R, Hookey LC, Ghali WA, Bourke MJ, Heitman SJ. Prophylactic Endoscopic Clipping Does Not Prevent Delayed Postpolypectomy Bleeding in Routine Clinical Practice: A Propensity Score-Matched Cohort Study. *American Journal of Gastroenterology*. 2020 May;115(5):774-782.
141. Kotze PG, Underwood FE, Damião AOMC, Ferraz JGP, Saad-Hossne R, Toro M, Iade B, Bosques-Padilla F, Teixeira FV, Juliao-Banos F, Simian D, Ghosh S, Panaccione R, Ng SC, **Kaplan GG***. Progression of Inflammatory Bowel Diseases Throughout Latin America and the Caribbean: a Systematic Review. *Clinical Gastroenterology and Hepatology*. 2020 Feb;18(2):304-312.
142. Murthy SK, Begum J, Benchimol EI, Bernstein CN, **Kaplan GG**, McCurdy JD, Singh H, Targownik L, Taljaard M. Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study. *Gut*. 2020 Feb;69(2):274-282.
143. Pang JXQ, Kheirkhahrahimabadi H, Bindra S, Bindra G, Panaccione R, Eksteen B, **Kaplan GG**, Nasser Y, Beck PL, Jijon HB. Differential effect of genetic burden on disease phenotypes in Crohn's disease and ulcerative colitis in a Canadian cohort. *Journal of the Canadian Association of Gastroenterology*. Feb 2020, gwaa002, <https://doi.org/10.1093/jcag/gwaa002>.
144. Ma C, Smith MK, Guizzetti L, Panaccione R, **Kaplan GG**, Novak KL, Lu C, Khanna R, Feagan BG, Singh S, Jairath V, Ananthakrishnan AN. Assessing National Trends and Disparities in Ambulatory, Emergency Department, and Inpatient Visits for Inflammatory Bowel Disease in the United States (2005-2016). *Clin Gastroenterol Hepatol*. 2020 Oct;18(11):2500-2509.e1. doi: 10.1016/j.cgh.2020.01.023.
145. Hazlewood GS, Pokharel G, Deardon R, Marshall DA, Bombardier C, Tomlinson G, Ma C, Seow CH, Panaccione R, **Kaplan GG***. Patient preferences for maintenance therapy in Crohn's disease: A discrete-choice experiment. *PLoS One*. 2020 Jan 16;15(1):e0227635.
146. Targownik LE, **Kaplan GG**, Witt J, Bernstein CN, Singh H, Tennakoon A, Aviña Zubieta A, Coward SB, Jones J, Kuenzig ME, Murthy SK, Nguyen GC, Peña-Sánchez JN, Benchimol EI. Longitudinal Trends in

the Direct Costs and Health Care Utilization Ascribable to Inflammatory Bowel Disease in the Biologic Era: Results From a Canadian Population-Based Analysis. *American Journal of Gastroenterology*. 2020 Jan;115(1):128-137.

147. **Kaplan GG***, Morrin L, van Zanten SV. Digestive Health Strategic Clinical Network: Striving for better care and outcomes in digestive health. *CMAJ: Canadian Medical Association Journal*. 2019 Dec 4;191(Suppl):S36-S38.
148. Quaresma AB, Coy CSR, Damião AOMC, **Kaplan GG**, Kotze PG. Biological Therapy Penetration for Inflammatory Bowel Disease in Latin America: Current Status and Future Challenges. *Arquivos de Gastroenterologia*. 2019 Sep 30;56(3):318-322.
149. Leung Y, Shim HH, Wilkens R, Tanyingoh D, Afshar EE, Sharifi N, Pauls M, Novak KL, **Kaplan GG**, Panaccione R, Wilson SR, Seow CH. The Role of Bowel Ultrasound in Detecting Subclinical Inflammation in Pregnant Women with Crohn's Disease. *Canadian Journal of Gastroenterology*. 2019 Dec;2(4):153-160.
150. Ma C, Almutairdi A, Tanyingoh D, Seow CH, Novak KL, Lu C, Panaccione R, **Kaplan GG**, Kotze PG. Reduction in surgical stoma rates in Crohn's disease: a population-based time trend analysis. *Colorectal Disease*. 2019 Nov;21(11):1279-1287.
151. Thomas T, Chandan JS, Li VSW, Lai CY, Tang W, Bhala N, **Kaplan GG**, Ng SC, Ghosh S. Global smoking trends in inflammatory bowel disease: A systematic review of inception cohorts. *PLoS One*. 2019 Sep 23;14(9):e0221961.
152. Targownik LE, Benchimol EI, Witt J, Bernstein CN, Singh H, Lix L, Tennakoon A, Zubieta AA, Coward S, Jones J, Kuenzig E, Murthy SK, Nguyen GC, Peña-Sánchez JN, **Kaplan G**. The Effect of Initiation of Anti-TNF Therapy on the Subsequent Direct Health Care Costs of Inflammatory Bowel Disease. *Inflammatory Bowel Diseases*. 2019 Sep 18;25(10):1718-1728.
153. Forbes N, Hilsden RJ, **Kaplan GG**, James MT, Lethebe C, Maxwell C, Heitman SJ. Practice patterns and predictors of prophylactic endoscopic clip usage during polypectomy. *Endoscopy International Open*. 2019 Sep;7(9):E1051-E1060.
154. Picardo S, **Kaplan GG**, Sharkey KA, Seow CH. Insights into the role of cannabis in the management of inflammatory bowel disease. *Therapeutic Advances in Gastroenterology*. 2019 Sep 3;12:1756284819870977.
155. Papamichael K, Cheifetz AS, Melmed GY, Irving PM, Castele NV, Kozuch PL, Raffals LE, Baidoo L, Bressler B, Devlin SM, Jones J, **Kaplan GG**, Sparrow MP, Velayos FS, Ullman T, Siegel CA. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases. *Clinical Gastroenterology and Hepatology*. 2019 Aug; 17(9):1655-1668.
156. Targownik LE, Benchimol EI, Bernstein CN, Singh H, Lix L, Tennakoon A, Leung S, Aviña A, Coward S, Jones J, **Kaplan G**, Murthy SK, Nguyen GC, Peña-Sánchez JN. Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study. *Clinical Gastroenterology and Hepatology*. 2019 Aug;17(9):1788-1798.
157. Forbes N, Frehlich L, James MT, Hilsden RJ, **Kaplan GG**, Wilson TA, Lorenzetti DL, Tate DJ, Bourke MJ, Heitman SJ. Routine Prophylactic Endoscopic Clipping Is Not Efficacious in the Prevention of Delayed Post-Polypectomy Bleeding: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Canadian Journal of Gastroenterology*. 2019 Aug;2(3):105-117.
158. O'Donnell S, Borowski K, Espin-Garcia O, Milgrom R, Kabakchiev B, Stempak J, Panikkath D, Eksteen B, Xu W, Steinhart AH, **Kaplan GG**, McGovern D, Silverberg M. The Unsolved Link of Genetic Markers

- and Crohn's Disease Progression: A North American Cohort Experience. *Inflammatory Bowel Diseases*. 2019 Aug 20;25(9):1541-1549.
159. Windsor JW, Kaplan GG*. Evolving Epidemiology of IBD. *Current Gastroenterology Reports*. 2019 Jul 23;21(8):40.
160. Kellar A, Wilson S, Kaplan G, DeBruyn J, Tanyingoh D, Novak KL. The Simple Pediatric Activity Ultrasound Score (SPAUSS) for the Accurate Detection of Pediatric Inflammatory Bowel Disease. *Journal of Pediatric Gastroenterology and Nutrition*. 2019 Jul;69(1):e1-e6.
161. Lee S, Crowe M, Seow CH, Kotze PG, Kaplan GG, Metcalfe A, Ricciuto A, Benchimol EI, Kuenzig ME. The impact of surgical therapies for inflammatory bowel disease on female fertility. *Cochrane Database of Systematic Reviews*. 2019 Jul 23;7:CD012711.
162. Quaresma AB, Kaplan GG, Kotze PG. The globalization of inflammatory bowel disease: the incidence and prevalence of inflammatory bowel disease in Brazil. *Current Opinion in Gastroenterology*. 2019 Jul;35(4):259-264.
163. JA King, FE Underwood, N Panaccione, Quan J, JW Windsor, PG Kotze, SC Ng, Ghosh S, PL Lakatos, T Jess, Panaccione R, Seow CH, S Ben-Horin, J Burisch, JF Colombel, EV Loftus, R Geary, J Halfvarson, Kaplan GG*. Trends in hospitalization rates for the inflammatory bowel diseases between the Western world and newly industrialized countries: A population-based study of the Organisation for Economic Co-operation and Development (OECD). *The Lancet Gastroenterology & Hepatology*. 2019 Apr;4(4):287-295.
164. Shaheen AA, Nguyen HH, Congly SE, Kaplan GG, Swain MG. Nationwide Estimates and Risk Factors of Hospital Readmission in Patients with Cirrhosis in the United States. *Liver International*. 2019 May;39(5):878-884.
165. Coward S, Clement F, Benchimol EI, CN Bernstein, A Avina-Zubieta, A Bitton, MW Carroll, G Hazlewood, K Jacobson, S Jelinski, R Deardon, JL Jones, Kuenzig ME, D Leddin, KA McBrien, SK Murthy, GC Nguyen, Otley AR, Panaccione R, Rezaie A, G Rosenfeld, JN Peña-Sánchez, H Singh, LE Targownik, and Kaplan GG*. Past and Future Burden of Inflammatory Bowel Diseases Based on Modeling of Population-based Data. *Gastroenterology*. 2019 Apr;156(5):1345-1353.
166. Frolkis AD, I Vallerand, A Shaheen, M Lowerison, Swain MG, Barnabe C, S Patten, Kaplan GG*. Depression increases the risk of inflammatory bowel disease, which may be mitigated by the use of antidepressants in the treatment of depression. *Gut*. 2019 Sep;68(9):1606-1612.
167. Benchimol EI, CN Bernstein, A Bitton, SK Murthy, GC Nguyen, K Lee, J Cooke-Lauder, JW Windsor, MW Carroll, Coward S, W El-Matary, Griffiths AM, JL Jones, Kuenzig ME, L Lee, DR Mack, M Mawani, Otley AR, H Singh, LE Targownik, AV Weizman, Kaplan GG*. The Impact of Inflammatory Bowel Disease in Canada 2018: A Scientific Report from the Canadian Gastro-Intestinal Epidemiology Consortium to Crohn's and Colitis Canada. *Journal of the Canadian Association of Gastroenterology*. 2019 Feb; 2(Suppl_1): S1-S5.
168. Kaplan GG*, CN Bernstein, Coward S, A Bitton, SK Murthy, GC Nguyen, K Lee, J Cooke-Lauder, Benchimol EI. The Impact of Inflammatory Bowel Disease in Canada 2018: Epidemiology. *Journal of the Canadian Association of Gastroenterology*. 2019 Feb; 2(Suppl_1): S6-S16.
169. Kuenzig ME, Benchimol EI, L Lee, Benchimol EI, Kaplan GG, GC Nguyen, CN Bernstein, A Bitton, K Lee, J Cooke-Lauder, SK Murthy. The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs & Health Services Utilization. *Journal of the Canadian Association of Gastroenterology*. 2019 Feb; 2(Suppl_1): S17-S33.
170. Kuenzig ME, L Lee, W El-Matary, AV Weizman, LE Targownik, H Singh, Benchimol EI, Kaplan GG, CN Bernstein, A Bitton, GC Nguyen, K Lee, J Cooke-Lauder, SK Murthy. The Impact of Inflammatory

- Bowel Disease in Canada 2018: Indirect Costs of IBD Care. *Journal of the Canadian Association of Gastroenterology*. 2019 Feb; 2(Suppl_1): S34-S41.
171. JL Jones, GC Nguyen, Benchimol EI, L Lee, Benchimol EI, CN Bernstein, A Bitton, **Kaplan GG**, SK Murthy, K Lee, J Cooke-Lauder, Otley AR. The Impact of Inflammatory Bowel Disease in Canada 2018: Quality of Life. *Journal of the Canadian Association of Gastroenterology*. 2019 Feb; 2(Suppl_1): S42-S48.
172. MW Carroll, Kuenzig ME, DR Mack, Otley AR, Griffiths AM, **Kaplan GG**, CN Bernstein, A Bitton, SK Murthy, GC Nguyen, K Lee, J Cooke-Lauder, Benchimol EI. The Impact of Inflammatory Bowel Disease in Canada 2018: Children and Adolescents with IBD. *Journal of the Canadian Association of Gastroenterology*. 2019 Feb; 2(Suppl_1): S49-S67.
173. GC Nguyen, LE Targownik, H Singh, Benchimol EI, A Bitton, SK Murthy, CN Bernstein, K Lee, J Cooke-Lauder, **Kaplan GG***. The Impact of Inflammatory Bowel Disease in Canada 2018: IBD in Seniors. *Journal of the Canadian Association of Gastroenterology*. 2019 Feb; 2(Suppl_1): S68-S72.
174. CN Bernstein, Benchimol EI, A Bitton, SK Murthy, GC Nguyen, K Lee, J Cooke-Lauder, **Kaplan GG***. The Impact of Inflammatory Bowel Disease in Canada 2018: Extraintestinal Diseases in IBD. *Journal of the Canadian Association of Gastroenterology*. 2019 Feb; 2(Suppl_1): S73-S80.
175. KL Rose, PM Sherman, J Cooke-Lauder, M Mawani, Benchimol EI, **Kaplan GG**, CN Bernstein, A Bitton, SK Murthy, GC Nguyen, K Lee. The Impact of Inflammatory Bowel Disease in Canada 2018: IBD Research Landscape in Canada. *Journal of the Canadian Association of Gastroenterology*. 2019 Feb; 2(Suppl_1): S81-S91.
176. [King JA](#), **Kaplan GG**, Godley J. Experiences of coeliac disease in a changing gluten-free landscape. *Journal of Human Nutrition and Dietetics*. 2019 Feb;32(1):72-79.
177. Lai CY, Sung J, Cheng F, Tang W, Wong SH, Chan PKS, Kamm MA, Sung JY, **Kaplan G**, Chan FKL, Ng SC. Systematic review with meta-analysis: review of donor features, procedures and outcomes in 168 clinical studies of faecal microbiota transplantation. *Alimentary Pharmacology and Therapeutics*. 2019 Feb;49(4):354-363.
178. Mosher V, Swain M, Pang J, **Kaplan G**, Sharkey K, MacQueen G, Goodyear BG. Primary biliary cholangitis patients exhibit MRI changes in structure and function of interoceptive brain regions. *PLoS One*. 2019 Feb 8;14(2):e0211906.
179. Ben-Horin S, Zhao Y, Guo J, Mao R, Novack L, Sergienko R, Zhang J, Kobayashi T, Hibi T, Chowers Y, Colombel JF, Peyrin-Biroulet L, **Kaplan G**, Chen MH. Efficacy of biological drugs in short-duration versus long-duration inflammatory bowel disease: a protocol for a systematic review and an individual-patient level meta-analysis of randomised controlled trials. *BMJ Open*. 2019 Jan 25;9(1):e024222.
180. Weizman AV, Nguyen GC, Seow CH, Targownik L, Murthy SK, Boland K, Afzal NM, Khanna R, Jones J, Afif W, Halder S, Reinglas J, Fowler S, Huang V, **Kaplan GG**, Melmed GY. Appropriateness of Biologics in the Management of Crohn's Disease Using RAND/UCLA Appropriateness Methodology. *Inflammatory Bowel Diseases*. 2019 Jan 10;25(2):328-335.
181. Ng SC, **Kaplan GG**, Tang W, Banerjee R, Adigopula B, Underwood FE, Tanyingoh D, Wei SC, Lin WC, Lin HH, Li J, Bell S, Niewiadomski O, Kamm MA, Zeng Z, Chen M, Hu P, Ong D, Ooi CJ, Ling KL, Miao Y, Miao J, de Silva HJ, Niriella M, Aniwan S, Limsrivilai J, Pisespongsa P, Wu K, Yang H, Ng KK, Yu HH, Wang Y, Ouyang Q, Abdullah M, Simadibrata M, Gunawan J, Hilmi I, Goh KL, Cao Q, Sheng H, Ong-Go A, Chong VH, Ching JYL, Wu JCY, Chan FKL, Sung JY. Population Density and Risk of Inflammatory Bowel Disease: A Prospective Population-Based Study in 13 Countries or Regions in Asia-Pacific. *American Journal of Gastroenterology*. 2019 Jan;114(1):107-115.

182. Kuenzig ME, Rezaie A, **Kaplan GG**, Otley AR, Steinhart AH, Griffiths AM, Benchimol EI, Seow CH. Budesonide for the Induction and Maintenance of Remission in Crohn's Disease: Systematic Review and Meta-Analysis for the Cochrane Collaboration. *Canadian Journal of Gastroenterology*. 2018 Dec;1(4):159-173.
183. Benchimol EI, Kuenzig ME, Bernstein CN, Nguyen GC, Guttman A, Jones JL, Potter BK, Targownik LE, Catley CA, Nugent ZJ, Tanyingoh D, Mojaverian N, Underwood FE, Siddiq S, Otley AR, Bitton A, Carroll MW, deBruyn JC, Dummer TJ, El-Matary W, Griffiths AM, Jacobson K, Leddin D, Lix LM, Mack DR, Murthy SK, Peña-Sánchez JN, Singh H, **Kaplan GG***; Canadian Gastro-Intestinal Epidemiology Consortium. Rural and urban disparities in the care of Canadian patients with inflammatory bowel disease: a population-based study. *Clinical Epidemiology*. 2018 Nov 8;10:1613-1626.
184. Shah SC, Khalili H, Gower-Rousseau C, Olen O, Benchimol EI, Lynge E, Nielsen KR, Brassard P, Vutcovici M, Bitton A, Bernstein CN, Leddin D, Tamim H, Stefansson T, Loftus EV Jr, Moum B, Tang W, Ng SC, Geary R, Sincic B, Bell S, Sands BE, Lakatos PL, Végh Z, Ott C, **Kaplan GG**, Burisch J, Colombel JF. Sex-based Differences in Incidence of Inflammatory Bowel Diseases-Pooled Analysis of Population-based Studies from Western Countries. *Gastroenterology*. 2018 Oct;155(4):1079-1089.
185. Kuenzig ME, Bishay K, Leigh R, **Kaplan GG**, Benchimol EI; Crowdscreen SR Review Team. Co-occurrence of Asthma and the Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. *Clinical and Translational Gastroenterology*. 2018 Sep 24;9(9):188.
186. Shim HH, Ma C, Kotze PG, Seow CH, Al-Farhan H, Al-Darmaki AK, Pang JXQ, Fedorak RN, Devlin SM, Dieleman LA, **Kaplan GG**, Novak KL, Kroeker KI, Halloran BP, Panaccione R. Preoperative Ustekinumab Treatment Is Not Associated With Increased Postoperative Complications in Crohn's Disease: A Canadian Multi-Centre Observational Cohort Study. *Canadian Journal of Gastroenterology*. 2018 Sep;1(3):115-123.
187. Mosher VAL, Swain MG, Pang JXQ, **Kaplan GG**, Sharkey KA, MacQueen GM, Goodyear BG. Magnetic resonance imaging evidence of hippocampal structural changes in patients with primary biliary cholangitis. *Clinical and Translational Gastroenterology*. 2018 Jul 6; 9(7):169.
188. Kotze PG, Ma C, Almutairdi A, Al-Darmaki A, Devlin SM, **Kaplan GG**, Seow CH, Novak KL, Lu C, Ferraz JGP, Stewart MJ, Buresi M, Jijon H, Mathivanan M, Heatherington J, Martin ML, Panaccione R. Real-world clinical, endoscopic and radiographic efficacy of vedolizumab for the treatment of inflammatory bowel disease. *Alimentary Pharmacology and Therapeutics*. 2018 Sep; 48(6):626-637.
189. Kuenzig ME, Sadatsafavi M, Aviña-Zubieta JA, Burne RM, Abrahamowicz M, Beauchamp ME, **Kaplan GG**, Benchimol EI. Asthma is not associated with the need for surgery in Crohn's disease when controlling for smoking status: a population-based cohort study. *Clinical Epidemiology*. 2018 Jul 12;10:831-840.
190. Vallerand IA, Lewinson RT, Frolkis AD, Lowerison MW, **Kaplan GG**, Swain MG, Bulloch AGM, Patten SB, Barnabe C. Depression as a risk factor for the development of rheumatoid arthritis: a population-based cohort study. *RMD Open*. 2018 Jul 11;4(2):e000670.
191. Laffin MR, Perry T, Park H, Gillevet P, Sikaroodi M, **Kaplan GG**, Fedorak RN, Kroeker K, Dieleman LA, Dicken B, Madsen KL. Endospore forming bacteria may be associated with maintenance of surgically-induced remission in Crohn's disease. *Scientific Reports*. 2018 Jun 27;8(1):9734.
192. Kotze PG, Ma C, Mckenna N, Almutairdi A, **Kaplan GG**, Raffals LE, Loftus EV Jr, Panaccione R, Lightner AL. Vedolizumab and early postoperative complications in nonintestinal surgery: a case-matched analysis. *Therapeutic Advances in Gastroenterology*. 2018 Jun 21;11: 1756284818783614.

193. Lewinson RT, Vallerand IA, Parsons LM, LaMothe JM, Frolkis AD, Lowerison MW, **Kaplan GG**, Patten SB, Barnabe C. Psoriasis and the risk of foot and ankle tendinopathy or enthesopathy in the absence of psoriatic arthritis: a population-based study. *RMD Open*. 2018 May 21;4(1):e000668.
194. Barnabe C, Zheng Y, Ohinmaa A, Crane L, White T, Hemmelgarn B, **Kaplan GG**, Martin L, Maksymowych WP. Effectiveness, Complications, and Costs of Rheumatoid Arthritis Treatment with Biologics in Alberta: Experience of Indigenous and Non-indigenous Patients. *Journal of Rheumatology*. 2018 Oct;45(10):1344-1352.
195. Gu P, Kuenzig ME, **Kaplan GG**, Pimentel M, Rezaie A. Fecal Incontinence in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. *Inflammatory Bowel Diseases*. 2018 May 18;24(6):1280-1290.
196. Roberts DJ, Harzan C, Kirkpatrick AW, Dixon E, Grondin SC, McBeth PB, **Kaplan GG**, Ball CG. One thousand consecutive in-hospital deaths following severe injury: Has the etiology of traumatic inpatient death changed in Canada? *Canadian Journal of Surgery*. 2018 Jun;61(3):150-152.
197. Aubin JM, Bressan AK, Grondin SC, Dixon E, MacLean AR, Gregg S, Tang P, **Kaplan GG**, Martel G, Ball CG. Assessing resectability of colorectal liver metastases: How do different subspecialties interpret the same data? *Canadian Journal of Surgery*. 2018 Aug; 61 (4): 251-256.
198. Shaheen AA, **Kaplan GG**, Almishri W, Vallerand I, Frolkis AD, Patten S, Swain MG. The impact of depression and antidepressant usage on primary biliary cholangitis clinical outcomes. *PLoS One*. 2018 Apr 4;13(4):e0194839.
199. Lee S, Metcalfe A, Raman M, Leung Y, Aghajafari F, Letourneau N, Panaccione R, **Kaplan GG**, Seow CH. Pregnant Women with Inflammatory Bowel Disease are at Increased Risk of Vitamin D Insufficiency: A Cross-Sectional Study. *Journal of Crohn's & Colitis*. 2018 May 25;12(6):702-709.
200. Rezaie A, Gu P, **Kaplan GG**, Pimentel M, Al-Darmaki AK. Dyssynergic Defecation in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. *Inflammatory Bowel Diseases*. 2018 Apr 23;24(5): 1065-1073.
201. Melmed GY, **Kaplan GG**, Sparrow MP, Velayos FS, Baidoo L, Bressler B, Cheifetz AS, Devlin SM, Irving PM, Jones J, Kozuch PL, Raffals LE, Siegel CA. Appropriateness of Combination Therapy in Inflammatory Bowel Disease: One Size Still Does Not Fit All. *Clinical Gastroenterology and Hepatology*. 2018 Nov;16(11):1829-1831.
202. Barnabe C, Crane L, White T, Hemmelgarn B, **Kaplan GG**, Martin L, Maksymowych WP. Patient-reported Outcomes, Resource Use, and Social Participation of Patients with Rheumatoid Arthritis Treated with Biologics in Alberta: Experience of Indigenous and Non-indigenous Patients. *Journal of Rheumatology*. 2018 Jun;45(6):760-765.
203. Vallerand IA, Lewinson RT, Parsons LM, Lowerison MW, Frolkis AD, **Kaplan GG**, Barnabe C, Bulloch AGM, Patten SB. Risk of depression among patients with acne in the U.K.: a population-based cohort study. *Br J Dermatol*. 2018 Mar;178(3):e194-e195.
204. Iacucci M, **Kaplan GG**, Panaccione R, Akinola O, Lethebe BC, Lowerison M, Leung Y, Novak KL, Seow CH, Urbanski S, Minoo P, Gui X, Ghosh S. A Randomized Trial Comparing High Definition Colonoscopy Alone With High Definition Dye Spraying and Electronic Virtual Chromoendoscopy for Detection of Colonic Neoplastic Lesions During IBD Surveillance Colonoscopy. *American Journal of Gastroenterology*. 2018 Feb;113(2):225-234.
205. SC Ng, HY Shi, N Hamidi, FE Underwood, W Tang, Benchimol EI, Panaccione R, Ghosh S, JCY Wu, FKL Chan, JYJ Sung, **Kaplan GG***. The Worldwide Incidence and Prevalence of Inflammatory Bowel Disease in the 21st Century: A Systematic Review of Population-Based Studies. *The Lancet*. 2017 Dec 23;390(10114):2769-2778.

206. D Kao, B Roach, M Silva, P Beck, Rioux K, **Kaplan GG**, H Chang, Coward S, KJ. Goodman, H Xu, Madsen K, A Mason, GK Wong, J Jovel, J Patterson, T Louie. Effect of Oral Capsule– vs Colonoscopy-Delivered Fecal Microbiota Transplantation on Recurrent *Clostridium difficile* Infection: A Randomized Clinical Trial. *JAMA*. 2017 Nov 28;318(20):1985-1993.
207. Ma C, Moran GW, Benchimol EI, Targownik LE, Heitman SJ, Hubbard JN, Seow CH, Novak KL, Ghosh S, Panaccione R, **Kaplan GG***. Surgical Rates for Crohn's Disease are Decreasing: A Population-Based Time Trend Analysis and Validation Study. *American Journal of Gastroenterology*. 2017 Dec; 112(12):1840-1848.
208. Khokhar B, Quan H, **Kaplan GG**, Butalia S, Rabi D. Exploring novel diabetes surveillance methods: a comparison of administrative, laboratory and pharmacy data case definitions using THIN. *Journal of Public Health (Oxford, England)*. 2017 Jul 28:1-7.
209. Benchimol EI, **Kaplan GG**, Otley AR, Nguyen GC, Underwood FE, Guttman A, Jones JL, Potter BK, Catley CA, Nugent Z, Cui Y, Tanyingoh D, Mojaverian N, Bitton A, Carroll MW, deBruyn J, Dummer TJB, El-Matary W, Griffiths AM, Jacobson K, Kuenzig ME, Leddin D, Lix LM, Mack DR, Murthy S, Peña Sánchez JN, Singh H, Targownik L, Vutcovici M, Bernstein CN. Rural and urban residence during early life is associated with a lower risk of inflammatory bowel disease: A population-based inception and birth cohort study. *American Journal of Gastroenterology*. 2017 Sep;112(9):1485.
210. Al-Darmaki A, Hubbard J, Seow CH, Leung Y, Novak K, Shaheen AA, Panaccione R, **Kaplan GG***. Clinical Predictors of the Risk of Early Colectomy in Ulcerative Colitis: A Population-based Study. *Inflammatory Bowel Diseases*. 2017 Aug;23(8):1272-1277.
211. Kuenzig ME, Yim J, Coward S, Eksteen B, Seow CH, Barnabe C, Barkema HW, Silverberg MS, Lakatos PL, Beck PL, Fedorak R, Dieleman LA, Madsen K, Panaccione R, Ghosh S, **Kaplan GG***. The NOD2-Smoking Interaction in Crohn's Disease is likely Specific to the 1007fs Mutation and may be Explained by Age at Diagnosis: A Meta-Analysis and Case-Only Study. *EBioMedicine*. 2017 Jul;21:188-196.
212. Novak KL, **Kaplan GG**, Panaccione R, Afshar EE, Tanyingoh D, Swain M, Kellar A, Wilson S. A Simple Ultrasound Score for the Accurate Detection of Inflammatory Activity in Crohn's Disease. *Inflammatory Bowel Diseases*. 2017 Nov; 23(11):2001-2010.
213. Li J, Ueno A, Iacucci M, Fort Gasia M, Jijon HB, Panaccione R, **Kaplan GG**, Beck PL, Luider J, Barkema HW, Qian J, Gui X, Ghosh S. Crossover Subsets of CD4+ T Lymphocytes in the Intestinal Lamina Propria of Patients with Crohn's Disease and Ulcerative Colitis. *Digestive Diseases and Sciences*. 2017 Sep; 62(9):2357-2368.
214. VAL Mosher, Swain MG, Pang JXQ, **Kaplan GG**, KA Sharkey, GM MacQueen, BG Goodyear. Primary Biliary Cholangitis Alters Functional Connections of the Brain's Deep Grey Matter. *Clinical and Translational Gastroenterology*. 2017 Jul 27;8(7):e107.
215. Nguyen GC, Boland K, Afif W, Bressler B, Jones JL, Weizman AV, Fowler S, Halder S, Huang VW, **Kaplan GG**, Khanna R, Murthy SK, Ruel J, Seow CH, Targownik LE, Chawla T, Guimaraes L, Fernandes A, Saleh S, Melmed GY. Modified Delphi Process for the Development of Choosing Wisely for Inflammatory Bowel Disease. *Inflammatory Bowel Diseases*. 2017 Jun;23(6):858-865.
216. JKY Hooi, WY Lai, WK Ng, MMY Suen, FE Underwood, Tanyingoh D, P Malfertheiner, DY Graham, VWS Wong, JCY Wu, FKL Chan, JY Sung, **Kaplan GG^**, SC Ng^ . Global Prevalence of *Helicobacter pylori*: Systematic Review and Meta-analysis of Studies Published From 1970 Through 2016. *Gastroenterology*. 2017 Aug;153(2):420-429. ^Co-Corresponding Authors.

217. M Ferris[^], Quan S[^], BS Kaplan, N Molodecky, CG Ball, GW Chernoff, N Bhala, Ghosh S, E Dixon, S Ng, and **Kaplan GG***. The Global Incidence of Appendicitis: A Systematic Review of Population-Based Studies. *Annals of Surgery*. 2017 Aug;266(2):237-241. [^]Co-First Authors.
218. Kuenzig ME, Barnabe C, Seow CH, Eksteen B, ME Negron, Rezaie A, Panaccione R, Benchimol EI, M Sadatsafavi, JA Aviña-Zubieta, **Kaplan GG***. Asthma is Associated With Subsequent Development of Inflammatory Bowel Disease: a Population-based Case–Control Study. *Clinical Gastroenterology & Hepatology*. 2017; 15(9):1405-12.
219. Benchimol EI, CN Bernstein A Bitton, MW Carroll, H Singh, Otley AR, M Vutcovici, W El-Matary, GC Nguyen, Griffiths AM, DR Mack, K Jacobson, N Mojaverian, Tanyingoh D, Y Cui, Z Nugent, J Coulombe, LE Targownik, JL Jones, D Leddin, SK Murthy, **Kaplan GG**. Trends in Epidemiology of Pediatric Inflammatory Bowel Disease in Canada: Distributed Network Analysis of Multiple Population-Based Provincial Health Administrative Databases. *American Journal of Gastroenterology*. 2017 Jul;112(7):1120-1134.
220. Ma C, Fedorak RN, **Kaplan GG**, Dieleman LA, Devlin SM, Stern N, Kroeker KI, Seow CH, Leung Y, Novak KL, Halloran BP, Huang VW, Wong K, Blustein PK, Ghosh S, Panaccione R. Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn's Disease: Real-world Experience from a Multicenter Cohort Study. *Inflammatory Bowel Diseases Journal*. 2017 May; 23(5): 833-839.
221. Seow C, Leung Y, N Vande Casteele, E Ehteshami Afshar, Tanyingoh D, G Bindra, M Stewart, P Beck, **Kaplan GG**, Ghosh S, Panaccione R. The Effect of Pregnancy on the Pharmacokinetics of Infliximab and Adalimumab in Inflammatory Bowel Disease. *Alimentary Pharmacology and Therapeutics*. 2017 May; 45(10): 1329-1338.
222. C Ma, R Fedorak, **Kaplan GG**, L Dieleman, S Devlin, N Stern, K Kroeker, Seow C, Leung Y, Novak K, B Halloran, V Huang, K Wong, P Blustein, Ghosh S, Panaccione R. Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn's disease: real world experience from a multicentre cohort. *Alimentary Pharmacology and Therapeutics*. 2017 May; 45(9): 1232-1243.
223. A Cholapranee, G Hazlewood, **Kaplan GG**, L Peyrin-Biroulet, A Ananthakrishnan. Systematic review with meta-analysis: Comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials. *Alimentary Pharmacology and Therapeutics*. 2017 May; 45(10): 1291-1302.
224. Tsolakis AV, James PD, **Kaplan GG**, Myers RP, Hubbard J, Wilson T, Zimmer S, Mohamed R, Cole M, Bass S, Swain MG, Heitman SJ. A clinical prediction rule to determine the need for repeat ERCP after endoscopic treatment of postsurgical bile leaks. *Gastrointestinal Endoscopy*. 2017 May; 85(5): 1047-1056.
225. RT Lewinson, IA Vallerand, MW Lowerison, LM Parsons, Frolkis AD, **Kaplan GG**, AGM Bulloch, Swain MG, SB Patten, Barnabe C. Depression and the Risk of Psoriatic Arthritis among Patients with Psoriasis: A Population-based Cohort Study. *The Journal of Investigative Dermatology*. 2017 Apr; 137(4): 828-835.
226. Coward S, Kuenzig ME, G Hazlewood, Clement F, K McBrien, R Holmes, Panaccione R, Ghosh S, Seow CH, Rezaie A, **Kaplan GG***. Comparative effectiveness of mesalamine, sulfasalazine, corticosteroids, and budesonide for the induction of remission in Crohn's disease: A Bayesian Network Meta-Analysis. *Inflammatory Bowel Diseases Journal*. 2017 Mar; 23(3): 461-472.
227. Liu Y, Hazlewood GS, **Kaplan GG**, Eksteen B, Barnabe C. The Impact of Obesity on Remission and Disease Activity in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. *Arthritis Care and Research*. 2017 Feb; 69(20): 157-165.

228. Mao EJ, Hazlewood GS, **Kaplan GG**, Peyrin-Biroulet L, Ananthakrishnan AN. Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis. *Alimentary Pharmacology and Therapeutics*. 2017 Jan;45(1):3-13.
229. **Kaplan GG***, Ng SC. Understanding and Preventing the Global Increase of Inflammatory Bowel Disease. *Gastroenterology*. 2017 Feb; 152(2):313-321.
230. **Kaplan GG*** and SC Ng. Globalization of IBD: Perspectives from the Evolution of IBD in the United Kingdom and China. *The Lancet Gastroenterology & Hepatology*. 2016 Dec; 1(4): 307-316.
231. Kuenzig ME, SM Lee, Eksteen B, Seow CH, Barnabe C, Panaccione R, **Kaplan GG***. Smoking Influences the Need for Surgery in Patients with the Inflammatory Bowel Diseases: a Systematic Review and Meta-Analysis Incorporating Disease Duration. *BMC Gastroenterology*. 2016 Dec 21; 16(1):143.
232. Coward S, Kareemi H, Clement F, Zimmer S, Dixon E, Ball CG, Heitman SJ, Swain M, Ghosh S, **Kaplan GG***. Incidence of Appendicitis over Time: A Comparative Analysis of an Administrative Healthcare Database and a Pathology-Proven Appendicitis Registry. *PLoS One*. 2016 Nov 7;11(11):e0165161.
233. Coward S, Leggett L, **Kaplan GG**, Clement F. Cost-effectiveness of screening for hepatitis C virus: a systematic review of economic evaluations. *BMJ Open*. 2016 Sep 6; 6(9): e011821.
234. G Sun, G Hazlewood, Bernatsky S, **Kaplan GG**, Eksteen B, Barnabe C. Association between Air Pollution and the Development of Rheumatic Disease: A Systematic Review. *International Journal of Rheumatology*, vol. 2016, Article ID 5356307, 11pages, 2016.
235. Lopes F, Matisz C, Reyes JL, Jijon H, Al-Darmaki A, **Kaplan GG**, McKay DM. Helminth Regulation of Immunity: A Three-pronged Approach to Treat Colitis. *Inflammatory Bowel Diseases*. 2016; Oct;22(10):2499-512.
236. Barnabe C, Healy B, Portolesi A, **Kaplan GG**, Hemmelgarn B, Weaselhead C. Claims for disease-modifying therapy by Alberta non-insured health benefits clients. *BMC Health Services Research*. 2016 Aug 24;16(1):430.
237. Butalia S, **Kaplan GG**, Khokhar B, Rabi DM. Environmental Risk Factors and Type 1 Diabetes: Past, Present, and Future. *Canadian Journal of Diabetes*. 2016 Aug 18. pii: S1499-2671(15)30052-6.
238. Khokhar B, Jette N, Metcalfe A, Cunningham CT, Quan H, **Kaplan GG**, Butalia S, Rabi D. Systematic review of validated case definitions for diabetes in ICD-9-coded and ICD-10-coded data in adult populations. *BMJ Open*. 2016 Aug 5;6(8): e009952.
239. Frolkis AD, DeBruyn J, N Jette, M Lowerison, J Engbers, W Ghali, JD Lewis, I Vallerand, S Patten, Eksteen B, Barnabe C, Panaccione R, Ghosh S, Wiebe S, **Kaplan GG***. The Association of Smoking and Surgery in Inflammatory Bowel Disease is Modified by Age at Diagnosis. *Clinical Translational Gastroenterology*. 2016 April 21; 7:e165.
240. Negrón ME, Rezaie A, Barkema HW, Rioux K, De Buck J, Checkley S, Beck PL, M Carroll, Fedorak RN, L Dieleman, Panaccione R, Ghosh S, and **Kaplan GG***. Ulcerative colitis patients with *Clostridium difficile* are at increased risk of death, colectomy, and post-operative complications: A population-based inception cohort study. *American Journal of Gastroenterology*. 2016 May; 111(5): 691-704.
241. MJ Diamant, S Schaffer, Coward S, Kuenzig ME, Hubbard J, Eksteen B, S Heitman, Panaccione R, Ghosh S, **Kaplan GG***. Smoking is Associated with an Increased Risk for Surgery in Diverticulitis: A Case Control Study. *PLoS One*. 2016 Jul 28;11(7):e0153871.
242. Tom MR, Li J, Ueno A, Fort Gasia M, Chan R, Hung DY, Chenoo S, Iacucci M, Jijon HB, **Kaplan GG**, Beck PL, Panaccione R, Barkema HW, Buret AG, Yajnik V, Ghosh S. Novel CD8+ T-Cell Subsets Demonstrating Plasticity in Patients with Inflammatory Bowel Disease. *Inflammatory Bowel Diseases*. 2016 Jul;22(7):1596-608.

243. Bressan AK, Ouellet JF, Tanyingoh D, Dixon E, Kaplan GG, Grondin SC, Myers RP, Mohamed R, Ball CG. Temporal trends in the use of diagnostic imaging for inpatients with pancreatic conditions: How much ionizing radiation are we using? *Canadian Journal of Surgery*. 2016 Jun;59(3):188-96.
244. Li J, Ueno A, Fort Gasia M, Luider J, Wang T, Hirota C, Jijon HB, Deane M, Tom M, Chan R, Barkema HW, Beck PL, Kaplan GG, Panaccione R, Qian J, Iacucci M, Gui X, Ghosh S. Profiles of Lamina Propria T Helper Cell Subsets Discriminate Between Ulcerative Colitis and Crohn's Disease. *Inflammatory Bowel Diseases*. 2016 Aug;22(8):1779-92.
245. Melmed GY, Irving PM, Jones J, Kaplan GG, Kozuch PL, Velayos FS, Baidoo L, Sparrow MP, Bressler B, Cheifetz AS, Devlin S, Raffals LE, Casteelle NV, Mould D, Colombel JF, Dubinsky M, Sandborn WJ, Siegel CA. Appropriateness of Testing for Anti-tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of Results. *Clinical Gastroenterology and Hepatology*. 2016; Sep;14(9):1302-9.
246. Novak KL, Jacob D, Kaplan GG, Boyce E, Ghosh S, Ma I, Lu C, Wilson S, Panaccione R. Point of Care Ultrasound Accurately Distinguishes Inflammatory from Non-Inflammatory Disease in Patients Presenting with Abdominal Pain and Diarrhea. *Canadian Journal of Gastroenterology & Hepatology*. 2016: 4023065. doi: 10.1155/2016/4023065. Epub 2016 Apr 20.
247. Kassam Z, Cribb Fabersunne C, Smith MB, Alm EJ, Kaplan GG, Nguyen GC, Ananthakrishnan AN. Clostridium difficile associated risk of death score (CARDS): a novel severity score to predict mortality among hospitalised patients with C. difficile infection. *Alimentary Pharmacology and Therapeutics*. 2016 Mar; 43(6):725-33.
248. Fort Gasia M, Ghosh S, Panaccione R, Ferraz JG, Kaplan GG, Leung Y, Novak KL, Seow CH, Iacucci M. Targeted Biopsies Identify Larger Proportions of Patients With Colonic Neoplasia Undergoing High-Definition Colonoscopy, Dye Chromoendoscopy, or Electronic Virtual Chromoendoscopy. *Clinical Gastroenterology and Hepatology*. 2016 May; 14(5): 704-712.
249. Devlin SM, Melmed GY, Irving PM, Rubin DT, Kornbluth A, Kozuch PL, Raffals LE, Velayos FS, Sparrow MP, Baidoo L, Bressler B, Cheifetz AS, Jones J, Kaplan GG, Siegel CA. Recommendations for Quality Colonoscopy Reporting for Inflammatory Bowel Disease Patients: Results from a RAND-Appropriateness Panel. *Inflammatory Bowel Diseases*. 2016 Jun; 22(6):1418-24.
250. Kevans D, Tyler AD, Holm K, Jørgensen KK, Vatn MH, Karlsen TH, Kaplan GG, Eksteen B, Gevers D, Hov JR, Silverberg MS. Characterization of Intestinal Microbiota in Ulcerative Colitis Patients with and without Primary Sclerosing Cholangitis. *Journal of Crohn's & Colitis*. 2016 Mar; 10(3):330-37.
251. DeBruyn J, Fonseca F, Ghosh S, Panaccione R, Gasia MF, Ueno A, Kaplan GG, Seow CH, Wrobel I. Immunogenicity of Influenza Vaccine for Patients with Inflammatory Bowel Disease on Maintenance Infliximab Therapy: A Randomized Trial. *Inflammatory Bowel Diseases*. 2016 Mar; 22(3):638-47.
252. Peng M, Chen G, Kaplan GG, Lix LM, Drummond N, Lucyk K, Garies S, Lowerison M, Wiebe S, Quan H. Methods of defining hypertension in electronic medical records-validation against national survey data. *Journal of Public Health*. 2016 Sep;38(3):e392-e399.
253. Atta CA, Fiest KM, Frolkis AD, Jette N, Pringsheim T, Germaine-Smith C, Rajapakse T, Roberts JI, Dykeman J, Kaplan GG, & Metcalfe A. Global birth prevalence of spina bifida: A systematic review and meta-analysis of regional differences by folic acid fortification status. *American Journal of Public Health*. 2016 Jan;106(1):159.
254. Kaplan GG. The Global Burden of Inflammatory Bowel Disease: From 2015 to 2025. *Nature Reviews: Gastroenterology and Hepatology*. 2015 Dec;12(12):720-7.

255. Blackmore C, Tanyingoh D, Kaplan GG, Dixon E, MacLean AR, Ball CG. A Comparison of Outcomes between Laparoscopic and Open Appendectomy in Canada. *Canadian Journal of Surgery*. 2015 Dec; 58(6):431-2.
256. Brown C, Gibson PR, Hart A, Kaplan GG, Kachroo S, Ding Q, Hautamaki E, Fan T, Black CM, Hu X, Beusterien K. Long-term outcomes of colectomy surgery among patients with ulcerative colitis. *Springer Plus*; 2015 Oct 5; 4:573.
257. Quan S*, Yang H, Tanyingoh D, Villeneuve PJ, Stieb DM, Johnson M, Hilsden R, Madsen K, Van Zanten SV, Novak K, Lang E, Ghosh S, and Kaplan GG. Upper Gastrointestinal Bleeding due to Peptic Ulcer Disease is Not Associated with Air Pollution: A Case-Crossover Study. *BMC Gastroenterology*. 2015 Oct 14; 15(1):131.
258. Pang JXQ, Ross E, Borman MA, Zimmer S, Kaplan GG, Heitman SJ, Swain MG, Burak KW, Quan H, Myers RP. Validation of coding algorithms for the identification of patients hospitalized for alcoholic hepatitis using administrative data. *BMC Gastroenterology*. 2015 Sept 11; 15(1): 116.
259. Bertazzon S, Johnson M, Eccles K, Kaplan GG. Accounting for spatial effects in land use regression for air pollution modelling. *Spatial and Spatio-temporal Epidemiology*. 2015 Oct; 14-15: 9-21.
260. Jones JL, Kaplan GG, Peyrin-Biroulet L, Baidoo L, Devlin S, Melmed GY, Tanyingoh D, Raffals L, Irving P, Kozuch P, Sparrow M, Velayos F, Bressler B, Cheifetz A, Colombel J-F, Siegel CA. Impact of concomitant immunomodulator treatment on efficacy and safety of anti-TNF therapy in Crohn's disease: a meta-analysis of subgroups using patient level data from placebo controlled trials. *Clinical Gastroenterology and Hepatology*. 2015 Dec;13(13):2233-2240.
261. Novak K, Tanyingoh D, F Petersen, T Kucharzik, Panaccione R, Ghosh S, Kaplan GG, A Wilson, K Klaus and C Maaser. Clinic-based point of care transabdominal ultrasound for monitoring crohn's disease: impact on clinical decision making. *Journal of Crohn's and Colitis*. 2015 Sep; 9(9):795-801.
262. Singh S*, Al-Darmaki A*, Frolkis AD*, Seow CH, Leung Y, Novak KL, Ghosh S, Eksteen B, Panaccione R and Kaplan GG. Post-operative Mortality Among Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis of Population-based Studies. *Gastroenterology*. 2015 Oct; 149(4):928-37.
263. Coward S*, Heitman SJ, Clement F, Hubbard J, Proulx M, Zimmer S, Panaccione R, Seow C, Leung Y, Datta N, Ghosh S, Myers R, Swain S, and Kaplan GG. Ulcerative Colitis Associated Hospitalization Costs: A Population-Based Study. *Canadian Journal of Gastroenterology and Hepatology*. 2015 Oct; 29(7): 357-62.
264. Moran GW*, Dubeau M, Kaplan GG, Yang H, Eksteen B, Ghosh S and Panaccione R. Clinical predictors of thiopurine-related adverse events in Crohn's disease. *World Journal of Gastroenterology*. 2015 Jul 7; 21(25): 7795-804.
265. Iacucci M, Gasia MF, Panaccione R, Kaplan GG, Ghosh S, Gui X. Complete mucosal healing defined by endoscopy Mayo subscore still demonstrates abnormalities by novel iSCAN endoscopic and refined histological gradings. *Endoscopy*. 2015 Aug; 47(8):726-34.
266. Bernatsky S, Smargiassi A, Johnson M, Kaplan GG, Barnabe C, Svenson L, Brand A, Bertazzon S, Hudson M, Clarke AE, Fortin P, Edworthy S, Bélisle P, Joseph L. Fine particulate air pollution, nitrogen dioxide, and systemic autoimmune rheumatic disease in Calgary, Alberta. *Environmental Research*. 2015 Jul;140:474-478.
267. Rezaie A*, Kuenzig ME*, Benchimol EI, Griffiths AM, Otley AR, Steinhart AH, Kaplan GG, Seow CH. Budesonide for induction of remission in Crohn's disease. *Cochrane Database of Systematic Reviews*. 2015 Jun 3; 6:CD000296.

268. Diamant MJ*, Coward S*, Buie WD, MacLean AR, Dixon E, Ball CG, Schaffer S, Kaplan GG. The Effect of Hospital Volume on in-Hospital Mortality Among Diverticulitis Patients - a Nationwide Analysis. **Canadian Journal of Gastroenterology and Hepatology**. 2015 May;29(4):193-7.
269. Hazlewood GS[^], Rezaie A[^]*, Borman M, Panaccione R, Ghosh S, Seow CH, Kuenzig E*, Tomlinson G, Siegel CA, Melmed GY, Kaplan GG. Comparative Effectiveness of Immunosuppressant and Biologics for Inducing and Maintaining Remission in Crohn's Disease: A Network Meta-Analysis. **Gastroenterology**. 2015 Feb; 148(2): 344-354. [^]Co-first authors.
270. Pang J, Ross E, Borman M, Zimmer S, Kaplan GG, S Heitman, Swain S, Burak K, Quan H, Myers R. Risk factors for mortality in patients with alcoholic hepatitis and assessment of prognostic models: a population-based study. **Canadian Journal of Gastroenterology and Hepatology**. 2015 Apr; 29(3): 131-138.
271. YPLEung Y, Kaplan GG, Coward S, Tanyingoh D, BJ Kaplan, DW Johnston, Barkema HW, Ghosh S, Panaccione R, and Seow CH. Intrapartum corticosteroid use significantly increases the risk of gestational diabetes in women with inflammatory bowel disease. **Journal of Crohn's and Colitis**. 2015 Mar; 9(3): 223-30.
272. Helen Becker, Daniel Grigat, Subrata Ghosh, GG. Kaplan, Levinus Dieleman, Richard Fedorak, Panaccione R, and HW. Barkema. Living with Inflammatory Bowel Disease – a Crohn's and Colitis Canada survey. **Canadian Journal of Gastroenterology and Hepatology**. 2015 Mar; 29(2): 77-84.
273. Kaplan GG, A Lim, Seow CH, Moran GW*, Ghosh S, Leung Y, DeBruyn J, GC Nguyen, Hubbard J, and Panaccione R. Colectomy is a risk factor for venous thromboembolism in ulcerative colitis. **World Journal of Gastroenterology**. 2015 January; 21(4) 1251-1260.
274. Coward S*, Heitman SJ, Clement F, M Negron*, Panaccione R, Ghosh S, Barkema HW, Seow C, YPLEung Y, and Kaplan GG. Funding a Smoking Cessation Program for Crohn's Disease: An Economic Evaluation. **American Journal of Gastroenterology**. 2015 Mar; 110(3): 368-77.
275. Iacucci M, C Hassan, M Fort Gasia, S Urbanski, X Gui, G Eustace, G Kaplan, Eksteen B, Panaccione R. Serrated adenoma prevalence in inflammatory bowel disease surveillance colonoscopy, and characteristics revealed by chromoendoscopy and virtual chromoendoscopy. **Canadian Journal of Gastroenterology and Hepatology**. 2014 Dec; 28 (11): 589-594.
276. MD Sadler*, NC Ravindran, Hubbard J, RP Myers, Ghosh S, Beck PL, E Dixon, Chad Ball, C Prusinkiewicz, Heitman SJ, and Kaplan GG. Predictors of Mortality Among Patients Undergoing Colectomy for Ischemic Colitis: A Population-Based U.S. Study. **Canadian Journal of Gastroenterology and Hepatology**. 2014 Dec; 28 (11): 600-4.
277. Stinton LM, Bentow C, Mahler M, Norman GL, Eksteen B, Mason AL, Kaplan GG, Lindkvist B, Hirschfield GM, Milkiewicz P, Cheung A, Janssen HL, Fritzlner MJ. PR3-ANCA: a promising biomarker in primary sclerosing cholangitis (PSC). **PLoS One**. 2014 Nov 14;9(11):e112877.
278. Kaplan GG. Global variations in environmental risk factors for the inflammatory bowel diseases. **Nature Reviews Gastroenterology and Hepatology**. 2014 Dec;11(12):708-9.
279. Negrón ME*, Kaplan GG, Barkema HW, Eksteen B, Clement F, Manns BJ, Coward S*, Panaccione R, Ghosh S, Heitman SJ. Colorectal Cancer Surveillance in Patients with Inflammatory Bowel Disease and Primary Sclerosing Cholangitis: An Economic Evaluation. **Inflammatory Bowel Diseases**. 2014 Nov; 20(11):2046-55.
280. Kuenzig ME*, Rezaie A*, Seow CH, Otley AR, Steinhart AH, Griffiths AM, Kaplan GG, Benchimol EI. Budesonide for maintenance of remission in Crohn's disease. **Cochrane Database of Systematic Reviews**. 2014 Aug 21;8:CD002913. [Epub ahead of print.]

281. Frolkis AD*, DS Lipton, Fiest KM, Negrón ME*, J Dykeman, DeBruyn J, N Jette, T Frolkis, Rezaie A*, Seow CH, Panaccione R, Ghosh S, Kaplan GG. Cumulative incidence of second intestinal resection in Crohn's disease: a systematic review and meta-analysis of population-based studies. **American Journal of Gastroenterology**. 2014 Nov; 109(11):1739-1748.
282. Quan S*, Frolkis A*, K Milne*, N Molodecky*, Yang H, E Dixon, CG. Ball, RP Myers, Ghosh S, Hilsden R, S Veldhuyzen van Zanten, and GG. Kaplan. Upper-Gastrointestinal Bleeding Secondary to Peptic Ulcer Disease: Incidence and Outcomes. **World Journal of Gastroenterology**. 2014 Dec 14; 20(46): 17568-17577.
283. Negrón ME*, Barkema HW, Rioux K, De Buck J, Checkley S, Proulx M, Frolkis A*, Beck PL, Dieleman LA, Panaccione R, Ghosh S, Kaplan GG. *Clostridium Difficile* Infection Worsens the Prognosis of Ulcerative Colitis. **Canadian Journal of Gastroenterology and Hepatology**. 2014 July/August; 28(7):373-380.
284. Kassam Z, Belga S, Roifman I, Hirota S, Jijon H, Kaplan GG, Ghosh S, Beck PL. Inflammatory Bowel Disease Cause-Specific Mortality: A Primer for Clinicians. **Inflammatory Bowel Diseases**. 2014 Dec; 20(12):2483-92. 2014 Sept 2 [Epub ahead of print.]
285. Reich KM, Chang HJ, Rezaie A, Wang H, Goodman KJ, Kaplan GG, Svenson LW, Lees G, Fedorak RN, Kroeker KI. The Incidence Rate of Colectomy for Medically-Refractory Ulcerative Colitis has Declined in Parallel with Increasing Anti-TNF Use: A Time-Trend Study. **Alimentary Pharmacology & Therapeutics**. 2014 Sept; 40(6): 629-38.
286. Frolkis A*, Kaplan GG, A Patel, P Faris, Quan H, N Jette, DeBruyn J. Short-term emergent readmission and postoperative complications in children and adults with inflammatory bowel disease who undergo intestinal resection: A population-based study. **Inflammatory Bowel Diseases**. 2014 Aug 20(8):1316-23.
287. Soon IS*, deBruyn JCC, Hubbard J, Wrobel I, Sauve R, Sigalet DL, Kaplan GG. Rising post-colectomy complications in children with ulcerative colitis despite stable colectomy rates in United States. **Journal of Crohn's and Colitis**. 2014 Nov 1; 8(11):1417-26.
288. Salim SY, Jovel J, Wine E, Kaplan GG, Vincent R, Thiesen A, Barkema HW, Madsen KL. Exposure to Ingested Airborne Pollutant Particulate Matter Increases Mucosal Exposure to Bacteria and Induces Early Onset of Inflammation in Neonatal IL-10 Deficient Mice. **Inflammatory Bowel Diseases**. 2014 Jul; 20(7): 1129-38.
289. Ball CG, Dixon E, MacLean AR, Kaplan GG, Nicholson L, Sutherland FR. The impact of an acute care surgery clinical care pathway for suspected appendicitis on the use of CT in the emergency department. **Canadian Journal of Surgery**. 2014 Jun; 57(3):194-8.
290. Nguyen GC, Devlin SM, Afif W, Bressler B, Gruchy SE, Kaplan GG, Oliveira L, Plamondon S, Seow CH, Williams C, Wong K, Yan BM, Jones J. Defining quality indicators for best-practice management of inflammatory bowel disease in Canada. **Canadian Journal of Gastroenterology**. 2014; 28(5): 275-285.
291. Pang JXQ, Zimmer S, S Niu, P Crotty, J Tracey, F Pradhan, AM Shaheen, CS Coffin, S Heitman, Kaplan GG, Swain MG, RP Myers. Liver stiffness by transient elastography predicts liver-related complications and mortality in patients with chronic liver disease. **PLOS One**. 2014 Apr 22; 9(4):e95776.
292. Pang JX, Pradhan F, Zimmer S, Niu S, Crotty P, Tracey J, Schneider C, Heitman SJ, Kaplan GG, Swain MG, Myers RP. The feasibility and reliability of transient elastography using Fibroscan: A practice audit of 2335 examinations. **Canadian Journal of Gastroenterology**. 2014 Mar; 28(3):143-9.

293. Moran GW*, Dubeau MF, Kaplan GG, Panaccione R, Ghosh S. Novel concepts in inflammatory bowel disease. *British Medical Bulletin*. 2014; 109:55-72. Epub 2014 Feb 5.
294. Ueno A, Jijon H, S Traves, R Chan, K Ford, Beck PL, Iacucci M, Gasia MF, Barkema HW, Panaccione R, Kaplan GG, D Proud, Ghosh S. Opposing effects of smoking in ulcerative colitis and Crohn's disease may be explained by differential effects on dendritic cells. *Inflammatory Bowel Diseases*. 2014 May; 20(5): 800-810.
295. Long MD, Hutfless S, Kappelman MD, Khalili H, Kaplan GG, Bernstein CN, Colombel JF, Gower-Rousseau C, Herrinton L, Velayos F, Loftus EV Jr, Nguyen GC, Ananthakrishnan AN, Sonnenberg A, Chan A, Sandler RS, Atreja A, Shah SA, Rothman K, Leleiko NS, Bright R, Boffetta P, Myers KD, Sands BE. Challenges in Designing a National Surveillance Program for Inflammatory Bowel Disease in the United States. *Inflammatory Bowel Diseases*. 2014 Feb; 20(2): 398-415.
296. Storr M, Devlin S, Kaplan GG, Panaccione R, Andrews CN. Cannabis use provides symptom relief in patients with inflammatory bowel disease but is associated with worse disease prognosis in patients with Crohn's disease. *Inflammatory Bowel Diseases*. 2014 Mar; 20(3): 472-80.
297. Johannson KA, Vittinghoff E, Lee K, Balmes JR, Kaplan GG, Kim DS, and Collard HR. Acute Exacerbation of Idiopathic Pulmonary Fibrosis Associated with Air Pollution Exposure. *European Respiratory Journal*. 2014 Apr; 43(4): 1124-21.
298. James PD, Kaplan GG, Myers RP, Hubbard J, Shaheen AAM, Tinmouth J, Yong E, Love J, and Heitman SJ. Decreasing mortality from acute biliary diseases requiring endoscopic retrograde cholangiopancreatography: A nationwide cohort study. *Clinical Gastroenterology and Hepatology*. 2014 July; 12(7): 1151-59.
299. Salim SY, Kaplan GG, Madsen KL. Air pollution effects on the gut microbiota: A link between exposure and inflammatory disease. *Gut Microbes*. 2014; Mar-Apr; 5(2): 215-219.
300. Moran GW*, Dubeau M, Kaplan GG, Yang H, Seow CH, Fedorak RN, LA Dieleman, Barkema HW, Ghosh S, Panaccione R. Phenotypic features of Crohn's disease associated with failure of medical treatment. *Clinical Gastroenterology and Hepatology*. 2014 Mar; 12(3):434-42.
301. Moran GW*, Lim AW, Bailey JL, Dubeau M, Leung Y, Devlin SM, Novak K, Kaplan GG, Iacucci M, Seow C, Martin L, Panaccione R, and Ghosh S. Review Article: Dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease. *Alimentary Pharmacology and Therapeutics*. 2013 November; 38(9): 1002-1024.
302. Frolkis AD*, Dykeman J, Negron ME *, DeBruyn J, Jette N, Fiest KM, Frolkis T, Barkema H, Rioux KP, Panaccione R, Ghosh S, Wiebe S, Kaplan GG. Risk of Surgery for the Inflammatory Bowel Diseases has Decreased Over Time: A Systematic Review and Meta-Analysis of Population-Based Studies. *Gastroenterology*. Nov 2013;145(5):996-1006.
303. Ueno A, Jijon H, R Chan, K Ford, C Hirota, Kaplan GG, Beck PL, Iacucci M, Gasia MF, Barkema HW, Panaccione R, Ghosh S. Increased prevalence of novel IL-17 secreting Foxp3 expressing CD4+ T cells and defective suppressive function of circulating Foxp3+ regulatory cells support Th17-Treg plasticity in inflammatory bowel disease patients. *Inflammatory Bowel Diseases*. 2013 Nov; 19(12):2522-34.
304. Chan AW, Munene G, Weaver J, MacLean A, Easaw J, Kaplan GG, Parker RD, and Dixon E. Cytoreductive Strategies in the Treatment of Carcinomatosis of Colorectal Origin: Results of a Transdisciplinary National Survey. *The Open Surgical Oncology Journal*. 2013; 4: 1-6.
305. DeBruyn J, Soon IS, Hubbard J, Wrobel I, Panaccione R, Kaplan GG. Nationwide temporal trends in incidence of hospitalization and surgical intestinal resection in pediatric inflammatory bowel diseases in the United States from 1997 to 2009. *Inflammatory Bowel Diseases*. 2013 Oct; 19(11):2423-32. Epub 2013 August 23.

306. Kish L, Salim SY, Hotte N, Tso R, Ethier CD, Vincent R, Kaplan GG, Barkema H, Madsen K. Environmental particulate matter induces murine intestinal inflammatory responses and alters the gut microbiome. *PLoS One*. 2013 Apr 24; 8(4): e62220.
307. Kaplan GG, Tanyingoh D, Dixon E, Johnson M, Wheeler AJ, Myers RP, Bertazzon S, Saini V, Madsen K, Ghosh S, and Villeneuve PJ. Daily Changes in Ambient Ozone Concentrations Associated with Increased Risk of Perforated Appendicitis: A Multi-City Case Crossover Study. *Environmental Health Perspectives*. 2013 Aug; 121(8): 939-43.
308. Moran GW*, Dubeau MF, Kaplan GG, Panaccione R, Ghosh, S. The increasing weight of Crohn's disease subjects in clinical trials: a hypothesis-generating time-trend analysis. *Inflammatory Bowel Diseases*. 2013 Dec; 19(13): 2949-56.
309. McColl RJ, Shaheen AA, Brar B, Kaplan G, Myers R, Sutherland F, Dixon E. Survival after hepatic resection: impact of surgeon training on long-term outcome. *Canadian Journal of Surgery*. 2013 Aug; 56(4): 256-62.
310. Soon I*, Butzner D, Kaplan GG, deBruyn J. Incidence and Prevalence of Eosinophilic Esophagitis in Children: Systematic Review and Meta-Analysis. *Journal of Pediatric Gastroenterology and Nutrition*. 2013 Jul; 57(1): 72-80.
311. Frolkis A*, Dieleman LA, Barkema HW, Panaccione R, Ghosh S, Fedorak R, Madsen K, and Kaplan GG. Environment and the Inflammatory Bowel Diseases. *Canadian Journal of Gastroenterology*. 2013; 27(3): e18-24.
312. Kaplan GG, Seow C, Ghosh S, Molodecky N*, Rezaie A*, Moran G*, Proulx M, Hubbard JN, MacLean A, Buie D, and Panaccione R. Decreasing Colectomy Rates for Ulcerative Colitis: A Population-Based Time Trend Study. *American Journal of Gastroenterology*. 2012 Dec; 107(12): 1879-87. Epub 2012 Nov 20.
313. Kaplan GG, Szyszkowicz M, Fichna J, Rowe BH, Porada E, Vincent R, Madsen K, Ghosh S, and Storr M. Non-specific abdominal pain and air pollution: a novel association. *PLoS One*. 2012; 7 (10): e47669.
314. Kirsten M Fiest, Jonathan Dykeman, Scott B Patten, Samuel Wiebe, Gilaad G Kaplan, Colleen J Maxwell, Andrew G.M. Bulloch, and Nathalie Jette. Depression in Epilepsy: A Systematic Review & Meta-Analysis. *Neurology*. 2013 Feb 5; 80(6): 590-9. Epub 2012 Nov 21.
315. Ma C*, Crespín M, Proulx MC, DeSilva S*, Hubbard J, Prusinkiewicz M*, Nguyen GC, Panaccione R, Ghosh S, Myers RP, Quan H, and Kaplan GG. Postoperative complications following colectomy for ulcerative colitis: A validation study. *BMC Gastroenterology*. 2012 Apr 27; 12: 39.
316. Myers RP, Hubbard JN, Shaheen AA, Dixon E, Kaplan GG. Hospital performance reports based on severity adjusted mortality rates in patients with cirrhosis depend on the method of risk adjustment. *Annals of Hepatology*. 2012 Jul; 11(4): 526-35.
317. Devlin SM, Cheifetz AS, Siegel C, Baidoo L, Bressler B, Raffals LE, Irving PM, Jones J, Kaplan GG, Kozuch PL, Melmed GY, Sparrow MP, Velayos FS. Patient-specific approach to combination versus monotherapy with the use of antitumor necrosis factor agents for inflammatory bowel disease. *Gastroenterology Clinics of North America*. 2012 Jun; 41(2): 411-28. Epub 2012 Feb 14.
318. Soon IS*, Molodecky N*, Rabi DM, Ghali WA, Barkema HW, and Kaplan GG. The relationship between urban environment and IBD: a systematic review and meta-analysis. *BMC Gastroenterology*. 2012 May 24; 12 (1): 51
319. Schicho R, Shaykhtudinov R, Ngo J, Nazyrova A, Schneider C, Panaccione R, Kaplan GG, Vogel HJ, Storr M. Quantitative Metabolomic Profiling of Serum, Plasma, and Urine by (1)H NMR Spectroscopy Discriminates between Patients with Inflammatory Bowel Disease and Healthy Individuals. *Journal of Proteome Research*. 2012 Jun 1; 11(6): 3344-57.

320. Dubeau MF *, Iacucci M, Beck PL, Moran GW*, Kaplan GG, Ghosh S, Panaccione R. Drug-induced inflammatory bowel disease (IBD) and IBD-like conditions. *Inflammatory Bowel Diseases*. 2013 Feb; 19(2): 445-56. Epub 2012 May 9.
321. Cheifetz A, Melmed G, Spiegel B, Talley J, Devlin S, Harrell L, Irving P, Jones J, Kaplan GG, Kozuch P, Sparrow M, Velayos FS, Baidoo L, Bressler B, Siegel C. Setting priorities for comparative effectiveness research in inflammatory bowel disease: results of an international provider survey, expert rand panel, and patient focus groups. *Inflammatory Bowel Diseases*. 2012 Dec; 18(12): 2294-300. Epub 2012 Feb 15.
322. Leung Y, Kaplan GG, King A, Kamhawi S, Stasiak S, Rioux K, and Rubin, D. Assessment of variables associated with smoking cessation in Crohn's Disease. *Digestive Diseases and Sciences*. 2012 Apr; 57(4): 1026-32.
323. Soon I*, Kaplan B, Proulx M, Wrobel I, DeBruyn J, and Kaplan GG. Postoperative Complications Following Colectomy for Ulcerative Colitis in Children: A Population-Based Study. *Journal of Pediatric Gastroenterology and Nutrition*. 2012 Jun; 54(6): 763-8. 2011. Epub 2012 Dec 12.
324. Molodecky N*, Soon IS*, Rabi D, Ghali W, Ferris M, Chernoff G, Benchimol E, Panaccione R, Ghosh S, Barkema H, and Kaplan GG. Increasing Incidence of Inflammatory Bowel Disease with Time and Among Regions, Based on Systematic Review. *Gastroenterology*. 2012 Jan; 142(1): 46-54.
325. de Silva S*, Ma C*, Proulx M, Crespín M, Kaplan BS, Hubbard J, Prusinkiewicz M*, Fong A, Panaccione R, Ghosh S, Beck PL, MacLean A, Buie D, and Kaplan GG. Postoperative Complications and Mortality Following a Colectomy for Ulcerative Colitis. *Clinical Gastroenterology and Hepatology*. 2011; 9(11): 972-80. Epub 2011 Jul 30.
326. Grendar J, Shaheen AA, Myers RP, Parker R, Vollmer Jr CM, Ball CG, Quan ML, Kaplan CC, Al-Manasra T, Dixon E. Predicting In-Hospital Mortality in Patients Undergoing Complex Gastrointestinal Surgery: What Is The Optimal Risk-Adjustment Methodology? *Archives Surgery*. 2012 Feb; 147(2): 126-135. [Epub 2011 Oct 17].
327. Congly SE, Shaheen AAM, Meddings L, Kaplan GG, and Myers RP. Amebic Liver Abscess in the United States: A Population-Based Study of Incidence, Temporal Trends, and Mortality. *Liver International*. 2011 Sep; 31(8): 1191-8.
328. Strauss J, Kaplan GG, Beck PL, Rioux K, Panaccione R, Devlin R, Lynch T, Allen-Vercoe E. Invasive potential of gut mucosa-derived fusobacterium nucleatum positively correlates with IBD status of the host. *Inflammatory Bowel Diseases*. 2011; 17(9): 1971-8. Jan 13. [Epub ahead of print.]
329. deBruyn JC, Hilsden R, Fonseca K, Russell ML, Kaplan GG, Vanderkooi O, Wrobel I. Immunogenicity and Safety of Influenza Vaccination in Children with Inflammatory Bowel Disease. *Inflammatory Bowel Diseases*. 2012; Jan; 18(1): 25-33.
330. Molodecky NA*, Kareemi H*, Parab R, Barkema HW, Quan H, Myers RP, and Kaplan GG. The Incidence of Primary Sclerosing Cholangitis: A Systematic Review and Meta-Analysis. *Hepatology*. 2011; 53(5): 712-20.
331. Molodecky NA*, Myers RP, Barkema HW, Quan H, and Kaplan GG. Validity of Administrative Data for the Diagnosis of Primary Sclerosing Cholangitis (PSC): A Population-Based Study. *Liver International*. 2011; May; 31(5): 712-20.
332. Shale M, Czub M, Kaplan GG, Panaccione R, and Ghosh S. Anti-tumor necrosis factor therapy & influenza: keeping it in perspective. *Therapeutic Advances in Gastroenterology*. 2010; 3(3): 173-7.
333. Szyszkowicz M, Eugeniusz Porada, Kaplan GG, Rowe BH. Ambient ozone and emergency department visits for cellulitis. *Int J Occup Med Environ Health*. 2010; 7(11): 4078-88.

334. Molodecky NA*, Panaccione R, Ghosh S, Barkema HW, Kaplan GG. Challenges associated with identifying the environmental determinants of the inflammatory bowel diseases. *Inflammatory Bowel Diseases*. 2011; 17(8):1792-1799.
335. Kaplan GG, Hubbard J, Panaccione R, Shaheen AM, Quan, H, Nguyen GC, Dixon E, Ghosh S, and Myers RP. The risk of comorbidities on postoperative outcomes in inflammatory bowel disease patients. *Archives of Surgery*. 2011; 146(8): 959-64.
336. Molodecky NA*, Kaplan GG. Environmental risk factors for inflammatory bowel disease. *Gastroenterology & Hepatology* 2010; 6(5): 339-46.
337. Kaplan GG, Hubbard JN, Korzenik J, Sands BE, Panaccione R, Ghosh S, Wheeler AJ, and Villeneuve P. The Inflammatory Bowel Diseases and Ambient Air Pollution: A Novel Association. *American Journal of Gastroenterology*. 2010; 105(11): 2412-9.
338. Melmed GY, Spiegel BM, Bressler B, Cheifetz AS, Devlin SM, Harrell LE, Irving PM, Jones J, Kaplan GG, Kozuch PL, Velayos FS, Baidoo L, Sparrow MP, and Siegel CA. Appropriateness of concomitant immunomodulators with anti-TNF agents for Crohn's disease. *Clinical Gastroenterology and Hepatology*. 2010; 8(8): 655-9.
339. Meddings L*, Myers RP, Shaheen AA, Laupland KB, Hubbard J, & Kaplan GG. A Population-Based Study of Pyogenic Liver Abscesses in the US: Incidence, Mortality, and Temporal Trends. *American Journal of Gastroenterology*. 2010; 105(1): 117-204.
340. Shale M, Seow C, Coffin C, Kaplan GG, Panaccione R, and Ghosh S. Viral infections in the anti-tumour necrosis factor therapy era in inflammatory bowel diseases. *Alimentary Pharmacology and Therapeutics*. 2010; 31(1): 20-34.
341. Seow CH, de Silva S*, Kaplan GG, Devlin SM, Ghosh S, Panaccione R. Managing the risks of IBD therapy. *Current Gastroenterology Reports*. 2009; 11(6): 509-17.
342. Szyszkowicz M, Kaplan GG, Grafstein E, Rowe BH. Emergency department visits for migraine and headache: a multi-city study. *International Journal of Occupational Medicine and Environmental Health*. 2009; 22(3): 235-42.
343. Kaplan GG, Dixon E, Panaccione R, Fong A, Chen L, Szyszkowicz M, Wheeler A, Heitman S, MacLean A, Buie D, Leung T, and Villeneuve P. Effect of ambient air pollution on the incidence of appendicitis. *CMAJ: Canadian Medical Association Journal*. 2009; 181(9): 591-7.
344. Ma C*, Panaccione J, Heitman S, Devlin S, Ghosh S, and Kaplan GG. Systematic Review: Short and long-term efficacy of adalimumab following discontinuation of infliximab. *Alimentary Pharmacology and Therapeutics*. 2009; 30(10): 977-86. Epub 2009 Jul 22.
345. Shale M, Kaplan GG, Panaccione R, and Ghosh S. Isotretinoin and intestinal inflammation: what gastroenterologists need to know. *Gut*. 2009; 58(6):737-41.
346. Leung TW, Dixon E, Gill M, Mador BD, Moulton KM, Kaplan GG, Maclean AR. Bowel Obstruction Following Appendectomy: What is the True Incidence? *Annals of Surgery*. 2009; 250(1): 51-53.
347. Shaheen AA, Kaplan GG, Hubbard JN, and Myers RP. Morbidity and mortality following coronary artery bypass graft surgery in patients with cirrhosis: a population-based study. *Liver International*. 2009; 29(8):1141-51.
348. Myers RP, Shaheen AA, Hubbard JN, Kaplan GG. Characteristics of Patients with Cirrhosis Who are Discharged from Hospital Against Medical Advice. *Clinical Gastroenterology and Hepatology*. 2009; 7(7):786-92.

349. Szyszkowicz M, Rowe, BH, and Kaplan GG. Ambient Sulphur Dioxide Exposure and Emergency Department Visits for Migraine in Vancouver, Canada. *International Journal of Medicine and Environmental Health*. 2009; 22(1): 1-6.
350. Myers RP, Kaplan GG, Shaheen AA. The effect of weekend versus weekday admission on outcomes of esophageal variceal hemorrhage. *Canadian Journal of Gastroenterology*. 2009; 23(7): 495-501.
351. Nguyen GC, Sam J, Murthy SK, Kaplan GG, Tinmouth JM, and LaVeist TA. Hospitalizations for Inflammatory Bowel Disease: Profile of the Uninsured in the United States. *Inflammatory Bowel Disease*. 2009 15(5): 726-33.
352. Kaplan GG, Panaccione P, Hubbard J, Nguyen GC, Shaheen AM, Ma C, Devlin SM, & Myers RP. IBD Patients Who Leave Hospital Against Medical Advice: Predictors and Temporal Trends. *Inflammatory Bowel Diseases*. 2009; 15(6): 845-851.
353. Myers RP, Hubbard JN, Shaheen AA, & Kaplan GG. Predicting in-hospital mortality in patients with cirrhosis: Results differ across risk adjustment methods. *Hepatology*. 2008; 49(2):568-577.
354. Ghosh S, Kaplan G, Panaccione R. Granulocyte-monocyte apheresis in ulcerative colitis – the end of the road? *Natural Clinical Practice: Gastroenterology & Hepatology*. 2009; 6(1):6-7.
355. Shaheen AA, Kaplan GG, Myers RP. Weekend versus weekday admission and mortality from gastrointestinal hemorrhage due to peptic ulcer disease. *Clinical Gastroenterology and Hepatology*. 2009; 7(3):303-10.
356. Kaplan GG, Jackson T, Sands BE, Frisch M, Andersson R, and Korzenik J. The risk of developing Crohn's disease after an appendectomy: A Meta-analysis. *American Journal of Gastroenterology*. 2008; 103(11): 2925-31.
357. McColl RJ, You X, Ghali WA, Kaplan G, Myers RP, Dixon E. Recent trends of hepatic resection in Canada: 1995-2004. *Journal of Gastrointestinal Surgery*. 2008; 12(11):1839-46.
358. DeSilva S*, Kaplan G, Panaccione R. Sequential Therapies for Crohn's disease: Optimizing conventional and biologics strategies. *Reviews in Gastroenterological Disorders*. 2008; 8(2):109-16.
359. Myers RP, Papay KD, Shaheen AA, Kaplan GG. The relationship between hospital volume and outcomes of esophageal variceal bleeding in the United States. *Clinical Gastroenterology and Hepatology*. 2008; 6(7):789-98.
360. Kaplan GG, McCarthy E, Ayanian J, Korzenik J, Hodin R, Sands BE. Impact of Hospital Volume on Postoperative Morbidity and Mortality Following a Colectomy for Ulcerative Colitis. *Gastroenterology*. 2008; 134(3):680-7.
361. Nguyen GC, Kaplan GG, Harris ML, & Brant SR. A National Survey of the Prevalence and Impact of *Clostridium Difficile* Infection Among Hospitalized IBD Patients. *American Journal of Gastroenterology*. 2008; 103(6): 1443-50.
362. Kaplan GG, Seminowich S, Williams J, Muruve D, Dupre M, Urbanski SJ, Yilmaz S, Burak KW, Beck PL. The Risk of Microscopic Colitis in Solid Organ Transplantation Patients: A Population Based Study. *Transplantation*. 2008; 85(1):48-54.
363. Williams JJ[^], Kaplan GG[^], Makhija S, Urbanski SJ, Dupre M, Panaccione R, and Beck PL. Microscopic Colitis - Defining Incidence Rates and Risk Factors: A Population-Based Study. *Clinical Gastroenterology and Hepatology*. 2008; 6(1): 35-40. [^]Co-first author.
364. Yan BM, Kaplan GG, Urbanski S, Nash CL, and Beck PL. Epidemiology of gastrointestinal stromal tumors (GIST) in a defined Canadian health region: a population-based study. *International Journal of Surgical Pathology*. 2008; 16(3):241-50.

365. Kaplan GG, Hur C, Korzenik J, and Sands BE. Infliximab dose escalation versus initiation of adalimumab for loss of response in Crohn's disease: A cost-effectiveness analysis. *Alimentary Pharmacologic Therapeutics*. 2007; 26(11): 1509-1520. Epub 2007 Oct 11.
366. Kaplan GG, Heitman S, Hilsden R, Urbanski S, Myers R, Lee SS, and Panaccione R. A population-based assessment of the surveillance practice of colonic dysplasia in primary sclerosing cholangitis. *Inflammatory Bowel Diseases*. 2007; 13(11): 1401-1407.
367. Kaplan GG, Pedersen BV, Andersson RE, Sands BE, Korzenik J, Frisch M. The risk of developing Crohn's disease after an appendectomy: a population-based cohort study in Sweden and Denmark. *Gut*. 2007; 56(10): 1387-1392.
368. Sands BE & Kaplan GG. The Role of TNF α in Ulcerative Colitis. *Journal of Clinical Pharmacology*. 2007; 47(8): 930-41.
369. Jackson TD, Kaplan GG, Arena G, Page J, Rogers SO. Laparoscopic versus open resection for colorectal cancer: a meta-analysis of oncologic outcomes. *Journal of the American College of Surgeons*. 2007; 204(3): 439-46.
370. Kaplan GG, Laupland KB, Butzner D, Urbanski SJ, Lee SS. The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. *American Journal of Gastroenterology*. 2007; 102:1-8.
371. Kaplan GG, Bates D, McDonald D, Panaccione R, Romagnuolo J. Inappropriate use of intravenous pantoprazole: extent of the problem and successful solutions. *Clinical Gastroenterology and Hepatology*. 2005; 3(12): 1207-1214.
372. Kaplan GG, Medlicott S, Culleton B and Laupland KB. Acute hepatic failure and multi-system organ failure secondary to replacement of the liver with metastatic melanoma. *BMC Cancer*. 2005; 5: 67.
373. Kaplan GG, Manns B, and McLaughlin K. Heparin induced thrombocytopenia secondary to intraperitoneal heparin exposure. *Nephrology Dialysis Transplantation*. 2005; 20(11): 2561-2562.
374. Kaplan GG, Gregson D, Laupland K. Population-based study of the epidemiology of and the risk factors for pyogenic liver abscess. *Clinical Gastroenterology and Hepatology*. 2004; 2(11): 1032-1038.

Publications: Non-Peer Reviewed Manuscripts and Editorials

1. Kaplan GG. Editorial: The rising burden of inflammatory bowel disease in Poland. *Pol Arch Intern Med*. 2022 May 30;132(5):16257. PMID: 35635405.
2. Kaplan GG, Windsor JW, Coward S. "Why we all need to be proactive about our bowels." *The Conversation*. June 11, 2018: <https://theconversation.com/why-we-all-need-to-be-proactive-about-our-bowels-96098>.
3. Kaplan GG. Editorial: Pumping Iron: Exploring Novel Gene-environment Interactions in the Inflammatory Bowel Diseases. *Inflammatory Bowel Diseases*. 2017 Jul;23(7):1096-1097.
4. Kaplan GG. Editorial: Does breathing polluted air increase the risk of upper gastrointestinal bleeding from peptic ulcer disease? *Lancet Planet Health*. 2017 May;1(2):e54-e55.
5. Kaplan GG. Editorial: The millennium study cohort – evaluating environmental determinates of IBD in the 21st century. *Alimentary Pharmacology and Therapeutics*. 2017 Jul; 46(1):63-64.
6. Kaplan GG. Commentary - Colon Cancer in Asian Patients with Ulcerative Colitis. *The Lancet Gastroenterology & Hepatology*. 2017 Apr; 2(4):238-239.

7. Kaplan GG. Editorial - Fiber and the Risk of Flaring in Patients with Inflammatory Bowel Diseases: Lessons From the Crohn's & Colitis Foundation of America Database. ***Clinical Gastroenterology and Hepatology***. 2016 Aug;14(8):1137-1139.
8. Kaplan GG. Editorial: Smoking Cessation for Crohn's Disease: Clearing the Haze. ***American Journal of Gastroenterology***. 2016 Mar; 111(3):420-422.
9. Kaplan GG, Jess T. Editorial: The Changing Landscape of IBD: East Meets West. ***Gastroenterology***. 2016 Jan; 150(1):24-26.
10. Hirota JA, Carlsten C, Sadatsafavi M, Kaplan G and Hirota SA. Airway diseases and inflammatory bowel diseases: is it something in the air (pollution)? ***European Respiratory Journal***. July 2015. 46; (1):287-288.
11. Kaplan GG. Editorial - The pitfalls and perils of using administrative databases to evaluate the incidence of IBD overtime. ***Inflammatory Bowel Diseases***. 2014 Oct; 20(10):1777-1779.
12. Kaplan GG. Editorial: Does consuming the recommended daily level of fiber prevent Crohn's disease? ***Gastroenterology***. 2013 Nov; 145(5):925-927.
13. Kaplan G. Editorial: Air Pollution and the Inflammatory Bowel Diseases. ***Inflammatory Bowel Diseases***. 2011 May; 17(5):1146-1148.
14. Kaplan G. Editorial: Age Distribution of IBD Hospitalization. ***Inflammatory Bowel Diseases***. 2010. 16(3):458-460.
15. Kaplan GG. Editorial: Administrative Database Studies in IBD: A Cautionary Tale. ***American Journal of Gastroenterology***. 2010; 105(8):1808-1810.
16. Kaplan GG, Molodecky N, Panaccione R. Environmental triggers of the inflammatory bowel diseases. ***IBD Monitor***. 2011; 11(2):1 to 5.
17. Kaplan GG, Hur C, Korzenik J, and Sands BE. Infliximab vs Adalimumab for Crohn's disease: authors' reply. ***Alimentary Pharmacologic Therapeutics***. 2008; 28(10):1266-1267.
18. Kaplan GG and Panaccione R. Use of combination therapy in IBD. ***Inflammatory Bowel Disease***. 2008; 14(S2):S219-S221.
19. Kaplan GG and Panaccione R. Selected Summary: The anti TNF race. The caution flag is raised again. ***Inflammatory Bowel Disease***. 2004;10:61-62.
20. Kaplan GG and Manns B. Renal regulation: The keys to preventing chronic renal failure. ***Canadian Journal of Continuing Medical Education***. 2003; 15(2):55-64.
21. Kaplan GG, Bates D, McDonald D, Romagnuolo J. Inappropriate prescribing leading to rapidly escalating costs of IV proton pump inhibitors in the Calgary Health Region. ***Pharma News***. 2002; 26(3):1-4.
22. Mellor J and Kaplan GG. Is it asthma or not? A plea for more objectivity. ***Canadian Journal of Continuing Medical Education***. 2000; 12(9):41-49.

Publications: Book Chapters

1. Kaplan GG, Ng SC. IBD 1. Epidemiology, Pathogenesis, and Diagnosis of Inflammatory Bowel Diseases. In: Sleisenger and Fordtran's Gastrointestinal and Liver Disease, 11th edition. Edited by

Gilaad G. Kaplan, MD, MPH, FRCPC, CAGF, AGAF, FCAHS, Killam Laureate

Feldman M, Friedman LS, Brandt LJ, Chung R, Rubin D, Wilcox CM. Saunders/Elsevier, Philadelphia, PA. pages, 2020.

2. Coward SC*, Kaplan GG. IBD in the New World, Old World, and Your World. In: Cohen R (ed), Inflammatory Bowel Disease. Humana Press: Springer International Publishing AG, 2017.
3. Soon IS*, Kaplan GG. Travelling with IBD. In: Irving P., Siegel C., Rampton D., Shanahan F. (eds), Clinical Dilemmas in IBD 2. Oxford: Blackwell Publishing Ltd, 2011.
4. Barkema HW, Hendrick S, De Buck JM, Ghosh S, Kaplan GG, and Rioux K. Crohn's Disease in Humans and Johne's Disease in Cattle – Linked Diseases? In: Krause D (ed), Zoonotic Pathogens in the Food Chain.